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1The effects of adenosine antagonists on distinct aspects of motivated behavior:
interaction with ethanol and dopamine depletion.
ABSTRACT
Adenosine is a neuromodulator in the central nervous system (CNS) that interacts with
other neurotransmitters and with some substances like alcohol, which elevates the
adenosinergic tone. It has been shown that increases in adenosine levels produce
sedation and fatigue, two behavioral effects that can have an impact on other more
complex processes such as anxiety or motivation. Adenosine acts on different receptors,
being adenosine A1 and A2A receptors the most relevant for their presence and
mechanism of action in specific brain areas involved in the modulation of mood and
motivational processes such as striatum, prefrontal cortex and amygdala. Caffeine is a
worldwide consumed methylxanthine that acts as a non-selective adenosine A1/A2A
receptor antagonist. This drug is generally consumed to reduce fatigue and increase
alert. More recently, caffeine, at high concentrations, is combined with alcoholic
beverages under the popular belief that can counteract some of the sedative and
impairing effects of ethanol. The knowledge about how high levels of caffeine can
affect complex motivated behaviors such alcohol abuse, or social interaction patterns is
limited, and potential side effects such as increases in anxiety and motor impairments
can modulate them. Thus, the first part of the present dissertation (Chapters 1-4),
reviews the literature on caffeine-ethanol interaction, and addresses the impact of high
doses of caffeine on anxiety and how they can modulate social interaction patterns in
animal models. High doses of caffeine are studied also in interaction with moderate
doses of ethanol that had demonstrated to produce anxiolysis. In order to provide
evidence about a potentially selective mechanism of action on adenosine A1 or on A2A
receptors, other selective and non-selective adenosine antagonists and A2A receptor KO
mice are also used.
On the other hand, A1 and A2A receptors have been proposed as therapeutical targets for
the treatment of motivational impairments such as psychomotor retardation and fatigue
observed in some psychopathologies such as depression. Mesolimbic dopamine (DA) is
involved in the regulation of the activational component of motivation and DA
depletion or antagonism has shown to impair this aspect of motivation in effort-based
decision making tasks, shifting preferences from high effort/high reward options to low
2effort/low reward options. Adenosine A1 and A2A are colocalized with DA D1 and D2
receptors respectively in striatal areas and they interact in antagonistic way at the
cellular and also the behavioral level. Several selective adenosine antagonists have
shown to revert the anergia-like effect induced by DA impairments. However, the
therapeutical impact of caffeine on those impairments has not been widely explored.
Thus, in Chapters 5-6 the impact of caffeine on depression is reviewed, and its potential
on effort-based decision-making tasks in animal models is studied after the
administration of a DA depleting agent. Cellular markers activated after adenosine and
DA receptor interactions were analyzed in order to elucidate the mechanism of action.
3Efecto de los antagonistas de adenosina en diferentes componentes de la conducta
motivada: estudios de interacción con alcohol y con disminución en los niveles de
dopamina.
RESUMEN
La adenosina es un neuromodulador del Sistema Nervioso Central (SNC) que interactúa
con otros neurotransmisores y otras sustancias como el alcohol, el cual incrementa los
niveles de adenosina. Se ha demostrado que estos incrementos adenosinérgicos
producen sedación y fatiga, dos efectos conductuales que pueden tener impacto en
procesos como la ansiedad o la motivación. La adenosina actúa en diferentes receptores,
siendo los A1 y los A2A los más relevantes por su presencia y mecanismo de acción en
áreas cerebrales involucradas en la modulación de procesos emocionales y
motivacionales como el estriado, el córtex prefrontal y la amígdala. La cafeína es una
metilxantina ampliamente consumida que actúa como antagonista no selectivo de los
receptores A1/A2A de adenosina. Esta droga es generalmente consumida para reducir la
fatiga e incrementar los niveles de alerta. Recientemente, la cafeína a dosis altas, se
ingiere junto a bebidas alcohólicas bajo la creencia popular de que esta metilxantina
puede compensar los efectos sedativos e intoxicantes del alcohol. El conocimiento
acerca de cómo altas concentraciones de cafeína pueden afectar directamente aspectos
complejos de conductas motivadas como el abuso de alcohol o la interacción social, es
limitado, y además estas conductas pueden verse moduladas también por los efectos
secundarios asociados a la cafeína, como es el incremento de ansiedad y las alteraciones
motoras. En este sentido, la primera parte de esta tesis (Capítulos 1-4), revisa la
literatura relacionada con la interacción cafeína-alcohol, y explora el impacto de dosis
altas de cafeína en ansiedad y como estas sustancias pueden modular la interacción
social en modelos animales. Con el objetivo de conocer el mecanismo de acción
selectivo de la cafeína sobre los receptores de adenosina A1 o A2A, se estudian también
otros antagonistas selectivos y no selectivos de los receptores de adenosina, así como
animales KO para los receptores de adenosina A2A.
Por otra parte, los receptores A1 y A2A, se han propuesto como dianas terapéuticas para
el tratamiento de alteraciones motivacionales como el enlentecimiento motor y la fatiga
observadas en algunas psicopatologías como la depresión. La dopamina (DA)
4mesolímbica está involucrada en la regulación del componente activacional de la
motivación. La disminución de los niveles de DA o el antagonismo dopaminérgico han
demostrado alterar este aspecto de la motivación en tareas de toma de decisiones
basadas en el esfuerzo, cambiando las preferencias del individuo desde la elección de
reforzadores con gran valor que requieren un alto esfuerzo a reforzadores de menor
valor que requieren menor esfuerzo. Los receptores de adenosina A1 y A2A están co-
localizados con los receptores de DA D1 y D2 respectivamente en estructuras estriatales
e interactúan de forma antagónica a nivel intracelular y conductual. Sin embargo, el
impacto terapéutico de la cafeína en dichas alteraciones motivacionales no ha sido
ampliamente estudiado. En este sentido, en los Capítulos 5-6, se revisa la literatura
sobre el impacto de la cafeína en la depresión, y se estudia su efecto potencial en tareas
de toma de decisiones basadas en el esfuerzo en modelos animales tras la
administración de un agente farmacológico que reduce los niveles de DA de manera
reversible. Con el objetivo  de conocer los mecanismos intracelulares que regulan estos
procesos, se estudia también el impacto de estas manipulaciones farmacológicas sobre
marcadores de activación de los receptores de DA y de adenosina.
5GENERAL INTRODUCTION
1. Adenosine as a neuromodulator in the CNS
Adenosine is considered a neuromodulator in the CNS, which regulates neuronal
excitability and neurotransmitter release, and modulates ion channel function through
four subtypes of G-protein-coupled receptors; A1, A2A, A2B, and A3 (Fredholm et al.,
2001). Unlike classical neurotransmitters that are synthesized, stored, and released into
the synapse in response to electrochemical stimulation, adenosine operates mainly
through volume transmission, and concentrations are regulated to a much greater extent
by ongoing production and transport (Burnstock, 1972, 2006, 2008).
Adenosine A1 receptors are present in almost all brain areas and their stimulation can
suppress neuronal excitability (Fredholm et al., 1994). Stimulation of A2A receptors has
the opposite effect to A1 receptor stimulation, and they are almost exclusively
concentrated in dopamine (DA) rich areas such as the striatum, where they reach high
levels of expression (Fredholm et al., 1994; Vontell et al., 2010). The role of A2B and A3
receptors has received considerably less attention, because they are present at very low
levels in the CNS (Zhou et al., 1992; Daly et al., 1983; Dixon et al., 1996). The
existence of pharmacological tools, such as selective adenosine receptor agonists and
antagonists, as well as the existence of genetic modified animals such as knockout (KO)
mice, has permitted the study of the role of A1 and A2A in the regulation of many
behaviors such as bradykinesia, catalepsy and tremor (Correa et al., 2004; Betz et al.,
2009; Hauber et al., 2001; Morelli et al., 2012), psychomotor stimulation or sedation (El
Yacoubi et al., 2003; Nagel et al., 2003; Pardo et al., 2014; Farrar et al., 2007; Font et
al., 2008; Mingote et al., 2008), sensorimotor gating (Hauber and Koch, 1997; Koch and
Hauber, 1998), memory (Hauber and Bareiss, 2001; Prediger et al., 2005), and in the
regulation of affective (Correa and Font, 2008; Prediger et al., 2004; Kaster et al.,
2007), and motivational processes (Salamone and Correa, 2009; Pereira et al., 2011;
Pardo et al., 2012; Correa et al., 2016).
2. Caffeine and ethanol interaction: actions on the adenosine system.
Two commonly consumed drugs that have an impact on the adenosinergic system are
caffeine and alcohol. Caffeine is a methylxanthine that acts as a non-selective adenosine
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antagonist (A1/A2A) (Fredholm et al., 2001). This mechanism of action mediates its
minor stimulant (Ferré, 2008; Urry and Landolt, 2015), anxiogenic (Prediger et al.,
2004; Correa and Font 2008) and motivational effects (Randall et al., 2011; Salamone et
al., 2009). However, the differential concentration of A1 and A2A receptors in distinctive
brain areas responsible for the modulation of different behaviors can lead to a
predominant role of A1 or of A2A receptors in these behavioral effects of caffeine.
Ethanol does not act directly on adenosine receptors, but can increase adenosine levels
by decreasing adenosine uptake (Diamond and Gordon, 1994) or by increasing
adenosine levels, since adenosine is a byproduct of ethanol metabolism (Carmichael et
al., 1991; Correa et al., 2012). There is some evidence that adenosine may contribute to
some of the sedative and motor incoordination effects of ethanol (Dar, 1990; Meng and
Dar, 1995; Correa and Font, 2008; Correa et al., 2012).
Interest in this methylxanthine and some of its metabolites, such as theophylline, has
grown since the introduction to the market of the so-called “energy drinks”. Caffeine,
and to some extent theophylline, are the main psychoactive components of these drinks
(a behavioral comparison between these two methylxantines is presented in Chapter 2
of the present dissertation). These highly caffeinated beverages are being increasingly
consumed, mainly among young populations, in combination with ethanol and under the
popular belief that caffeine can compensate the intoxicating effects of alcohol (for a
review see Correa et al., 2014). However, data from human studies and animal models
show controversial results (as summarized in Chapter 1). Moreover, the interaction
between high doses of caffeine and ethanol has not been extensively characterized in
relation to some behaviors traditionally regulated by ethanol, such as anxiety or social
interaction. Thus, chapters 3 and 4 present data on the impact of caffeine and selective
adenosine receptor antagonism alone or in combination with ethanol, on social behavior
and anxiety. The study of these two drugs in combination can reveal the nature of their
interaction and shed light on the role of A1 and A2A adenosine receptors on these
actions.
3. Social interaction and its modulation by anxiety.
Social behavior has been widely explored as a natural reinforcer in the overall context
of the study of motivation (Martin et al., 2014; Pansskep and Lahvis, 2010; Martin and
GENERAL INTRODUCTION
7
Iceberg, 2015). Most of these studies used maternal behavior, or access to opposite sex
conspecifics, as reinforcers (Matthews et al., 2005; Martín-Sánchez et al., 2015; Pereira
and Ferreira, 2016), although rodents express a robust motivation to approach
conspecifics in general (Brodkin et al. 2004; Moy et al. 2004, 2006; Terranova et al.,
1993). Approach towards a conspecific, also referred to as social approach, is a basic
behavioral component of all social interactions (Pankssep and Lahvis, 2010). This
apparently simple behavior has reinforcing properties evaluated in classical paradigms
such as social conditioned place preference, or operant tasks that use sex-matched
conspecifics as reinforcers (Pankssep and Lahvis, 2010; Martin and Iceberg, 2015).
Time spent approaching and exploring a conspecific as opposed to exploration of a non-
social stimulus can offer information about the preference for social stimuli, and is a
measure of appetitive social motivation.
In addition to the intrinsic motivational properties of social interaction, this behavior has
shown to be sensitive to anxiolytic or anxiogenic effects of drugs and, in fact, social
interaction tasks have been widely used as animal models of anxiety (File and Seth,
2003; File, 1980). Acutely administered caffeine and ethanol have been shown to have
opposite effects on anxiety (Gulick and Gould, 2009; Correa et al., 2008). As reported
in Chapter 2, caffeine (Jain et al., 2005; Prediger et al., 2004), as well as its metabolite
theophylline, induce anxiogenic effects at moderate and high doses. The anxiolytic
effects of ethanol have been widely explored in mice and rats (Correa et al., 2008;
Prediger et al., 2004). Each of these drugs has shown to affect social interaction in a
manner that is consistent with their anxiogenic or anxiolytic profile; anxiolytic drugs
will enhance social interaction and anxiogenic drugs will decrease it (Prediger et al.,
2004). However, a direct positive relationship between anxiety and social interaction is
not always so clear, and contradictory results have been found depending on the animal
model and parameters used (Baldwin et al., 1989; Baldwin and File, 1989; Hilakivi and
Seth, 1989; Nadal et al., 1993; Guy and Gardner, 1985). Chapter 4 characterizes social
behaviors and anxiety in adenosine A2A receptor KO mice.
It has been suggested that the opposite effects of ethanol and caffeine on anxiety are due
to opposing actions on the adenosine system (Prediger et al., 2004; Correa and Font
2008): ethanol increases adenosine levels, while caffeine acts as a non-selective
adenosine A1/A2A receptor antagonist. The region specific concentration of adenosine
A1 and A2A receptors in the brain suggests that these receptors could play a differential
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role in many behaviors. For instance, the broad distribution of A1 receptors in the brain,
with a relatively high concentration in the hipoccampus (Murphy and Snyder, 1982),
suggests that they may play an important role in memory consolidation (Hauber and
Bareiss, 2001) and possibly, social memories. On the other hand, adenosine A2A
receptors are highly concentrated in olfactory tubercle, and striatum (Fredholm et al.,
2001; Schiffmann et al., 2007; Vontell et al., 2012), regions that are involved in social
behavior, motivation and motor processes (Cabib et al., 2000; Salamone and Correa,
2002; Koch and Hauber, 1998). Thus, the ability of caffeine and selective A1 and/or A2A
receptor antagonists, or genetic deletion, either alone or in combination with ethanol, to
affect social motivation and long-term memory was studied in chapters 3 and 4. The
use of a novel paradigm that allows free allocation of time to explore social versus non-
social stimuli, a situation in which social contact is not possible, gives a measure of
preference that is less affected by anxiety and social patterns like submission-
dominance.
4. Functional co-localization of DA and Adenosine receptors: relevance for the
activational component of motivation.
Mesolimbic DA is an important component of the neural circuitry that regulates
behavioral activation, energy expenditure, and the ability of organisms to overcome
work-related response costs in motivated behaviors (Salamone and Correa 2002, 2009,
2012; Robbins and Everitt 2007; Floresco et al. 2008; Mai et al., 2012). This
activational aspect of motivation can be evaluated with tasks that offer the choice for
distinct reinforcers that can be obtained by instrumental behaviors with different work
requirements. Such tasks include operant procedures offering choices between
responding on ratio schedules for preferred reinforcers versus approaching and
consuming a less preferred food (Salamone et al., 1991, 2002; Randall et al., 2012;
Sommer et al., 2014), and a T-maze barrier task (Salamone et al., 1994; Mott et al.,
2009; Pardo et al., 2012), which are used in the present thesis in the experiment shown
in Chapter 5. Effort discounting tasks (Floresco et al., 2008; Bardgett et al., 2009) also
are described in the literature. Across these tasks, low doses of DA antagonists and
accumbens (NAcb) DA depletions have been demonstrated to shift choice behavior,
decreasing selection of high effort/high reward options, and increasing selection of low
effort/low reward choices (Salamone and Correa, 2002, 2012; Salamone et al., 2015;
GENERAL INTRODUCTION
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Mai et al., 2012; Sommer et al., 2014), leaving the primary value of the reinforcer intact
(Salamone and Correa, 2002, 2012). The study of this activational aspect of motivation
has clinical significance. Symptoms such as lethargy, tiredness or anergia are observed
in many pathologies including depression (Salamone et al., 2016). In fact, patients with
depression also have shown impairments in an effort-based decision-making task
adapted for humans (Treadway et al., 2012).
Considerable evidence indicates that brain adenosine receptor mechanisms interact with
DA systems in the regulation of motivational processes (Salamone and Correa, 2009;
Farrar et al., 2007). In this regard, several recent studies have focused upon the
functional significance of adenosine receptors and their interactions with DA receptors,
in relation to aspects of behavioral activation and effort-related processes (Correa et al.,
2015; Pardo et al., 2012;Yohn et al., 2015; Farrar et al., 2007; Ferré, 2008).
As mentioned before, adenosine receptors are highly expressed in DA rich brain areas
such as neostriatum and nucleus accumbens (Vontell et al., 2010), and adenosine
receptors interact in those areas with DA receptors, having antagonistic effects on
metabotropic intracellular signaling cascades (Ferré, et al., 2008, 2004; Ferré 2008). In
this sense, adenosine A2A agonists have been shown to induce effects that resemble
those produced by DA antagonists or DA depletions, inducing anergia-like effects in an
effort-based decision making task (Font et al., 2008), whereas selective adenosine
antagonists of A2A receptors (and to a much lesser extent of A1 receptors), have been
shown to attenuate anergia-like effects induced by DA antagonists or depletors
(Salamone et al., 2009; Pardo et al., 2012; Nunes et al., 2013; Yohn et al., 2014). In this
regard, a selective A2A receptor antagonist MSX-3 reversed the anergia-like effects
induced by a DA depletor agent (tetrabenazine, TBZ) in concurrent operant /chow
feeding choice tasks and in a T-maze barrier task (Nunes et al., 2013; Randall et al.,
2014; Yohn et al., 2015). The same pattern of results has been observed in different
effort-choice tasks using D2 antagonists combined with the non-selective (A1/A2A)
antagonists caffeine and theophylline (Salamone et al., 2009; Pardo et al., 2012). These
agents restored totally or partially the shift on the choice behavior from the low
effort/low reward option to the high effort/high reward option induced by a DA
antagonist or DA depletor in concurrent choice tasks (Salamone et al., 2009; Pardo et
al., 2012; Nunes et al., 2013; Randall et al., 2014; Yohn et al., 2014). Consistent with
these results, A2A KO mice were protected from the anergia-like effects induced by the
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DA D2 antagonist haloperidol (Pardo et al., 2012; Correa et al., 2015). Although several
adenosine antagonists have been tested and have are effective preventing or blocking
the effects of DA interferences on motivation, the effects of caffeine have not been
widely explored in rodents (Salamone et al., 2009), and the data about its impact on
depression is anecdotal in humans. Thus, chapter 5 summarizes the research about
possible therapeutic actions of the non-selective A1/A2A receptor caffeine on depression,
emphasizing its effects on motivational symptoms. Moreover, a T-maze barrier task for
mice was used to study the impact of caffeine in effort based-decision making. In
addition, in chapter 6, the effects of caffeine are evaluated in a recently developed task
for mice (Correa et al., 2015), a 3-choice running wheel (RW) T-maze task (Correa et
al., 2015), that evaluates preference for activity-based reinforcers, and has shown to be
sensitive to the effects of DA D2 antagonism. Caffeine is proposed as a therapeutic
agent to reverse or attenuate the anergia-like effects induced by DA depletions.
Moreover, intracellular markers of DA and adenosine receptor activation are quantified
in order to explore the predominant role of D1-A1 or D2-A2A receptor interaction on
caffeine-TBZ effects.
5. Functional co-localization of DA and Adenosine receptors: intracellular cascade.
Several lines of evidence indicate that adenosine receptors and DA receptors interact at
the cellular level (Ferré 2008; Ferré et al., 2008; Salamone et al., 2010; Santerre et al.
2012; Nunes et al. 2013). Striatal areas such as neostriatum and nucleus accumbens are
very rich in adenosine A2A receptors and DA D2 receptors, and these two receptors are
co-localized on encephalin positive medium spiny neurons (Demet et al., 2002; Ferré et
al., 2004; 2008). There also is co-localization of DA D1 receptors and adenosine A1
receptors in these brain regions, and these receptors also interact (Ferré 2008; Ferré et
al., 2008). This neuronal co-localization and intracellular convergence can explain why
A2A receptor antagonists are effective in reversing the effort-related actions of D2
antagonists such as haloperidol and eticlopride, and why it is more difficult for
adenosine A1 receptor antagonists to reverse the effects of D2 receptor blockade
(Salamone et al., 2009; Pardo et al., 2012; Hauber et al., 2001).
GENERAL INTRODUCTION
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5.1. DARPP-32 phosphorylation at threonine 34 and 75 as an index of DA
receptor D1 or D2 activation.
As discussed above, a wide range of behavioral studies have been performed in order to
study DA-adenosine interactions, and more specifically characterize the ability of D1-A1
and D2-A2A receptor interactions to modulate the brain circuitry regulating effort-related
decision making (Salamone et al., 2010; Pardo et al., 2012, 2015; Yohn et al., 2014).
Some of these studies have also focused on the effects of this interaction at the
intracellular level (Santerre et al., 2012; Nunes et al., 2013; Svenningson et al., 1999).
It has been observed that a D2 antagonist, haloperidol, induced an increase on cFos
protein synthesis (an index of neuronal activation) and this increase was reversed by
selective A2A antagonists (Santerre et al., 2012; Pardo et al., 2012). This interaction on
cFos was also observed after the administration of haloperidol to KOA2A mice (Correa
et al., 2015; Pardo et al., 2012). Haloperidol induced a shift in effort-based choice in
WT animals but not in KOA2A mice, and it also increased cFos synthesis in WT but not
in KOA2A mice, showing again a relation between intracellular markers of neural
activity and motivated behavior (Correa et al., 2015; Pardo et al., 2012). However, in
order to identify an specific pathway of activation, that is, to understand the
involvement of D1 or D2 DA receptors and A1 or A2A receptors, more specific
intracellular markers should be evaluated.
Dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32) is highly
present in medium spiny neurons (MSNs) in dorsal and ventral striatum projection
neurons (Walaas, 1984; Ouimet et al., 1998; Greengard, 2001). There are two subtypes
of MNS, which selectively express one of two peptides; enkephalin or dynorphin.
Enkephalinergic MSNs predominantly express dopamine D2 and A2A receptors, while
dynorphinergic MSNs, which also express the peptide substance P, predominantly
express dopamine D1 receptors and adenosine receptors of the A1 subtype (Ferré et al.
1997; Agnati et al. 2003). DARPP-32 is phosphorylated after activation of D1-A1 or D2-
A2A receptors and can be used as an index of DA activation (Svenningsson et al., 1997,
2004; Nunes et al., 2013). DARPP-32 function depends on its relative state of
phosphorylation at two main regulatory sites, threonine 34 and 75 (Thr34 and Thr75).
When DARPP-32 is phosphorylated at Thr34 by protein kinase A (PKA) it becomes a
potent inhibitor of protein phosphatase 1 (PP-1), which in turn regulates the
phosphorylation state of several classes of effector proteins including transcription
GENERAL INTRODUCTION
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factors, ionotropic receptors, and ion channels (Greengard et al.,1999). When
phosphorylated at Thr75 by cdk5, DARPP-32 becomes an inhibitor of PKA signaling,
thereby relieving inhibition of PP-1 (Bibb et al., 1999). The phosphorilation of DARPP-
32 at Thr34 or Thr75, seems to be directly related with activation or DA D1 or D2
receptors and also is modulated by adenosine receptors (Nunes et al., 2013;
Svenningsson et al., 1998; 2004; 1999).
Activation of either D1 or A2A receptors increases the activity of adenylyl cyclase and
the resulting increase in cyclic AMP levels activates cyclic AMP-dependent protein
kinase (cAMP-PK), which, in turn results in an increase of the phosphorylated form of
DARPP-32 (pDARPP-32(Thr34)) (Figure 1). In this sense, DA D1 receptor agonist
SKF 81297, or A2A receptor agonist CGS21680, increased pDARPP-32(Thr34)
(Svenningson et al., 1998). This effect was blocked by D2 receptor agonist quinpirole
(Svenningson et al., 1998). However, the D2 antagonist eticlopride increased pDARPP-
32(Thr34), and such effect was not observed in A2AKO mice and in animals pre-treated
with a selective adenosine A2A antagonist SHC58261 (Svenningsson et al., 1999).
Etriclopride-induced increases in pDARPP-32(Thr34) was also decreased by
pretreatment with the D1 antagonist SHC23390 (Svenningson et al., 1999). Moreover,
the D1 antagonist SHC23390 but not the A2A receptors antagonist SHC58261 was able
to abolish the pDARPP-32(Thr34) increase induced by cocaine (Svenningson et al.,
1999). On the other hand, activation of D2 receptors decreases cAMP levels, thereby
increasing pDARPP-32(Thr75), however this pathway has received less attention
(Greengard et al., 1999). It seem that opposite modulation of D1 and D2 and also A2A
receptor agonism or antagonism on DARPP-32 phosphorylation is taking place in
different populations of neurons (Nunes et al., 2013; Svenningon et al., 1998; 1999)
(Figure 1).
In the present thesis (Chapter 6), in order to study the effects of the drugs used in the
behavioral procedures (the DA depleting agent TBZ alone or in combination with
caffeine as a non-selective A1/A2A receptor antagonist) on intracellular markers of
D1/A1 and D2/A2A receptor activity, DARPP-32, pDARPP-32(Thr34) and pDARPP-
32(Thr75) were quantified by western blot.
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Figure 1. Diagram showing the intracellular cascade in the A2A–D2, A1–D1, and A1–A2A receptor
heteromers and effect of DA on DARPP-32 phophorylation. D1 receptor stimulation increases c-AMP
production and PKA activity, which phosphorylates DARPP-32 to yield pDARPP-32(Thr34). D2 receptor
stimulation decreases c-AMP production and PKA activity, which decreases the dephosphorylation of
pDARPP-32(Thr34) and therefore increases on pDARPP-32(Thr75) expression (for details, see
Svenningsson et al., 2004; Bateup et al., 2008; Yger and Girault, 2011; Ferré 2008; Nunes et al., 2013).
5.2. TBZ as a tool to induce anergia-like effects in animal models: impact on
DARPP-32 phosphorlation patterns.
The pharmacological tool used in Chapter 6 to induced
anergia-like effects is the monoamine depleting agent TBZ.
This drug is a selective and reversible inhibitor of vesicular
monoamine transporter-2 (VMAT-2). It blocks storage and
depletes monoamines (Figure 2), but its greatest impact is
upon striatal DA (Pettibone et al., 1984; Tanra et al., 1995;
Nunes et al., 2014). TBZ is used to treat hyperkinetic
movements in Huntington’s disease, but depressive
symptoms including fatigue are major side effects (Frank, 2009, 2010). TBZ has been
used in studies involving animal models of depression (Kent et al., 1986; Wang et al.,
2010), and also has been shown to induce anergia-like effects on effort-based decision-
making tasks in rats producing decreases on selection of high effort/high reward options
and a compensatory increase in selection of low effort/low reward choices (Yohn et al.,
2014; Nunes et al., 2013; Pardo et al., 2015).
Figure 2. Tetrabenazine (TBZ)
mechanism of action.
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Figure 3. TBZ, which depletes DA, was hypothesized to have the opposite effect of DA, increasing
pDARPP-32(Thr75) in substance-P-positive neurons and pDARPP-32(Thr34) in enkephalin-positive
neurons (For more details: Nunes et al., 2013)
TBZ substantially reduced extracellular DA in NAcb core measured by microdialysis,
and also affected DA-related signal transduction in a manner consistent with reduced
NAcb D1 and D2 receptor transmission (Robertson et al., 1992; Santerre et al., 2012;
Nunes et al., 2013). TBZ increased cFos immunoreactivity in NAcb core and shell,
which is consistent with a reduction in D2 transmission (Robertson et al., 1992; Santerre
et al., 2012). In addition, immunocytochemical studies have evaluated the different
forms of phosphorylated DARPP-32 after TBZ administration. This drug significantly
increased NAcb expression of both pDARPP-32(Thr34) and pDARPP-32(Thr75), and
previous results suggest that TBZ-induced increases in pDARPP-32(Thr75) would
reflect reduced transmission at DA D1 receptors, whereas the increase in pDARPP-
32(Thr34) would mark reduced transmission at D2 receptors (Svenningsson et al., 2004,
1999; Bateup et al., 2008; Yger and Girault, 2011; Nunes et al., 2013) (see Figure 3).
Nunes et al., (2013) showed an increase pDARPP-32(Thr34) and pDARPP-32(Thr75)
in NAcb after TBZ administration in rats. Administration of the selective adenosine A2A
antagonist MSX-3 reversed the increase of pDARPP-32(Thr34) but not the pDARPP-
32(Thr75) increase induced by TBZ (Nunes et al., 2013). Again, this was consistent
with studies showing that adenosine A2A receptors are co-localized with D2 receptors on
enkephalin positive neurons, but not with D1 receptors on substance-P positive neurons
(Svenningsson et al., 1999), and that A2A and D2 receptors can form heteromers and
interact via convergence onto c-AMP signal transduction cascades with opposite effects
(Ferré et al., 2008; Svenningsson et al., 1999). Moreover, TBZ at the same doses used in
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the immunochemical study, shifted response choice in rats, producing a decrease in
lever pressing and a concomitant increase in chow intake in the concurrent fixed-ratio
5/chow feeding choice task (Nunes et al., 2013) and this effect was reversed by MSX-3
(Nunes et al., 2013). Thus, these markers can be studied as an index of DA-adenosine
activity in the context of the study of motivation, and probably are involved in the
behavioral effects observed after DA-adenosine manipulations, as suggested by
previous studies showing that DARPP-32-KO mice are less sensitive to catalepsy
induced by a DA D2 antagonist (Fienberg et al., 1999).
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OBJECTIVES
The present dissertation reviews and studies the role of caffeine as a non-selective
adenosine A1 and A2A receptor antagonist in different mood and motivational processes.
The effects of caffeine will be compared with other selective and non-selective
adenosine antagonists.
Because ethanol is often consumed in combination with high doses of caffeine, and
since ethanol increases adenosine levels, several studies will address the interacting
effects of both substances on a motivated behavior that is also modulated by anxiety,
i.e., social interaction.
Adenosine receptors are co-localized with DA receptors and their activation leads to
functionally opposite effects. Thus, a second group of studies will evaluate the
interaction between caffeine and a DA depleting agent on the activational component of
motivation and its implications for depression.
Chapter 1 reviews human and animal studies that have focused so far on the behavioral
interaction between caffeine and ethanol, explaining the potential mechanism of action
for the interaction.
Chapter 2 compares the effect of high doses of caffeine and its active metabolite
theophylline (also present in some “energy drinks”), on behavioral activation,
coordination, anxiety and endocrine parameters.
Chapters 3 studies the effect of a broad range of doses of caffeine and selective
adenosine antagonists on their own or in combination with ethanol in order to explore
the adenosinergic substrate underlying the effect of caffeine-ethanol combinations,
focusing on their effects on social motivation and long-term social memory.
Chapter 4 evaluates the impact of A2A receptor deletion on social interaction and its
interaction with ethanol. The impact of the A2A deletion on social interaction will be
compared to its effect on anxiety.
Chapter 5 reviews the literature about the possible therapeutic effects on of caffeine on
depression in humans. In addition it reviews animal data on the impact of caffeine and
selective adenosine antagonists on animal models of depression, including a study about
the impact of caffeine on anergia-like impairments induced by a DA depleting agent
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(tetrabenazine (TBZ), which is known to induce symptoms of depression in humans),
using a T-maze barrier choice task for mice.
Chapter 6 explores the effect of caffeine on motivational impairments induced in mice
by a DA depleting agent (TBZ), using a novel 3-choice T-maze task for the assessment
of preferences between reinforcers with different effort demands. Intracellular markers
of DA receptor activity are also evaluated in order to assess the interaction between D2-
A2A or D1-A1 receptors after TBZ-caffeine administration.
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The Impact of Caffeine on the Behavioral Effects of Ethanol
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28
CHAPTER 1
29
Journal of Caffeine Research. 2013;3(1):9-21.
doi: 10.1089/jcr.2013.0003
The impact of caffeine on the behavioral effects of ethanol related to abuse and
addiction: a review of animal studies.
López-Cruz L1, Salamone JD2 and Correa M1,2,*.
1Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, 12071 Castelló, Spain
2Department of Psychology, University of Connecticut, Storrs, CT, USA 06269-1020
Running title: Caffeine and ethanol interaction: animal studies
*Corresponding author: Mercè Correa, Ph.D.
Àrea de Psicobiologia, Universitat Jaume I,
Campus Riu Sec, 12071 Castelló, Spain.
Tel: +34-964-729841.
Fax: +34-964-729267.
E-mail address: correa@psb.uji.es
CHAPTER 1
30
Acknowledgments: This research was supported by a grant from Plan Nacional de
Drogas (2010/024), and from Ministerio de Educación, FPU (AP2010-3793), Spain.
CHAPTER 1
31
ABSTRACT:
The impact of caffeine on the behavioral effects of ethanol, including ethanol consumption
and abuse, has become a topic of great interest due to the rise in popularity of so-called
“energy drinks”. Energy drinks high in caffeine are frequently taken in combination with
ethanol under the popular belief that caffeine can offset some of the intoxicating effects of
ethanol. However, scientific research has not universally supported the idea that caffeine
can reduce the effects of ethanol in humans or in rodents, and the mechanisms mediating
caffeine-ethanol interactions are not well understood. Caffeine and ethanol have a common
biological substrate; both act on neurochemical processes related to the neuromodulator
adenosine. Caffeine acts as a non-selective adenosine A1 and A2A receptor antagonist,
while ethanol has been demonstrated to increase the basal adenosinergic tone via multiple
mechanisms. Since adenosine transmission modulates multiple behavioral processes, the
interaction of both drugs can regulate a wide range of effects related to alcohol
consumption and the development of ethanol addiction. In the present review we discuss
the relatively small number of animal studies that have assessed the interactions between
caffeine and ethanol, as well as the interactions between ethanol and subtype selective
adenosine receptor antagonists, in order to understand the basic findings and determine the
possible mechanisms of action underlying caffeine-ethanol interactions.
KEYWORDS: ethanol intake, energy drink, adenosine, methylxanthine, anxiety,
locomotion, withdrawal.
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1. Caffeine as a modulator of ethanol abuse
Caffeine and ethanol are widely consumed recreational drugs.1,2 Alcohol abuse is a
worldwide health problem, with serious medical, economic, and social consequences.3,4 On
the other hand, caffeine intake, even in excess, appears to be relatively well accepted
because methylxanthines have activating and attention preserving properties that can help
productivity and enhance performance. Interest in caffeine has grown ever since the
introduction to the market of the so-called “energy drinks”, which contain caffeine and
related substances in quite high concentrations. These drinks are being increasingly
consumed, often in combination with substances that have abuse potential.5 In addition,
research with animals has demonstrated the ability of methylxanthines, and in particular
caffeine, to modulate the psychopharmacological effects of drugs of abuse such as
methamphetamine6, amphetamine7, nicotine8,9, cocaine10, and ethanol.11 The reasons for
combining caffeine with ethanol may stem from the popular belief that caffeine can
antagonize the intoxicating effects of alcohol.12 Some studies have supported this
hypothesis, demonstrating that caffeine attenuates ethanol-induced changes in
psychological parameters in humans such as information processing, memory,
psychomotor performance, and others (for a review13).
Caffeine has been shown to indirectly modulate the activity of many neurotransmitters and
neuromodulators, including dopamine, acetylcholine or glutamate14-17 in various brain
areas. But in terms of direct actions, caffeine is most widely described as an adenosine
receptor antagonist that is nonselective for A1 and A2A subtypes of adenosine receptors in
the central nervous system (CSN). 1,17-19 Several papers have demonstrated that there are
interactions between adenosine and ethanol. Ethanol can increase extracellular adenosine
levels by increasing adenosine release20,21, and by decreasing adenosine uptake22 that takes
place via a facilitative nucleoside transporter.23,24 Inhibition of this transporter in the
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presence of ethanol would lead to an increase in extracellular adenosine and could thereby
modulate some of the effects of ethanol.21 Secondarily, ethanol increases adenosine levels
because acetate generated by ethanol metabolism promotes adenosine synthesis25 (see
Figure 1).
Fig. 1. Schematic showing ethanol regulation of adenosine production (1) release (2), and uptake (3), as well
as caffeine blockade of adenosine receptors (4) in the CNS. Abbreviations: A1R and A2AR, adenosine A1 and
A2A receptors; ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; ATP, adenosine triphosphate;
AMP, adenosine monpohospahte; CAT-H2O2, catalase; CYP-2E1, cytochrome P4502E1; ENT, equilibrative
nucleoside transporters.
In contrast to the studies showing that caffeine can blunt the effects of ethanol, there also is
evidence that fails to support the idea of an antagonistic behavioral interaction between
caffeine and ethanol, either in humans26,27 (for review13), or in rodents.28,29,30 A
considerable number of studies employing experimental animal models have been
performed to elucidate the impact of caffeine on the effects of ethanol and on ethanol
consumption. In the present review we have emphasized those studies addressing
behaviors that can be relevant for the development of alcohol consumption, abuse, and
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addiction as a compulsive habit, as well as studies that evaluate signs of dependence after
withdrawal, such as physical abstinence and craving, which are factors that can lead to
relapse.
Drug addictions, including alcoholism, can be conceptualized as disorders of motivation
characterized by an excessive control of the drug over behavior.31-33 This disorder involves
a reorganization of the preference structure of the person, dramatic changes in the
allocation of behavioral resources towards the addictive substance34,35, and alterations in
the elasticity of demand for the drug.36 Typically, there is a heightened tendency to engage
in drug-reinforced instrumental behavior and drug consumption, often at the expense of
other behavioral activities. Addicts will go to great lengths to obtain the drug, overcoming
numerous obstacles and constraints. In addition, the development of addiction is attributed
to a profound sensitization in the neural processes that mediate drug-seeking behavior,
which can facilitate the incentive properties of drugs and drug-related stimuli as the
addiction process proceeds.37,38 Thus, as addiction progresses, the drug itself, as well as
drug-associated stimuli, trigger an automatic seeking response that ultimately resolves in
the consumption of the drug. This automatism has compulsive characteristics that are
devoid of instrumental feedback, leading to the formation of drug-related habits.39,40 Thus,
addiction is a very complex set of behavioral and physiological processes that range all the
way from drug consumption, to tolerance for some effects, sensitization of motor activity,
establishment of implicit and explicit learning, initial sensitivity to reward and punishment,
attention shifts, responsivity to Pavlovian cues, and other processes.
In the present review, studies addressing the impact of caffeine on some of those behaviors
modulated by ethanol will be summarized. Because the opposing actions of ethanol and
caffeine on the adenosine system, studies focusing on the effects of selective adenosine
receptor agonists and antagonists and their interaction with ethanol will be also presented
in an attempt to shed light upon potential receptor mechanisms involved.
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2. Caffeine-ethanol interactions: effects on locomotion
Evaluation of the behavioral stimulant or suppressant actions of drugs is frequently
conducted by analyzing the locomotor activity of animals.41,42 Although ethanol is
generally classed as a sedative-hypnotic and caffeine is considered to be a minor stimulant,
both drugs are able to stimulate locomotor activity in rodents at some dose43-48, typically
with bell-shaped (or inverted-u) dose response functions. Rodents (more in mice than rats)
show a time- and dose-dependent locomotor response to acute ethanol administration, with
low doses stimulating and high doses reducing locomotion.46,49-52 Methylxanthines such as
caffeine also can affect locomotor activity in a biphasic way.53-56 However, few studies
have evaluated caffeine-ethanol interactions using locomotion as a measure.51,53,57,58
Waldeck (1974) evaluated the effect of ethanol (1, 3 or 4 g/kg, intraperitoneal; IP) and
caffeine (25, 50 or 100 mg/kg, IP) on locomotor activity in female mice, and observed that
a moderate dose of caffeine (25 mg/kg) that stimulated locomotion also potentiated the
stimulation induced by ethanol administered at the lowest dose (1 g/kg), although it
abolished the stimulant effect of a higher dose of ethanol (3 g/kg). On the other hand, a
motor suppressant dose of caffeine (100 mg/kg) totally blocked the stimulant effect of
ethanol (1 g/kg). Moreover, the motor suppressant effect of the higher dose of ethanol (4
g/kg) was potentiated by all doses of caffeine employed51. These results with female mice
are in close agreement with the observations obtained from cats reported by Pilcher (1911).
This author concluded that “when small doses of caffeine and alcohol are combined, the
result is generally a qualitative algebraic summation of both actions, i.e. each drug
produces, qualitatively, its ordinary effects. However, when large doses of the two drugs
are combined, the effects of the stimulant drug tend to be reversed, resulting in a greater
suppression than the suppressant drug alone”.57
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Oral administration of both drugs in mice could be a useful tool for studying the effects of
ethanol-caffeine interactions, since both drugs are consumed orally in humans. Indeed, as
mentioned above, energy drinks contain high concentrations of caffeine, and their
consumption in combination with alcoholic beverages is a common practice among young
people. The popular belief suggests that, in humans, energy drinks could reduce the
intensity of the motor suppressant effects of ethanol.26 However, only one study has
explored the effects of ethanol on the stimulant effects of energy drinks in animal
models.59 In this study done in mice, the oral administration of energy drinks did not
significantly alter the effects of moderate oral doses of ethanol (0.5, 1.0 or 1.5 g/kg), but
was able to reduce the suppressant effects of a higher dose of ethanol (2.5 g/kg). It is
possible that in this study some effects could be attributed to other stimulant components
of the energy drinks, such as taurine, which has been shown to interact with ethanol on
locomotion.60,61 However, acute oral co-administration of caffeine at a low dose (10
mg/kg) combined with ethanol (1.6, 2.4 and 3.2 g/kg) was demonstrated to increase
locomotor activity compared with the effect observed after separate administration of each
individual drug.53
It is also relevant to consider the effects of acute administration of caffeine or ethanol on
the chronic actions of these substances.58,62-64 Chronic caffeine intake reduces spontaneous
locomotion in mice62, and rats.58 However, chronic caffeine consumption (0.1% during 30
days) increased sensitivity (relative to water consumption) to the activating effects of an
acute dose of ethanol (1.5 g/kg, IP) in rats.58 In contrast, in mice exposed to chronic
caffeine (1 g/L during 7 days), acute doses of ethanol (1.5 and 2.5 g/kg, IP) significantly
induced locomotion, but never to the level of animals in the water control group.62-64
Furthermore, acute caffeine administration (10-35 mg/kg) increased locomotion to a
similar extent in mice chronically consuming ethanol (5%, v/v) and those in the water
control group (in this case ethanol did not affect spontaneous locomotion). Thus, chronic
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consumption of ethanol did not change the acute stimulant effects of caffeine.62 The same
pattern of results was found after acute administration of 5'-N-ethylcarboxamidoadenosine
(NECA), an adenosine agonist with high affinity for both A1 and A2A adenosine receptors.
In this case, NECA suppressed locomotion in a similar manner in mice chronically
consuming either water or ethanol.62
Adolescence is a vulnerable time for organisms exposed to drugs of abuse such as
ethanol.65 It is widely acknowledged that the human adolescent brain is not fully
mature66,67, and there is evidence from animal studies that exposure to alcohol during
adolescence can affect subsequent brain/behavior development.68,69 Voluntary consumption
of ethanol (at a concentration of 8.5 g/L that led to a dose of 1.0-1.5 g/kg), caffeine (at a
concentration of 170 mg/L that led to a dose of 20-30 mg/kg), or an ethanol-caffeine
combination during late adolescence in male and female rats had effects on subsequent
adult behavior that were dependent on the sex of the rats.70 Males showed more ambulation
following exposure to the alcohol-caffeine mixture, while females exposed to the mixture
showed the opposite effects, i.e., suppressed ambulation.70 This pattern of results could be
related to sex differences in the sensitivity to the neurotoxic effects of caffeine.71 In
hippocampal cultures pre-exposed to 5 mM ethanol for 10 days, caffeine (5 or 20 µM)
produced greater neurotoxicity in cultures from female tissues than from male ones,
specifically in the dentate gyrus and CA1 region.71 These results demonstrate the
importance of including both sexes in investigations of this sort.
In summary, the interacting effects of caffeine and ethanol on locomotor activity are quite
complex. It seems that at low doses, acute caffeine administration can increase the
stimulant effects of acute doses of ethanol. However, when caffeine or ethanol doses are
higher, a potentiation of the suppressant effects of both substances is most evident. On the
other hand, chronic administration of either substance does not appear to change the acute
doses at which locomotion can be stimulated.
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3. Caffeine-ethanol interactions: effects on motor coordination
At medium to high doses, a typical action of ethanol is to impair motor coordination.72-76
This effect generally shows tolerance with repeated ethanol exposure.77,78 The
development of tolerance appears to be relevant for the emergence of ethanol abuse and
dependence, because it can attenuate the performance impairing effect of the drug, which
promotes the use of escalating doses.79 Several studies have investigated the ability of
caffeine to modulate ethanol-induced motor incoordination and have explored the possible
involvement of adenosine receptors.28,29,76,80-82
A single injection of a broad range of doses of caffeine (5 - 75 µg) administered in the
brain ventricles (ICV) or peripherally (2.5 - 62.5 mg/kg, IP) did not alter motor
coordination in mice evaluated in the rotarod test.80,81 However, pretreatment with low
doses of caffeine (2.5-25.0 µg ICV, or 2.5-5.0 mg/kg IP) was effective in decreasing the
degree and duration of motor incoordination produced by a single dose of ethanol (2 g/kg,
IP). The antagonism by caffeine of ethanol-induced motor incoordination was dose related,
since higher doses of caffeine (75 µg ICV, or 62.5 mg/kg IP) enhanced ethanol-induced
motor incoordination.80,81 The methylxanthine (and caffeine metabolite) theophylline was
less potent, but dose-dependently attenuated (100-150 µg, ICV, 50 mg/kg IP) the motor
incoordinating effect of acute ethanol (1.5-2 g/kg, IP).73,74 On the other hand, potentiation
of ethanol-induced ataxia was also observed after pretreatment with another
methylxanthine, 3-isobutyl-1-methylxanthine (IBMX).81
Chronic oral administration of caffeine for 10 days (45 and 90 mg/kg/day) and IBMX (30
and 60 mg/kg/day), potentiate acute ethanol-induced motor incoordination (1.5 g/kg, IP),
an effect that was associated with increased adenosine A1 receptor binding compared to tap
water controls.28 However, no interaction with ethanol-induced motor incoordination (1.5
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g/kg, IP) was observed after chronic theophylline (75 and 150 mg/kg/day) consumption.28
This lack of effect of chronic theophylline on motor incoordination induced by ethanol was
paralleled with the lack of changes in A1 receptor density.28
More recently, it has been demonstrated that acute oral co-administration of caffeine (20
mg/kg) and ethanol (2.5 g/kg) attenuated the ethanol-induced motor impairment in rats
evaluated in the accelerating rotarod.29 This effect was also observed after acute IP
administration of an A1 selective receptor antagonist (8-cyclopentyl-1,3-dipropylxanthine;
DPCPX) injected after oral ethanol administration, but not with an A2A selective receptor
antagonist 2-(2-Furanyl)-7-(2-phenylethyl)-7H- pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidin-5-a mine (SCH 58261), suggesting again that A1 adenosine receptors are
involved in motor incoordination induced by ethanol.29 However, microinfusions of both
the A1 receptor-selective agonist cyclohexyladenosine (CHA) and the A2A selective agonist
5’-Nethylcarboxamido-2-[2-(4-phenyl-(3-propanoic acid)] (CGS21680) into the rat motor
cortex significantly accentuated motor incoordination induced by ethanol (1.5 g/kg IP) in a
dose-related manner.76 CHA was more potent than CGS21680 in producing this effect.
However, the potentiation induced by A1 and A2A agonists was attenuated by the A1-
selective antagonist DPCPX but not by the A2A receptor-selective antagonist 8-(3-
chlorostyryl)caffeine (CSC), further emphasizing the involvement of the adenosine Al
receptor subtype in these effects.76
The involvement of different adenosine receptors in the development of rapid tolerance to
ethanol-induced motor incoordination in mice has also been evaluated.82 A single
administration of caffeine (3, 10 or 30 mg/kg, IP) or selective antagonists of A1 or A2A
receptors did not change the performance of animals treated with ethanol (2.5 g/kg) on the
first day of testing. However, caffeine administered on the first day was able to block the
development of tolerance to ethanol that was manifested on the second day. Moreover,
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caffeine’s blockade of the rapid tolerance to ethanol-induced incoordination appears to be
mediated by A1 rather than A2A receptors, because DPCPX but not 4-(2-[7-Amino-2-(2-
furyl)[1,2,4]tri azolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385) also
blocked rapid tolerance. These data are in agreement with previous studies29,76, and it is
reasonable to suggest that this effect may be due to the high number of A1 receptors in
areas controlling motor coordination, such as the cortex and cerebellum.83
To summarize, acute low doses of caffeine can reduce the incoordination effects of
ethanol, but high doses of caffeine can potentiated them. Moreover, adenosine A1 receptors
appear to be more important for these effects than A2A receptors. The ability of caffeine to
attenuate the rapid tolerance to ethanol-induced incoordination effects also has been
attributed more to A1 than A2A receptors.
4. Caffeine-ethanol interactions: sedation and narcosis
Ethanol intoxication produces sedative and, at high doses, even hypnotic effects.72,84-86 In
contrast, caffeine enhances wakefulness and alertness, effects that are associated with its
ability to block adenosine receptors.87-91 Although the effects of ethanol or caffeine on
sedation and alertness have been widely described, their interaction is much less well
characterized, and only a few studies have explored the impact of caffeine on the narcosis
or loss of the righting reflex (LORR) induced by ethanol in rodents.28,92-95
For example, it has been demonstrated in mice that when coffee (15 mg/ml) or caffeine
(0.5 mg/ml) were orally administered before ethanol (75% v/v), the latency to LORR
increased.92 However, this effect was not observed when caffeine was administered after
ethanol. Moreover, this effect was not due to pharmacokinetic interference, since no
decrease in plasma ethanol levels was detected in mice pretreated with coffee or caffeine.92
In another study in mice, an intermediate dose of caffeine (25 mg/kg, IP) administered
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before an IP injection of narcotic doses of ethanol also blunted the effect of ethanol, in this
case by reducing the duration of LORR.93 This effect was not seen with higher doses of
caffeine (40-100 mg/kg).81,93 Theophylline (50 mg/kg, IP), produced the same pattern of
effects, prolonging the onset and shortening the duration of ethanol-induced LORR81,73,
however IBMX (12.5 mg/kg IP) did not altered LORR induced by ethanol.81
Comparisons between caffeine and theophylline have also been conducted in long-sleep
(LS) and short-sleep (SS) mice, which are selectively bred for differences in sensitivity to
the LORR induced by ethanol but also have differential sensitivity to purinergic agonists
and antagonists.94 LS and SS mice showed differences in sensitivity to the non-selective
adenosine antagonists, theophylline and caffeine.95 These drugs also produced a distinct
pattern of effects in the two strains of mice; while theophylline reduced the duration of
LORR induced by ethanol in both strains of animals (at a broader range of doses in LS
mice), caffeine only did so in LS mice. Moreover, caffeine at doses of 10 and 20 mg/kg
increased LORR in SS mice. Theophylline did not change blood or brain ethanol
elimination rate, but the effects of caffeine on blood ethanol levels were affected.95 The A1
receptor-selective agonists CHA and l-phenylisopropyladenosine (PIA), as well as the non-
selective A1-A2A agonists, 2-chloroadenosine (CAD) and N-ethylcarboxamidoadenosine
(NEC), increased LORR in both LS and SS mice.95 In general, LS mice were more affected
than SS mice by purinergic drugs, suggesting that there may be differences in the
adenosine systems of these lines of mice; this observation may aid in understanding how
they differ in ethanol sensitivity as well.
As discussed above, adenosine is involved in mediating many of ethanol’s intoxicating
effects, such as ataxia 74,96,97 and sedation (for review98,99). However, in rodents, adenosine
analogues seem to increase LORR only during interactions with hypnotic drugs, rather
than causing a direct deep hypnotic effect or unconsciousness.100 Thus, dipyrimadole (30-
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40 mg/kg IP), an inhibitor of adenosine uptake, increased duration of LORR in mice only
following the administration of hypnotic doses of ethanol (3.5-4.0 g/kg, IP).73,93 In regard
to the specific adenosine receptors implicated in the modulation of the hypnotic effects of
alcohol, more recent studies using novel selective A2A antagonists suggest that A2A rather
than A1 receptors seem to mediate this effect. The A2A antagonist SCH58261 but not the
A1 antagonist DPCPX blocked LORR induced by ethanol.93 In addition, female and male
mice lacking the adenosine A2A receptor (i.e., A2A KO mice) showed a reduced duration of
LORR compared to their wild-type (WT) siblings after ethanol administration.93,101
In summary, adenosine agonists seem to potentiate the duration of LORR, while adenosine
antagonists reduce LORR induced by high doses of ethanol. In general, non-selective
adenosine receptor antagonists, as well as selective A2A antagonism or genetic deletion,
reduce ethanol induced LORR.
5. Caffeine-ethanol interactions: effects on learning and memory.
High doses of ethanol can also cause learning impairments, amnesia, or impaired retrieval
of information, effects that can persist long after the drug wears off.102-104 Complete or
partial memory impairment occurs commonly from episodes of binge drinking in both
alcoholics and nonalcoholics.105 This memory impairment may reflect a disruption of
encoding, storage, consolidation, and/or retrieval capability.106,107 Other studies have
shown that moderate doses of ethanol delivered after learning generally enhance or have
little effect on memory examined the next day108,109, and caffeine at moderate doses has
been shown to facilitate memory acquisition and retention in animals assessed on various
learning tasks.110-113
A few papers have focused on the interaction between caffeine and ethanol on memory in
rodents.114,115 Ethanol and caffeine co-administration has demonstrated to be
neuroprotective in different models of ischemia.114,116,117 Thus, an acute administration of
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caffeinol (combination of 10 mg/kg caffeine plus 0.65 g/kg alcohol, IP) 15 minutes after
traumatic brain injury in rats, produced an improvement in working memory tasks in the
Morris water maze, compared to vehicle treated animals.114 This protection was not due to
effects on motor performance.
Retrograde amnesic effects of ethanol, caffeine or a combination of both agents have been
evaluated in rats with an olfactory memory test that uses social odors.115 A high dose of
ethanol (3.0 g/kg, IP) administered after exposure to a novel odor produced memory recall
or retrograde memory impairments the following day, and caffeine (5 mg/kg, IP), either 20
min before or 1 h after exposure to the novel odor prevented this ethanol disruption in
recognition memory.115
In humans, ethanol and caffeine can also produce state-dependent memory effects.118,119
State dependent learning or memory is the term applied to the condition in which a
behavior that is learned in a drug state is most readily recalled when the organism is in the
same drug state.120 In rodents, administration of ethanol before training can impair the
retrieval of tasks learned in a state- dependent manner, which is reversible by re-
administering ethanol before the retrieval test.121,122 This type of study also reflects the
ability of ethanol to serve as an interoceptive cue that can aid learning and performance of
a specific operant response.123 Defined in this way, acute ethanol administration can exert
state-dependent effects on conditioned avoidance responding.124,125 However, caffeine (100
mg/kg, IP) does not change the performance of rats already trained to discriminate the
interoceptive cue produced by ethanol administration (1.5 g/kg, IP) in an active avoidance
task performed in a typical 3-chamber apparatus.126
The interaction between caffeine and ethanol also has been evaluated using the acquisition
of an avoidance task performed in a plus-maze discrimination apparatus.127 This apparatus
uses an elevated plus-maze consisting of two opposing open arms and two opposing
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enclosed arms. During training, animals are free to explore all four arms but are
conditioned to avoid one of the enclosed arms (the aversive arm) by the presentation of
both light and white noise stimuli when they enter that arm. During the testing session (24h
after the training session), animals are free to explore all four arms again, but no cues are
presented. Time in the aversive arm was used as an index of memory. Ethanol alone (1.0
and 1.4 g/kg, IP) or in combination with caffeine (20 and 40 mg/kg, IP) administered
before the training session produced a learning deficit manifested during the test session.
Only the highest dose of caffeine alone (40 mg/kg) produced that effect. However, that was
not due to a state-dependent effect since the administration of this dose of caffeine before
the test did not reverse the learning deficit.127
Caffeine also does not change the conditioned avoidance of a sweet solution produced by
ethanol. This conditioned taste avoidance (CTA) is produced by administering an acute
dose of ethanol following voluntary consumption of sacharine, and is observed as a
reduction in saccharine consumption the following day.128 Caffeine (2.5-10 mg/kg, IP) did
not block the association between taste and ethanol effects (1.0-1.5 g/kg, IP), thus
saccharine consumption was not restored. However, caffeine by itself was able to produce
CTA at a moderate dose (20 mg/kg, IP).128
Taken together, these studies indicate that caffeine appears to prevent explicit memory
deficits induced by high doses of ethanol, but does not affect the perception of the
interoceptive cue generated by ethanol, and it does not prevent the disruptive effects of
ethanol on avoindance learning in discriminative procedures, suggesting a lack of effect of
caffeine on implicit learning processes regulated by ethanol.
6. Caffeine-ethanol interactions: effects on anxiety and stress
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Considerable evidence indicates that ethanol is capable of reducing anxiety levels in
humans and other animals129-131, and adenosine has been proposed as a mediator of this
anxiolytic effect.132-134 In this regard, adenosine itself, as well as adenosine receptor
agonists, have anxiolytic effects as assessed by a number of ethological tests in rodent
models.135,136 On the other hand, methylxantines such as caffeine and theophylline have
been demonstrated to increase anxiety in humans137-140 and in rodents in different anxiety
paradigms.127,141-144
Caffeine modulation of the effects of ethanol on anxiety has been explored in a handful of
studies70,127,132, which also assessed the role of adenosine receptor subtypes in this
interaction. Thus, caffeine, across a broad range of doses that extended into the anxiogenic
range (10-40 mg/kg) was shown to reduce the anxiolytic-like effect of ethanol (1.0-1.4
g/kg, IP) in the elevated plus-maze in mice.127,132 The effects of caffeine on acutely
administered ethanol appeared to be mediated by A1 adenosine receptors, since the
selective adenosine A1 receptor antagonist DPCPX but not the A2A receptor antagonist
ZM241385 significantly reduced the anxiolytic-like effect of ethanol (1.2 g/kg).132
Moreover, an anxiolytic response was observed after co-administration of non-anxiolytic
doses of the A1 adenosine agonist 2-Chloro-N6-cyclopentyladenosine (CCPA) and
ethanol.132
A different pattern emerges when these substances are administered chronically. The
anxiety-related effects of chronic oral consumption of alcohol (1.0-1.5 g/kg) combined
with oral consumption of caffeine (20-30 mg/kg) during adolescence was evaluated in
male and female rats when they reached mid-adulthood.70 Males that had previously
consumed alcohol plus caffeine showed anxiolysis in the light and dark box and in the
open field. However, females exposed to the drug mixture showed an anxiogenic-like
effect.70 Thus, as described above, results in females and males seem to be opposite.
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Caffeine and ethanol not only regulate anxiety-like behavior, but also regulate stress
responses involving activation of the hypothalamo–pituitary–adrenal (HPA) axis.144-151
HPA axis activation ultimately leads to increases in the biosynthesis and systemic secretion
of adrenocorticosteroids. The effects of alcohol and other drugs of abuse on this axis are
relevant because a link between the stress response and drug abuse and addiction has been
observed. Stress is one of the main factors stimulating drug consumption and the relapse to
drug taking in abstinent addicts.152,153 Furthermore, chronic drug exposure affects the brain
stress response systems. Thus, drug abuse is often accompanied by enhanced brain stress
responses, which in turn may contribute to the addiction process.153
In regard to ethanol and caffeine, moderate acute doses of ethanol145-148 or caffeine144,149-151
have been shown to increase plasma corticosterone levels in rodents and cortisol in
humans. But only one study so far has explored the interaction of caffeine and ethanol on
corticosterone release.154 In this study, a low dose of caffeine (5 mg/kg IP) delivered before
a low dose of ethanol (0.8 g/kg IP) elevated plasma corticosterone levels. This increase
was not observed after ethanol or caffeine were administered alone.154
In summary, more studies need to evaluate this complex interaction, but so far, the
evidence suggests that caffeine and ethanol can counteract each other’s effects on acute
anxiety levels in rodents, and some of this evidence points to A1 adenosine receptors as
being responsible for the anxiolytic effects of ethanol as well as of the reversal of this
effect by caffeine. It would be very important to have a clearer view of the interaction
between these substances after chronic consumption, because tension reduction theories
suggest that the anxiolytic effects of alcohol facilitate alcohol use by anxious
individuals.155,156 Moreover, a growing body of evidence shows that corticosterone may
directly modulate alcohol drinking.157-160
7. Effect of caffeine on alcohol self-administration
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Epidemiology studies have shown that a positive correlation may exist between the
consumption of caffeine and that of ethanol.161,162 Moreover, it has been demonstrated that
people who use energy drinks consume alcohol more frequently than people who do not
(for review13). Studies in rodents have shown a complex relationship between caffeine and
ethanol intake.11,163-165 Caffeine administered in the diet of malnourished female rats has
been shown to facilitate voluntary ethanol drinking in a free access two-bottle paradigm163-
164
, and removal of caffeine from the diet restored alcohol consumption to baseline levels.
This effect was not taste-related, because quinine did not produce the same pattern as
caffeine.164 However, slow-release caffeine pellets (200 mg/day during 21 days) failed to
alter ethanol intake in an un-limited free choice paradigm in female rats.166. This lack of
effect was specific to caffeine, since slow-release pellets containing other stimulants did
increase ethanol consumption.166 Caffeine administered acutely did not produce a
consistent pattern of effects; a low dose of caffeine (5 mg/kg, IP) promoted ethanol
drinking in male rats using a limited-access two-bottle choice paradigm.11 However, a high
acute dose of caffeine (50 mg/kg, IP) decreased ethanol as well as food intake in deprived
male and female rats.167 The lack of caffeine effects on ethanol intake has been also
demonstrated in a recent study.168 The presence of caffeine (1g/L) in alcoholic solutions
(10% v/v) did not increase the ethanol consumption of male rats exposed to a free-choice
procedure during 50 days. Interestingly, it did prevent the alcohol deprivation effect
(ADE), blocking an increase of ethanol intake after an abstinent period of 7 days.168
Because ADE has been suggested as an animal model of human alcohol craving and
relapse169, the effect of caffeine on such effect is a very relevant finding.
Research on the role of adenosine receptor subtypes in ethanol intake has mainly focused
on A2A receptors. Ethanol intake and preference was increased in male and female KOA2A
mice compared to their WT counterparts in a free choice task.101 Results in the same
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direction have been observed in studies employing pharmacological manipulation of
adenosine transmission. Both acute and subchronic (7 days) IP administration of the A2A
receptor antagonist 8-Ethoxy-9-ethyl-9H-purin-6-amine (ANR94) increased levels of
ethanol intake in alcohol-preferring rats assessed in a free choice task.170 Conversely, a
reduction of ethanol intake was observed after acute IP administration of the A2A receptor
agonists CGS21680 and 5′-N-ethylcarboxamido-2-(2-phenethylthio (VT7).170
The involvement of adenosine A2A receptors in ethanol seeking and intake also has been
evaluated in operant chambers in which animals have to exert various levels of effort to
have access to ethanol (e.g. lever pressing on fixed ratio (FR) schedules ranging from FR1
to FR3.170-173 In this case, the pattern of effects produced by different A2A receptor
antagonists was more complex. While SCH58261 reduced the number of ethanol-
reinforced responses and ethanol consumption173, ANR94 increased responding.170
Moreover, DMPX had a multiphasic effect on the number of lever presses and amount of
ethanol consumed during operant self-administration.171,172 The A2A agonists CGS21680
and VT7 decreased lever pressing and alcohol consumption in alcohol-preferring rats
tested on a FR1 schedule.170 Using the same behavioral procedure, no effect was observed
with an adenosine A1 antagonist DPCPX.171,173
Taken together, it appears that the results so far are not conclusive. The specific effects of
adenosine antagonism on ethanol self-administration may depend on factors such as food
restriction, sex, ethanol-intake or reinforcement paradigms, or other factors. For instance, it
has been suggested that the suppressive effects of caffeine on ethanol intake seen in some
studies could be due to the use of high toxic doses of caffeine.166,167 However, the fact that
chronic caffeine blocked the ADE effect168 suggests that caffeine could be promising as a
treatment for protrective abstinence, although more studies should assess this point.
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Free intake
Drug Mechanism of
action Sex/Species
Ethanol
concentration
Ethanol
Intake Refs.
Caffeine
Non selective
antagonist
A1/A2A
Male and
female rats 10% (v/v) Increase 11, 163,164
Male and
female rats
5% (w/v)
10% (v/v) Decrease 166, 167
Male rats 10%(v/v) No effect 168
ANR94 A2A antagonist Male alcohol-preferring rats 10% (v/v) Increase 170
A2A genetic deletion Male andfemale mice 3%-20% (v/v) Increase 101
CGS 21680 A2A agonist Male alcohol-preferring rats 10% (v/v) Decrease 170
VT7 A2A agonist Male alcohol-preferring rats 10% (v/v) Decrease 170
Operant self-administration
Drug Mechanism of
action Sex/Species
Ethanol
concentration/
schedule
Ethanol
Intake Refs.
ANR94 A2A antagonist Male alcohol-preferring rats 10 % (v/v), FR1 Increase 170
SCH58261 A2A antagonist Male alcohol-preferring rats 10 % (v/v), FR3 Decrease 173
DMPX A2A antagonist
Male rats 10% (w/v)FR1 Decrease 172
Male rats 10 % (v/v),FR3
Bimodal
effect 171
DPCPX A1 antagonist
Male
Alcohol-
preferring rats
10 % (v/v), FR3 No effect 171, 173
CGS21680 A2A agonist Male alcohol-preferring rats 10 % (v/v), FR1 Decrease 170
VT7 A2A agonist Male alcohol-preferring rats 10 % (v/v), FR1 Decrease 161
Table 1. Summary of the effects of pharmacological and genetic manipulations of adenosine receptors on
free ethanol intake and operant self-administration.
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8. Effect of caffeine on ethanol withdrawal
Withdrawal is a defining characteristic of drug dependence and is often characterized by
impaired physiological function and enhanced negative affect, symptoms strongly
associated with relapse.174 Symptoms of ethanol withdrawal appear between 12 and 24 hrs
after the time when ethanol levels in blood are no longer detectable. For instance, acute
withdrawal appears several hours after a high dose of ethanol has been administered, and
produces a mild set of symptoms (i.e., hangover) that, among other effects, can include
increased anxiety.133 Moreover, the withdrawal syndrome after chronic administration or
chronic consumption of significant amounts of ethanol is also characterized by an
increased anxiety response (for review175). Other common symptoms of this syndrome in
rodents are marked hyperalgesia176, tremors, piloerection177,178, changes in
cardiovascular179 and gastrointestinal functions177, seizures or convulsions180,181, which
corresponds to the withdrawal symptoms observed in humans (for review see 175,177).
Although there are no animal studies focusing on the impact of caffeine on anxiety induced
by ethanol withdrawal, other adenosine receptor modulators have been shown to regulate
signs of ethanol withdrawal. The administration of adenosine 18 h after an acute ethanol
injection in mice, which is at the onset of the peak of withdrawal as characterized by high
levels of anxiety, reduced increases in anxiety observed in an elevated plus-maze.133 This
reversal effect was also observed after the administration of a selective adenosine A1
receptor agonist CCPA, but not after a selective adenosine A2A receptor agonist N6-[2-(3,5-
dimethoxyphenyl)-2-(2methylphenyl)ethyl]adenosine (DPMA).133 Moreover, the
anxiolytic effect of CCPA on ethanol withdrawal-induced anxiety was reversed by the
selective adenosine A1 antagonist DPCPX.133 The results from studies involving chronic
ethanol administration appear to be different from those observed after acute ethanol
administration. In this case the A1 receptor antagonist CPT reduced the anxiogenic effect
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produced by ethanol withdrawal in the elevated plus-maze and in the dark/light test in
rats.176
Removal of a liquid diet containing ethanol (6.7%, v/v) after chronic exposure led to
handling-induced hyperexcitability, a less frequently used behavioral measure of
withdrawal.182 Administration of an adenosine A1 receptor agonist R-PIA and the
adenosine A2A receptor agonist CGS21680 significantly reduced this withdrawal sign,
suggesting the involvement of both A1 and A2A receptors.182 In this study there were no
changes in adenosine A1 and A2A receptors or in adenosine transporter binding sites in the
frontal cortex and cerebellum. However, a reduction in adenosine transporter binding sites
was observed in the striatum of ethanol-withdrawn mice.182
The administration of adenosine, adenosine analogs, or dipyridamole (an inhibitor of
adenosine reuptake) has been shown to reduce the number of rats in which audiogenic
convulsions appeared during ethanol withdrawal.180 The adenosine A1 receptor agonist
CCPA also produced a dose-dependent reduction of the convulsions induced by an intense
audiogenic stimulus, as well as tremors, which were apparent 24 h after repeated high
doses of oral ethanol administration (12-18 g/kg per day) in rats.183 Moreover,
administration of the adenosine A1 antagonist DPCPX completely abolished the
antagonistic effects of the adenosine A1 agonist CCPA on both tremors and audiogenic
seizures during ethanol withdrawal.183 The A2A adenosine receptor also has been
implicated in withdrawal-induced convulsions.184,185 In fact, these receptors are expressed
in areas of the brain involved in epileptogenesis, including the striatum, neocortex and
hippocampus.186 A2AR KO mice are less susceptible to seizures caused by ethanol
withdrawal that was induced by the cessation after 10 consecutive days of ethanol intake
(up to 6.3% v/v). This effect has also been observed when the A2A adenosine receptor
antagonist ZM 241385 was administered during the last 5 of 10 days of ethanol intake.181
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Similarly, subchronic coadministration of theophylline (1 g/kg, IP; twice daily) during
chronic ethanol intake (6.5% w/v) was demonstrated to decrease hyperalgesia and
withdrawal scores in rats during ethanol withdrawal.187 However, the “protective” effect of
A2A receptor antagonism or repeated theophylline administration was not observed after the
acute administration of caffeine or theophylline (5-25 mg/kg, IP); in this case, there was no
effect on the audiogenic seizures observed during ethanol withdrawal in rats.180 However,
caffeine and theophylline did antagonize the suppressive effects of adenosine analogs on
these withdrawal symptoms.180
In summary, adenosine seems to play an important role in the regulation of ethanol
withdrawal. Agonism of the adenosinergic system, especially via stimulation of A1
adenosine receptors, reduces some of the withdrawal symptoms that occur after acute or
chronic ethanol administration. More importantly, pharmacological antagonism or genetic
deletion of adenosine A1 and/or A2A receptors could have a role in prevention of
withdrawal during ethanol intake.181,187 Nevertheless, most of these studies have employed
manipulations affecting specific adenosine receptor subtypes rather than caffeine itself, and
therefore have not directly assessed the popular believe that a cup of strong coffee can
antagonize some of the symptoms of ethanol-withdrawal, especially after an acute episode
of alcohol consumption in non alcoholic individuals.
9. Future directions
After reviewing the literature on caffeine-ethanol interactions one can see that a significant
body of work has been performed. However, a clear pattern of results does not easily
emerge. Further experiments are needed to establish the specific range of doses, patterns of
administration, sex differences, and other factors that could clarify some of the apparent
contradictions in the results observed in many of the studies presented above.
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More importantly, there is a dearth of studies about the interactions of both agents on
processes that are particularly relevant for addiction, such as Pavlovian conditioning, habit
formation, or motor sensitization, which seem to contribute to the acquisition and
intensification of compulsive drug-seeking behavior.38,40 Although sensitization of
locomotor activity by caffeine as well as cross-sensitization with other drugs such as
amphetamine188 and nicotine189 has been observed, so far there are no studies of possible
cross-sensitization between ethanol and caffeine. In fact, preliminary studies from our
laboratory show that caffeine reduces locomotion in animals repeatedly exposed to a
sensitizing dose of ethanol.190 Furthermore, the effects of caffeine-ethanol interactions on
learning processes are not well understood, in part due to the complexity of learning
processes per se. Caffeine has been demonstrated to induce conditioned place
preference191-193, and also to modulate conditioned place preference induced by
methamphetamine or cocaine6 It also would be important to study the effects of caffeine on
the acquisition of Pavlovian cues associated with ethanol in this paradigm.
In summary, despite the fact that this area of inquiry has grown increasingly important due
to the potential dangers of combining high-caffeine “energy” drinks with ethanol, animal
researchers have only scratched the surface of this complex and multifaceted field.
Additional investigations will be required to identify how caffeine and ethanol interact to
modulate the behavioral processes related to ethanol consumption, dependence, abuse and
addiction.
10. References
1. Fredholm BB, Bätting K, Holmén J, et al.  Actions of caffeine in the brain with special
reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83-
133.
CHAPTER 1
54
2. DeWit H, Pierri J, Johanson CE. Assessing individual differences in ethanol preference
using a cumulative dosing procedure. Psychopharmachology. 1988;1:113-119.
3. Rehm JT, Bondy SJ, Sempos CT, Vuong CV. Alcohol consumption and coronary heart
disease morbidity and mortality. Am J  Epidemiol. 1997;146:495-501.
4. Hingson RA, Howland J. Alcohol and non traffic unintended injuries. Addiction. 1993;
88:877-883.
5. Morelli M, Simola N. Methylxanthines and Drug Dependence: A focus on interactions
with substances of abuse. In: Methylxanthines. Fredholm BB (Ed). Springer; 2011:
pp.484-501.
6. Tuazon DB, Suzuki T, Misawa M, et al. Methylxanthines (caffeine and theophylline)
blocked methamphetamine-induced conditioned place preference in mice but enhaned
that induced by cocaine. Ann N Y Acad Sci. 1992;654:531-533.
7. Simola N, Tronci E, Pinna A, Morelli M. Subchronic-intermittent caffeine amplifies the
motor effects of amphetamine in rats. Amino Acids. 2006;31:359-363.
8. Shoaib M, Swanner LS, Yasar S, Golberg SR. Chronic caffeine exposure potentiates
nicotine self-administration in rats. Psychopharmacology (Berl). 1999;142:327-333.
9. Gasior M, Jaszyna M, Munzar P, Witkin JM, Goldberg SR. Caffeine potentiates the
discriminative-stimulus effects of nicotine in rats. Psychopharmacology. 2002;162:385-
395.
10. Green TA, Schenk S. Dopaminergic mechanism for caffeine-produced cocaine seeking
in rats. Neuropsychopharmacology. 2002;26:422-430.
11. Kunin D, Gaskin S, Rogan F, Smith BR, Amit Z. Caffeine promotes ethanol drinking in
rats. Examination using a limited-access free choice paradigm. Alcohol. 2000;21:271-
277.
CHAPTER 1
55
12. Hasenfratz M, Bunge A, Dal Prá G, Bättig K. Antagonistic effects of caffeine and
alcohol on mental performance parameters. Pharmacol Biochem Behav. 1993;46:463-
465.
13. Ferré S, O'Brien MC. Alcohol and Caffeine: The Perfect Storm. J Caffeine Res.
2011;1:153-162.
14. Ferré S. Role of the central ascending neurotransmitter systems in the psychostimulant
effects of caffeine. J Alzheimers Dis. 2010;20 (Suppl 1):S35-S49.
15. Acquas E, Tanda G, Di Chiara G. Differential effects of caffeine on dopamine and
acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats.
Neuropsychopharmacology. 2002;27:182-193.
16. Acquas E, Vinci S, Ibba F, Spiga S, De Luca MA, Di Chiara G. Role of dopamine D(1)
receptors in caffeine-mediated ERK phosphorylation in the rat brain. Synapse.
2010;64:341-349.
17. Cauli O, Morelli M. Caffeine and the dopaminergic system. Behav Pharmacol.
2005;16:63-77.
18. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of
Pharmacology: XXV. Nomenclature and classification of adenosine receptors.
Pharmacol Rev. 2001;53:527-552.
19. Ferré S, Ciruela F, Borycz J, et al. Adenosine A1-A2A receptor heteromers: new targets
for caffeine in the brain. Front Biosci. 2008;13:2391-2399.
20. Clark M, Dar MS. Effect of acute ethanol on release of endogenous adenosine from rat
cerebellar synaptosomes. J Neurochem. 1989;52:1859-1865.
21. Fredholm BB, Wallman-Johansson A. Effects of ethanol and acetate on adenosine
production in rat hippocampal slices. Pharmacol Toxicol. 1996;79:120-123.
CHAPTER 1
56
22. Diamond I, Gordon AS. Cellular and molecular neuroscience of alcoholism. Physiol
Rev. 1997;77:1-20.
23. Nagy LE, Diamond I, Casso DJ, Franklin C, Gordon AS. Ethanol increases extracellular
adenosine by inhibiting adenosine uptake via the nucleoside transporter. J Biol Chem.
1990;265:1946-1951.
24. Nagy LE. Ethanol metabolism and inhibition of nucleoside uptake lead to increased
extracellular adenosine in hepatocytes. Am J Physiol. 1992;262:1175-1180.
25. Carmichael FJ, Israel Y, Crawford M, et al. Central nervous system effects of acetate:
Contribution to the central effects of ethanol. Journal of Pharmacology and
Experimental Therapeutics. 1991;259:403-408.
26. Ferreira SE, de Mello MT, Pompéia S, de Souza-Formigoni ML. Effects of energy drink
ingestion on alcohol intoxication. Alcohol Clin Exp Res. 2006;30:598-605.
27. Liguori A, Robinson JH. Caffeine antagonism of alcohol-induced driving impairment.
Drug Alcohol Depend. 2001;63:123-129.
28. Dar  MS, Wooles WR. Effect of chronically administered methylxanthines on ethanol-
induced motor incoordination. Life Sci. 1986;39:1429-1437.
29. Connole L, Harkin A, Maginn M. Adenosine A1 receptor blockade mimics caffeine's
attenuation of ethanol-induced motor incoordination. Basic Clin Pharmacol Toxicol.
2004;95:299-304.
30. Kunin D, Bloch RT, Terada Y, Rogan F, Smith BR, Amit Z. Caffeine promotes an
ethanol-induced conditioned taste aversion: a dose-dependent interaction. Exp Clin
Psychopharmacol. 2001;9:326-33.
31. Di Chiara G. A motivational learning hypothesis of the role of dopamine in compulsive
drug use. J Psychopharmacol. 1998;12:54-67.
CHAPTER 1
57
32. O’Brien CP, Childress AR, McLellan AT, Ehrman R. Classical conditioning in drug-
dependent humans. Ann N Y Acad Sci. 1992;654:400-415.
33. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization
theory of addiction. Brain Res Brain Res Rev. 1993;18:247-291.
34. Heyman GM. Addiction: A disorder of choice. Cambridge, MA: Harvard University
Press; 2009.
35. Vezina P, Lorrain DS, Arnold GM, Austin JD, Suto N. Sensitization of Midbrain
Dopamine Neuron Reactivity Promotes the Pursuit of Amphetamine. J Neurosci.
2002;22:4654-4662.
36. Heyman GM. An economic approach to animal models of alcoholism. Alcohol Res
Health. 2000;24:132-139.
37. Stewart J, De Wit H, Eikelboom R. Role of unconditioned and conditioned drug effects
in the self-administration of opiates and stimulants. Psychol Rev. 1984;91:251-268.
38. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an
incentive-sensitization view. Addiction. 2000;95 (Suppl 2):91-117.
39. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from
actions to habits to compulsion. Nat Neurosci. 2005;8:1981-1989.
40. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ. Parallel and interactive
learning processes within the basal ganglia: relevance for the understanding of
addiction. 2009;199:89-102.
41. Dunne F, O'Halloran A, Kelly JP. Development of a home cage locomotor tracking
system capable of detecting the stimulant and sedative properties of drugs in rats. Prog
Neuropsychopharmacol Biol Psychiatry. 2007;31:1456-1463.
CHAPTER 1
58
42. Himmel HM. Safety pharmacology assessment of central nervous system function in
juvenile and adult rats: effects of pharmacological reference compounds. J Pharmacol
Toxicol Methods. 2008;58:129-146.
43. Read GW, Cutting W, Furst A. Comparison of excited phases after sedativesand
tranquilizers. Psyhopharmacologia (Berl).1960;1:346-350.
44. Carlsson A, Engel J, Svensson TH. Inhibition of ethanol-induced excitation in mice and
rats by a-methyl-p-tyrosine. Psychopharmacology (Berl). 1972;26:307-312.
45. Correa M, Miquel M, Sanchis-Segura C, Aragon, CMG. Acute lead acetate
administration potentiates ethanol-induced locomotor activity in mice: the role of brain
catalase. Alcohol Clin Exp Res. 1999:23;799-805.
46. Correa M, Sanchis-Segura C, Pastor R, Aragon CMG. Ethanol intake and motor
sensitization: the role of brain catalase activity in mice with different genotypes. Physiol
Behav. 2004:82;231-240.
47. Correa M, Viaggi C, Escrig MA, Pascual M, Guerri C, Vaglini F, Aragon CMG, Corsini
GU. Ethanol intake and ethanol-induced locomotion and locomotor sensitization in
Cyp2e1 knockout mice. Pharmacogenet Genomics. 2009;19:217-225.
48. Sanchis-Segura C, Correa M, Aragon CM. Lesion on the hypothalamic arcuate nucleus
by estradiol valerate results in a blockade of ethanol-induced locomotion. Behav Brain
Res. 2000;114:57-63.
49. Phillips TJ, Shen EH. Neurochemical bases of locomotion and ethanol stimulant effects.
In: International Review of Neurobiology. R.J. Bradley, R.A. Harris, P.Jenner (Eds).
San Diego, Inc: Academic Press; 1996: pp 243-282.
50. Pohorecky LA. Biphasic action of ethanol. Biobehav Rev. 1977;1:231-240.
51. Waldeck B. Ethanol and Caffeine: A Complex Interaction with Respect to Locomotor
Activity and Central Catecholamines.  Psychopharmacologia (Berl). 1974;36:209-220.
CHAPTER 1
59
52. Correa M, Arizzi MN, Betz A, Mingote S, Salamone JD. Open field locomotor effects
in rats after intraventricular injections of ethanol and the ethanol metabolites
acetaldehyde and acetate. Brain Res Bull. 2003;197-202
53. Kuribara H, Asahi T, Tadokoro S. Ethanol enhances, but diazepam and pentobarbital
reduce the ambulation-increasing effect of caffeine in mice. Arukoru Kenkyuto
Yakubutsu Ison. 1992;27:528-539.
54. Haghgoo S, Hasegawa T, Nadai M, et al. Brain distribution characteristics of xanthine
derivatives and relation to their locomotor activity in mice. J Pharm Pharmacol.
1995;47:412-419.
55. El Yacoubi M, Ledent C, Menard JF, et al. The stimulant effects of caffeine on
locomotor behaviour in mice are mediated through its blockade of adenosine A(2A)
receptors. British Journal of Pharmacology. 2000;129:1465-1473.
56. Zhang Q, Yu YP, Ye YL, Zhang JT, Zhang WP, Wei WQ. Spatiotemporal properties of
locomotor activity after administration of central nervous stimulants and sedatives in
mice. Pharmacol biochem Behav. 2011;97:577-585.
57. Pilcher, JD. Alcohol and caffeine: A study of antagonism and synergism. J Pharmacol
exp Ther. 1911: 8; 267-298.
58. Sudakov SK, Rusakova IV, Medvedeva OF. Effect of chronic caffeine consumption on
changes in locomotor activity of WAG/G and Fischer-344 rats induced by nicotine,
ethanol, and morphine. Bull Exp Biol Med. 2003;136:563-565.
59. Ferreira SE, Hartmann Quadros IM, Trindade AA, Takahashi S, Koyama RG, Souza-
Formigoni ML. Can energy drinks reduce the depressor effect of ethanol? An
experimental study in mice. Physiol Behav. 2004;82:841-847.
60. Aragon CM, Trudeau LE, Amit Z. Effect of taurine on ethanol induced changes in
open-field locomotor activity. Psychopharmacology (Berl). 1992;107:337-340.
CHAPTER 1
60
61. Miquel M, Correa M, Sanchis-Segura C, Aragon CM. The ethanol-induced open-field
activity in rodents treated with isethionic acid, a central metabolite of taurine. Life Sci.
1999:64;1613-1621.
62. Daly JW, Shi D, Wong V, Nikodijevic O. Chronic effects of ethanol on central
adenosine function of mice. Brain Res. 1994;650:153-156.
63. Nikodijević O, Jacobson KA, Daly JW. Effects of combinations of methylxanthines and
adenosine analogs on locomotor activity in control and chronic caffeine-treated mice.
Drug Dev Res. 1993;30:104-110.
64. Nikodijević O, Jacobson KA, Daly JW. Locomotor activity in mice during chronic
treatment with caffeine and withdrawal. Pharmacol Biochem Behav. 1993;44:199-216.
65. Arnett, J. Reckless behavior in adolescence: a developmental perspective. Dev Rev.
1992;12:339-373.
66. Casey BJ, Getz  S, Galvan A. The adolescent brain. Dev Rev. 2008;28:62-77.
67. Smith RF. Animal models of periadolescent substance abuse. Neurotoxicol Teratol.
2003;25:291-301.
68. Gilpin NW, Karanikas CA, Richardson HN. Adolescent Binge Drinking Leads to
Changes in Alcohol Drinking, Anxiety, and Amygdalar Corticotropin Releasing Factor
Cells in Adulthood in Male Rats. PLoS One. 2012;7:e31466.
69. Huang C, Titus JA, Bell RL, Kapros T, Chen J, Huang R. A mouse model for
adolescent alcohol abuse: stunted growth and effects in brain. Alcohol Clin Exp Res.
2012;36:1728-1737.
70. Hughes RN. Adult anxiety-related behavior of rats following consumption during late
adolescence of alcohol alone and in combination with caffeine. Alcohol. 2011;45:365-
372.
CHAPTER 1
61
71. Butler TR, Smith KJ, Berry JN, Sharrett-Field LJ, Prendergast MA. Sex differences in
caffeine neurotoxicity following chronic ethanol exposure and withdrawal. Alcohol
Alcohol. 2009;44:567-574.
72. Chuck TL, McLaughlin PJ, Arizzi-LaFrance MN, Salamone JD, Correa M. Comparison
between multiple behavioral effects of peripheral ethanol administration in rats:
Sedation, ataxia, and bradykinesia. Life Sci. 2006:79;154-161.
73. Dar MS, Mustafa, S. J., Wooles, W. R.  Possible role of adenosine in the CNS effects of
ethanol. Life Sci. 1983;33:1363-1374.
74. Dar MS. Central adenosinergic system involvement in ethanol-induced motor
incoordination in mice. J Pharmacol Exp Ther. 1990;255(3):1202-1209.
75. Dar MS. Mouse cerebellar adenosinergic modulation of ethanol-induced
motor incoordination: possible involvement of cAMP. Brain Res. 1997;792: 263-274.
76. Barwick VS, Dar MS. Adenosinergic modulation of ethanol-induced motor
incoordination in the rat motor cortex. Prog Neuropsychopharmacol Biol Psychiatry.
1998;22:587-607.
77. Crabbe JC, Rigter H, Uijlen J, Strijbos C.  Rapid development of tolerance to the
hypothermic effect of ethanol in mice. J Pharmacol Exp Ther. 1979;208:128-133.
78. Khanna JM, Morato GS, Kalant H. Effect of NMDA antagonists, an NMDA agonist,
and serotonin depletion on acute tolerance to ethanol. Pharmacol Biochem Behav.
2002;72:291-298.
79. American Psychiatric Association. Diagnostic and Statistical Manual of Mental
Disorders, 4th edn. DSM IV. Washington:DC; 1994.
80. Dar, MS. The biphasic effects of centrally and peripherally administered caffeine on
acute ethanol-induced MI in mice. J Pharm Pharmacol. 1988;40:482-487.
81. Dar MS, Jones M, Close G, Mustafa SJ, Wooles WR. Behavioral interactions of ethanol
and methylxanthines. Psychopharmacology. 1987;91:1-4
CHAPTER 1
62
82. Batista LC, Prediger RD, Morato GS, Takahashi RN. Blockade of adenosine and
dopamine receptors inhibits the development of rapid tolerance to ethanol in mice.
Psychopharmacology (Berl). 2005;181:714-721.
83. Ribeiro JA, Sebastiao AM, de Mendoça A. Adenosine receptors in the nervous system:
pathophysiological implications. Prog Neurobiol. 2002;68:377-392.
84. Correa M, Sanchis-Segura C, Aragon, CMG. Influence of brain catalase on ethanol-
induced loss of righting reflex in mice. Drug Alcohol Depend. 2001;65:9-15.
85. Correa M, Pascual M, Sanchis-Segura C, Guerri C, Aragon CM. Lead-induced catalase
activity diferentially modulates behaviors induced by short-chain alcohols. Pharmacol
Biochem Behav. 2005;82:443-452.
86. Miquel M, Correa M, Aragon CMG. Methionine enhances alcohol-induced narcosis in
mice. Pharmacol Biochem Behav. 1999;64:89-93.
87. Fredholm BB. Are methylxanthine’s effects due to antagonism of endogenous
adenosine? Trends Pharmacol Sci. 1980;1:129-132.
88. Snyder SH, Katims JJ, Annau Z, Bruns RF, Daly JW. Adenosine receptors and
behavioral actions of methylxanthines. Proc Natl Acad Sci U S A. 1981;78:3260-3264.
89. Daly JW, Butts-Lamb P, Padjett W. Subclasses of adenosine receptors in the central
nervous system: interaction with caffeine and related methylxanthines. Cell Moll
Neurobiol. 1983;3:69-80.
90. Yanik G, Glaum S, Radulovacki M. The dose–response effects of caffeine on sleep in
rats. Brain Res. 1987;403:177-180.
91. Ledent C, Vaugeois JM., Schiffmann, SN, et al. Aggressiveness, hypoalgesia and high
blood pressure in mice lacking the adenosine A2a receptor. Nature. 1997;388: 674-678.
92. Koo MW. Effects of ginseng on ethanol induced sedation in mice. Life Sci.
1999;64:153-160.
CHAPTER 1
63
93. El Yacoubi M, Ledent C, M Parmentier M, Costentin J, Vaugeois JM. Caffeine reduces
hypnotic effects of alcohol through adenosine A2A receptor blockade.
Neuropharmacology. 2003:45;977-985.
94. Proctor WR, Dunwiddie TV. Behavioral sensitivity to purinergic drugs parallels ethanol
sensitivity in selectively bred mice. Science. 1984;224:519-521.
95. Smolen TN, Smolen A. Purinergic modulation of ethanol-induced sleep time in long-
sleep and short-sleep mice. Alcohol. 1991;8:123-130.
96. Dar MS. Involvement of kappa-opioids in the mouse cerebellar adenosinergic
modulation of ethanol-induced motor incoordination. Alcohol Clin Exp
Res. 1998;22:444-454.
97. Dar MS, Mustafa SJ. Acute ethanol/cannabinoid-induced ataxia and its antagonism by
oral/systemic/ intracerebellar A1 adenosine receptor antisense in mice. Brain Res. 2002;
957:53-60.
98. Ruby CL, Adams CA, Knight EJ, Nam HW, Choi DS. An essential role for adenosine
signaling in alcohol abuse. Curr Drug Abuse Rev. 2010;3:163-74.
99. Asatryan L, Nam HW, Lee MR, Thakkar MM, et al. Implication of the purinergic
system in alcohol use disorders. Alcohol Clin Exp Res. 2011;35:584-94.
100. Dunwiddie TV. The physiological role of adenosine in the central nervous system.
International Review of Neurobiology. 1985;27:63-139.
101. Naassila M, Ledent C, Daoust M. Low ethanol sensitivity and increased ethanol
consumption in mice lacking adenosine A2A receptors. J Neurosci. 2002;22:10487-
10493.
102. Goodwin DW. Alcohol amnesia. Addiction. 1995:90;315-317.
103. Hartzler B, Fromme K. Fragmentary and en bloc blackouts: similarity and distinction
among episodes of alcohol-induced memory loss. J Stud Alcohol. 2003;64:547-550.
CHAPTER 1
64
104. Wixted JT. A theory about why we forget what we once knew. Curr Dir Psychol Sci.
2005;14:6-9.
105. White AM. What happened? Alcohol, memory blackouts, and the brain. Alcohol Res
Health. 2003;27:186-196.
106. Gold PE. The many faces of amnesia. Learn Memory. 2006;13:506-514.
107. Weitemier AZ, Ryabinin AE. Alcohol-induced memory impairment in trace fear
conditioning: a hippocampus-specific effect. Hippocampus. 2003;13:305-315.
108. Alkana RL, Parker ES. Memory facilitation by post-training injection of ethanol.
Psychopharmacology. 1979;66:117-119.
109. Manrique HM, Miquel M, Aragon CM. Brain catalase mediates potentiation of social
recognition memory produced by ethanol in mice. Drug Alcohol Depend. 2005;79:343-
350.
110. Angelucci ME, Cesário C, Hiroi RH, Rosalen PL, Da Cunha C. Effects of caffeine on
learning and memory in rats tested in the Morris water maze. Braz J Med Biol Res.
2002;35:1201-1208.
111. Izquierdo JA, Costas SM, Justel EA, Rabiller G. Effect of caffeine on the memory of
the mouse. Psychopharmacology. 1979;61:29-30.
112. Furusawa K. Drug effects on cognitive function in mice determined by the non-
matching to sample task using a 4-arm maze. Jpn J Pharmacol. 1991;56:483-493.
113. Molinengo L, Scordo I, Pastorello B. Action of caffeine, L-PIA and their combination
on memory retention in the rat. Life Sci. 1994;54:1247-1250.
114. Dash PK, Moore AN, Moody MR, Treadwell R, Felix JL, Clifton GL. Post-trauma
administration of caffeine plus ethanol reduces contusion volume and improves working
memory in rats. J Neurotrauma. 2004;21:1573-1583.
115. Spinetta MJ, Woodlee MT, Feinberg LM, et al. Alcohol-induced retrograde memory
impairment in rats: prevention by caffeine. Psychopharmacology. 2008;201:361-371.
CHAPTER 1
65
116. Strong R, Grotta JC, Aronowski J. Combination of low dose ethanol and caffeine
protects brain from damage produced by focal ischemia in rats. Neuropharmacology.
2000;39:515-522.
117. Piriyawat P, Labiche LA, Burgin WS, Aronowski JA, Grotta JC. Pilot dose-escalation
study of caffeine plus ethanol (caffeinol) in acute ischemic stroke. Stroke. 2003
May;34(5):1242-5
118. Kelemen WL, Creely CE. State-Dependent Memory Effects Using Caffeine and
Placebo Do Not Extend to Metamemory. J Gen Psychol. 2003;130:70-86.
119. Duka T, Weissenborn R,  Dienes Z. State-dependent effects of alcohol on recollective
experience, familiarity and awareness of memories. Psychopharmacology.
2011;153:295-306.
120. Overton DA. State-dependent learning produced by alcohol and its relevance to
alcoholism. In: The Biology of Alcoholism, Vol. II: Physiology and Behavior. B.
Kissen and H. Begleiter (Eds). New York ,Plenum Press; 1974: pp.368-373.
121. Nakagawa Y, Iwasaki T. EtOH-induced state-dependent learning is mediated by 5-
hydroxytryptamine3 receptors but not by N-methyl-D-aspartate receptor complex. Brain
Res. 1996;706:227-232.
122. Rezayof A, Motevasseli T, Rassouli Y, Zarrindast MR. Dorsal hippocampal
dopamine receptors are involved in mediating ethanol state-dependent memory. Life
Sci. 2007;80:285-292.
123. Solinas M, Panlilio LV, Justinova Z,Yasar S, Goldberg SR. Using drug-discrimination
techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc.
2006;1:1194-206.
124. Crow, Lowell T. Effects of alcohol on conditioned avoidance responding. Physiol
Behav. 1966;1:89-91.
CHAPTER 1
66
125. Overton D. State-dependent learning produced by depressant and atropine-like drugs.
Psychopharmacology(Berl). 1966;10:6-31.
126. Schechter MD. Effect of propranolol, d-amphetamine and caffeine on ethanol as a
discriminative cue. Eur J Pharmacol. 1974;29:52-57.
127. Gulick D, Gould TJ. Effects of Ethanol and Caffeine on Behavior in C57BL/6 Mice in
the Plus-Maze Discriminative Avoidance Task. Behav Neurosci. 2009:123;1271-1278.
128. Kunin D, Bloch RT, Terada Y, Rogan F, Smith BR, Amit Z. Caffeine promotes an
ethanol-induced conditioned taste aversion: a dose-dependent interaction. Exp Clin
Psychopharmacol. 2001;9:326-333.
129. Correa M, Manrique HM, Font L, Escrig MA, Aragon CM. Reduction in the
anxiolytic effects of ethanol by centrally formed acetaldehyde: the role of catalase
inhibitors and acetaldehyde-sequestering agents. Psychopharmacology. 2008;200;455-
464.
130. Kushner M, Sher K, Beitman B. The relation between alcohol problems and the
anxiety disorders. Am J Psychiatry. 1990;147:685-695.
131. Cappell H, Greeley J. Alcohol and tension reduction: an update on research and
theory. In: Psychological theories of drinking. H. Blaine and K. Leonard (Eds).
Guilford, New York; 1987: pp.15-51.
132. Prediger RD, Batista LC, Takahashi RN. Adenosine A1 receptors modulate the
anxiolytic-like effect of ethanol in the elevated plus-maze in mice. Eur J Pharmacol.
2004;499:147-154.
133. Prediger RD, Da Silva GE, Batista LC. Bittencourt AL, Takahashi RN. Activation of
adenosine A1 receptors reduces anxiety-like behavior during acute ethanol withdrawal
(hangover) in mice. Neuropsychopharmacology. 2006;31:2210-2220.
134. Correa M, Font L. Is there a major role for adenosine A2A receptors in anxiety? Front
Biosci. 2008;1:4058-4070.
CHAPTER 1
67
135. Okuyama E, Ebihara H, Takeuchi H, Yamazaki M. Adenosine, the anxiolytic-like
principle of the Arillus of Euphoria longana. Plant Med. 1992:65;115-119.
136. Florio C, Prezioso A, Papaioannou A, Vertua R.Adenosine A1 receptors modulate
anxiety in CD1 mice. Psychopharmacology. 1998;136:311-319.
137. Uhde TW, Boulenger JP, Jimerson DC, Post RM. Caffeine: relationship to human
anxiety, plasma MHPG and cortisol. Psychopharmacol Bull. 1984;20:426-430.
138. Bruce MS. The anxiogenic effects of caffeine. Postgrad Med J. 1990;(Suppl 2)66:18-
24.
139. Boulenger JP, Uhde TW, Wolf EA 3rd, Post RM. Increased sensitivity to caffeine in
patients with panic disorders: preliminary evidence. Arch Gen
Psychiatry.1984;41:1067-1071.
140. Gea J, de Pablo J, Marti J, Picado C, Pujol A, Agustí-Vidal A. Anxiety crisis (panic
attack) secondary to the administration of theophylline in an oral sustained-release
preparation. Rev Clin Esp. 1988;183-280.
141. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM. The anxiogenic-
like effect of caffeine in two experimental procedures measuring anxiety in the mouse is
not shared by selective A(2A) adenosine receptor antagonists. Psychopharmacology
(Berl). 2000;148:153-163.
142. Bhattacharya SK, Satyan KS, Chakrabarti A. Anxiogenic action of caffeine: an
experimental study in rats. J Psychopharmacol. 1997;11:219-224
143. Correa M, López-Cruz L, Pardo M, Valverde O, Ledent C, Salamone JD. Effects of
the nonselective adenosine antagonists caffeine and theophylline on measures of motor
activity and anxiety in mice: studies of acute and chronic administration and
comparison with adenosine A2A receptor KO mice. Society for Neuroscience; 2011.
Online. 103.09/XX6.
CHAPTER 1
68
144. López-Cruz, Pardo M, Dosda A, Salamone JD, Correa M. Comparison Between high
doses of caffeine and theophylline on motor and anxiogenic effects in CD1 mice:
studies of acute and chronic administration.  Behavioural Pharmacology 2011;eS22: 71-
72.
145. Ellis FW. Effect of ethanol on plasma corticosterone levels. J Pharmacol Exp. Ther
1966;153:121-127.
146. Kakihana R, Butte JC, Noble EP. Corticosterone response to ethanol in inbred strains
of mice. Nature. 1968; 218:360-336.
147. Roberts AJ, Crabbe JC, Keith LD. Genetic differences in hypothalamic–pituitary–
adrenal axis responsiveness to acute ethanol and acute ethanol withdrawal. Brain Res.
1992;579:296-302.
148. Escrig MA, Pardo M, Aragon CM, Correa A M. Anxiogenic and stress-inducing
effects of peripherally administered acetaldehyde in mice: similarities with the
disulfiram-ethanol reaction. Pharmacology Biochemistry and Behavior. 2012;100:404-
412.
149. Nicholson SA (1989) Stimulatory effect of caffeine on plasma corticosterone and
pituitary-adrenocortical axis in the rat. J Endocrinol. 1989:122;535-543.
150. Patz MD, Day HE, Burow A, Campeau S. Modulation of the hypothalamo-pituitary
adrenocortical axis by caffeine. Psychoneuroendocrinology. 2005;31:493-500.
151. Lin AS, Uhde TW, Slate SO, McCann UD. Effects of intravenous caffeine
administered to healthy males during sleep. Depress Anxiety. 1997;5:21-28.
152. Delaney WP, Grube JW, Greiner B, Fisher JM, Ragland DR. Job stress, unwinding
and drinking in transit operators. J Stud Alcohol. 2002;63:420-429.
153. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology.
2010;35:217-238.
CHAPTER 1
69
154. Kunin D, Gaskin S, Rogan F, Smith BR, Amit Z. Augmentation of corticosterone
release by means of a caffeine-ethanol interaction in rats. Alcohol. 2000;22:53-56.
155. Kalodner CR, Delucia JL, Ursprung, AW. An examination of the tension reduction
hypothesis: the relationship between anxiety and alcohol in college students. Addict
Behav. 1989;14; 649-654.
156. Spencer RL, Hutchison KE. Alcohol, aging and the stress response. Alcohol Res
Health. 1999;23:272-283.
157. Fahlke C, Hard E, Hansen, S. Facilitation of ethanol consumption by
intracerebroventricular infusions of corticosterone. Psychopharmacology (Berlin).
1996;127:133-139.
158. Lamblin, F, De Witte P. Adrenalectomy prevents the development of alcohol
preference in male rats. Alcohol. 1996;13:233-238.
159. Pastor R, Reed C, Burkhart-Kasch S, et al. Ethanol concentration-dependent effects
and the role of stress on ethanol drinking in corticotropin-releasing factor type 1 and
double type 1 and 2 receptor knockout mice. Psychopharmacology (Berl).
2011;218:169-177.
160. Vendruscolo LF, Barbier E, Schlosburg JE. Corticosteroid-dependent plasticity
mediates compulsive alcohol drinking in rats. J Neurosci. 2012;32:7563-7571.
161. Itsvan J, Matarazzo JD. Tobacco, alcohol, and caffeine use: a review of their
interrelationships. Psycol Bull. 1984;95:301-326.
162. Kozlowski LT, Henningfield JE, Keenan RM, et al. Patterns of alcohol, cigarette, and
caffeine and other durg use in tow drug abusing populations. J Subs Abuse Treat.
1993;10:171-179.
163. Gilbert, RM. Dietary caffeine and EtOH consumption by rats. J Stud Alcohol.
1976;37:11-18.
CHAPTER 1
70
164. Gilbert RM. Augmentation of EtOH-consumption by caffeine in malnourished rats. J
Stud Alcohol. 1979:40;19-27.
165. Register, UD, MArhs SR, Thurston CT, et al. Influence of nutrients on the intake of
alcohol. J Amer  Diet Assoc. 1972;61:159-162.
166. Potthoff AD, Ellison G, Nelson L. Ethanol intake increases during continuous
administration of amphetamine and nicotine, but not several other drugs. Pharmacol
Biochem Behav. 1983;18:489-493.
167. Dietze MA, Kulkosky PJ. Effects of caffeine and bombesin on ethanol and food
intake. Life Sci. 1991;48:1837-1844.
168. Carvalho CR, Cruz JS, Takahashi RN. Prolonged Exposure to Caffeinated Alcoholic
Solutions Prevents the Alcohol Deprivation Effect in Rats. J Caffeine Res. 2012;2;83-
89.
169. Heyser CJ, Schulteis G, Koob GF. Increased ethanol self-administration after a period
of imposed ethanol deprivation in rats trained in a limited access paradigm. Alcohol
Clin Exp Res. 1997;21:784-791.
170. Micioni Di Bonaventura MV, Cifani C, Lambertucci C, et al. Effects of A₂A
adenosine receptor blockade or stimulation on alcohol intake in alcohol-preferring rats.
Psychopharmacology (Berl). 2012;219:945-957.
171. Arolfo MP, Yao L, Gordon AS, Diamond I, Janak PH. Ethanol operant self-
administration in rats is regulated by adenosine A2 receptors. Alcohol Clin Exp
Res. 2004;28:1308-1316.
172. Thorsell A, Johnson J, Heilig M. Effect of the adenosine . Alcohol Clin Exp Res.
2007;31:1302-1307.
173. Adams CL, Cowen MS, Short JL, Lawrence AJ. Combined antagonism of glutamate
mGlu5 and adenosine A2A receptors interact to regulate alcohol-seeking in rats. Int J
Neuropsychopharmacoly. 2008;11:229-241.
CHAPTER 1
71
174. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. Science.
1987;236:410-416.
175. Finn DA, Crabbe JC. Exploring alcohol withdrawal syndrome. Alcohol Health Res
World. 1997;21;149-156.
176. Gatch MB, Lal H. Effects of ethanol and ethanol withdrawal on nociception in rats.
Alcohol Clin Exp Res.1999;23:328-333.
177. Friedman HJ. Assessment of physical dependence on and withdrawal from ethanol in
animals. In: Alcohol Tolerance and Dependence. H. Rigter and J.C. Crabbe (Eds).
Amsterdam: Elsevier/North-Holland Biomedical Press; 1980: pp. 93-121.
178. Frye GD, McCown TJ, Breese GR. Differential sensitivity of ethanol withdrawal signs
in the rat to gamma-aminobutyric acid (GABA) mimetics: Blockade of audiogenic
seizures but not forelimb tremors. Journal of Pharmacology and Experimental
Therapeutics.1983;226:720-725.
179. Crandall DL, Ferraro GD, Lozito RJ, Cervoni P, Clark LT. Cardiovascular effects of
intermittent drinking: Assessment of a novel animal model of human alcoholism. J
Hypertens. 1989;7:683-687.
180. Malec D, Michalska E, Pikulicka J. Influence of adenosinergic drugs on ethanol
withdrawal syndrome in rats. Pol J Pharmacol. 1996;48:583-588.
181. El Yacoubi M, Ledent C, Parmentier M, Daoust M, Costentin J, Vaugeois J. Absence
of the adenosine A(2A) receptor or its chronic blockade decrease ethanol withdrawal-
induced seizures in mice. Neuropharmacology. 2001;40:424-432.
182. Kaplan GB, Bharmal NH, Leite-Morris KA, Adams WR. Role of adenosine A1 and
A2A receptors in the alcohol withdrawal syndrome. Alcohol. 1999;19:157-162.
183. Concas A, Mascia MP, Cuccheddu T, et al. Chronic ethanol intoxication enhances
[3H]CCPA binding and does not reduce A1 adenosine receptor function in rat
cerebellum. Pharmacol Biochem Behav. 1996;53:249-255.
CHAPTER 1
72
184. Morgan PF, Durcan, M.J. Caffeine-induced seizures: apparent proconvulsant action of
N-ethyl carboxamidoadenosine (NECA). Life Sci.1990;47:1-8.
185. De Sarro G, De Sarro A, Di Paola ED, Bertorelli R. Effects of adenosine receptor
agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur J Pharmacol.
1999;371:137-145.
186. Johansson B, Georgiev V, Parkinson FE, Fredholm BB. The binding of the adenosine
A2A receptor selective agonist [3H]CGS 21680 to rat cortex differs from its binding to
rat striatum. Eur J Pharmacol. 1999;247:103-110.
187. Gatch MB, Selvig M. Theophylline blocks ethanol withdrawal-induced hyperalgesia
Alcohol Alcohol. 2002;37:313-317.
188. Simola N, Cauli O, Morelli M. Sensitization to caffeine and cross-sensitization to
amphetamine: influence of individual response to caffeine. Behav Brain Res.
2006;172:72-79.
189. Celik E, Uzbay IT, Karakas S. Caffeine and amphetamine produce cross-sensitization
to nicotine-induced locomotor activity in mice. Prog Neuropsychopharmacol Biol
Psychiatry. 2006;30:50-55.
190. López-Cruz L, Pardo M, San Miguel N, Salamone JD, Correa M. Impact of high doses
of caffeine on acute and sensitized motor activity induced by ethanol in mice. Presented
at: Federation of European Neuroscience Societies. Barcelona, 2012.
191. Hsu CW, Chen CY, Wang CS, Chiu TH. Caffeine and a selective adenosine A2A
receptor antagonist induce reward and sensitization behavior associated with increased
phospho-Thr75-DARPP-32 in mice. Psychopharmacology (Berl) 2009;204:313-325.
192. Bedingfield JB, King DA, Holloway FA. Cocaine and caffeine: conditioned place
preference, locomotor activity, and additivity. Pharmacol Biochem Behav. 1998;
61:291-296.
CHAPTER 1
73
193. Patkina NA, Zvartau EE. Caffeine place conditioning in rats: comparison with cocaine
and ethanol. Eur Neuropsychopharmacol. 1998;8:287-291.
74
75
CHAPTER 2:
Differences between the nonselective adenosine receptor
antagonists caffeine and theophylline in motor and mood
effects: Studies using medium to high doses in animal models.
76
CHAPTER 2
77
Behavioural Brain Research. 2014;270:213-222.
doi: 10.1016/j.bbr.2014.05.020.
Differences between the nonselective adenosine receptor antagonists caffeine and
theophylline in motor and mood effects: studies using medium to high doses in
animal models.
Laura López-Cruza, Marta Pardoa, John D. Salamoneb, Mercè Correa a,b
aÀrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, 12071 Castelló, Spain.
bDept. of Psychology, University of Connecticut, Storrs, CT, USA 06269-1020.
Corresponding Author: Dr. Mercè Correa, Àrea de Psicobiologia, Campus de Riu Sec,
Universitat Jaume I, 12071 Castelló, Spain (email: correa@psb.uji.es). Tel: +34
964729841. Fax: +34 964729267
Acknowledgements: This work was supported by a grant to Mercè Correa from Plan
Nacional de Drogas (2010/024), Spain, and to John Salamone from the National Institute
of Mental Health (MH078023). Laura López-Cruz was supported by a personal grant
awarded by FPU (AP2010-3793) Ministerio de Educación, Spain and Marta Pardo was
supported by Fundació Bancaixa-UJI.
CHAPTER 2
78
Abstract
Rationale. Caffeine and theophylline are methylxanthines that are broadly consumed,
sometimes at high doses, and act as minor psychostimulants. Both are nonselective
adenosine antagonists for A1 and A2A receptors, which are colocalized with dopamine D1
and D2 receptors in striatal areas. Adenosine antagonists generally have opposite actions
to those of dopamine antagonists. Although the effects of caffeine are widely known,
theophylline has been much less well characterized, especially at high doses.
Methods. Adult male CD1 mice were used to study the effect of a broad range of doses
(25.0, 50.0 or 100.0 mg/kg) of caffeine and theophylline on measures of spontaneous
locomotion and coordination, as well as the pattern of c-Fos immunoreactivity in brain
areas rich in adenosine and dopamine receptors. In addition, we evaluated possible
anxiety and stress effects of these doses.
Results. Caffeine, at these doses, impaired or suppressed locomotion in several
paradigms. However, theophylline was less potent than caffeine at suppressing motor
parameters, and even stimulated locomotion. Both drugs induced corticosterone release,
however caffeine was more efficacious at intermediate doses. While caffeine showed an
anxiogenic profile at all doses, theophylline only did so at the highest dose used (50
mg/kg). Only theophylline increased c-Fos immunoreactivity in cortical areas.
Conclusion. Theophylline has fewer disruptive effects than caffeine on motor parameters
and produces less stress and anxiety effects. These results are relevant for understanding
the potential side effects of methylxanthines when consumed at high doses.
Key Words: methylxantines; incoordination; behavioral activation; anxiety; striatum;
prefrontal.
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1. Introduction
Caffeine is the most widely used psychoactive substance worldwide [1,2]. Average
consumption ranges from 100 to 400 mg per day, but consumption increased in some
groups of consumers with the introduction in the market of energy drinks [2].
Theophylline is a metabolite of caffeine that is also present in teas, as well as some
common dietary products [3].
Both methylxanthines exert their psychostimulant effects mainly through adenosine
receptor blockade [4,5]. Adenosine is a neuromodulator that is involved in multiple
functions such as sleep, attention, locomotion, and anxiety [6-8]. Adenosine acts on four
G-protein-coupled receptors: A1, A2A, A2B and A3 [4]. A1 and A2A receptors are the main
target for both caffeine and theophylline [4,5]. Whereas A1 receptors are widely
expressed in the brain, A2A receptors are mainly concentrated in the striatal complex
[4,9]. On striatal medium spiny neurons, A1 receptors are colocalized with dopamine D1
receptors while A2A receptors are colocalized and interact with D2 receptors; adenosine
and dopamine receptors can interact by forming heteromeric complexes, and also by
convergence onto the same signal transduction pathways [10,11]. Moreover, there is a
substantial amount of behavioral and neurochemical data showing that antagonism of
adenosine receptors, either with nonselective or A2A selective drugs, can reverse the
effects of dopamine D2 receptor antagonists on motor and motivational functions that
involve nucleus accumbens (Acb) and neostriatum [12-15]. Caffeine is being considered
as a possible therapeutic agent because of its ability to interact with dopamine receptors
and affect signal transduction in striatal neurons. In addition, caffeine has been proposed
as a neuroprotective agent to counteract the effects of dopaminergic neural loss [16,17].
Thus, caffeine is potentially useful for the pharmacological treatment of some
symptoms of Parkinson disease [18-20], depression [21] and other disorders that
involve dopamine transmission or basal ganglia circuitry.
However, although low doses of caffeine stimulate locomotion and do not impair motor
coordination in rodents [6,22,23], high doses can suppress locomotion [6,24,25]. High
doses of caffeine that are able to suppress locomotion also increase c-fos markers
throughout the striatum [26,27]. In addition, high doses of caffeine have been shown to
increase physiological parameters of stress such as plasma cortisol levels in humans
[28], and corticosterone levels in rats [8,29], and also to promote anxiety in humans (for
a review see [7]), and anxiogenic-like behaviors in animal models [30,31].
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Theophylline, despite its similar therapeutical potential [13,32] has been much less
explored, but it has been demonstrated that theophylline can suppress parkinsonian
symptoms in humans [33,34]. As is the case with caffeine, low doses of theophylline
can induce motor stimulant effects in rodents [32,35]. Nevertheless, there is a general
lack of information about the effects of theophylline, especially at higher doses.
Thus, the present experiments were undertaken to explore and compare systematically
the effects of moderate to high doses of caffeine and theophylline on measures of motor
activity, anxiety and neuroendocrine parameters, as well as their effect on c-Fos
immunoreactivity (to provide a marker of neuronal activation in dopamine and
adenosine-receptor rich brain areas). The effects of both drugs on different aspects of
exploration, vigorous exercise, and motor coordination, as well as the knowledge of
their impact on mood and stress responses, could be useful information for
understanding their potential side effects at high doses.
2. Materials and methods
2.1 Animals
CD1 adult male mice (N=406) purchased from Harlan-Interfauna Ibérica S.A.
(Barcelona, Spain) were 9 weeks old (30-45 g) at the beginning of the study. Mice were
housed in groups of three or four per cage, with standard laboratory rodent chow and tap
water available ad libitum. Subjects were maintained at 22 + 2 ºC with 12-h light/dark
cycles (lights on at 13:00 hours). To habituate the animals to the procedures, they were
handled and received a single saline injection the day before experimental procedures
started. Different groups of animals were used in each experiment, except for the anxiety
tests in which the same animals were serially tested in both paradigms. All animals were
under a protocol approved by the Institutional Animal Care and Use Committee of
Universitat Jaume I, and all experimental procedures complied with European
Community Council directive (86/609/ECC).
2.2. Drugs
Caffeine and Theophylline (Sigma-Aldrich, Spain) were dissolved in 0.9% w/v saline.
Saline solution was used as the vehicle control. All solutions were administered
intraperitoneally (IP) 30 minutes before behavioral testing, 90 minutes before brain
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extraction in the immunohistochemical study and 60 minutes before blood samples were
collected.
2.3. Behavioral apparatus and testing procedures
2.3.1. Locomotion in the open field arena (OF). The OF apparatus consisted of a clear
glass cylinder 25 cm in diameter and 30 cm high. The floor of the cylinder was divided
into four equal quadrants by two intersecting lines drawn on the floor. The behavioral
test room was illuminated with a soft light, and external noise was attenuated. Tests were
videotaped and locomotor activity was registered manually during 10 minutes. An
activity count was registered as horizontal locomotion each time the animal crossed one
quadrant with four legs. Animals were not pre-exposed to the OF in order to study
novelty-induced exploration and locomotion.
2.3.2. Locomotion in the running wheel (RW). The RW consists of a stainless steel
activity wheel (circumference = 24 cm) situated in a Plexiglas box (35 x 20 cm) with a
magnetic switch attached to a LCD counter for recording number of wheel turns.
Animals were exposed to the RW during 30 minutes in two consecutive days previous to
the test. The test day, counts on the wheel were registered during 30 minutes. The RW
generates stable basal high levels of activity when the animals are trained, and thus is
useful for evaluating conditions that suppress voluntary self-induced locomotion.
2.3.3. Motor coordination in the rotarod. The rotarod apparatus (UGO Basile, 7650)
consisted of an elevated rotating rod that requires coordinated movement in order to
avoid falling. Each mouse was placed in the rotating rod accelerating from 4 rpm to 20
rpm in increments of 4 rpm every 30 seconds. Animals were trained during 5 trials, and
tested for 5 more trials. A 390 seconds maximum cut-off on the rod was used. The
apparatus automatically recorded the time (in seconds) at the moment in which the
animal fell off the rod.
2.3.4. Anxiety in the elevated plus maze (EPM). The EPM consists of two open and two
enclosed arms arranged in a plus conﬁguration. This anxiety paradigm measures the
avoidance that rodents show to elevated open spaces. The behavioral test room was
illuminated with a soft light. Animals were placed in the central platform facing the
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closed arm and assessed during 5 minutes. Tests were videotaped and a trained observer
registered time spent in the open arms, ratio of entries in the open arms to total arm
entries, latency to enter the open arms and total entries in the 4 arms as an index of
locomotion. An entry into an arm was recorded when the animal crossed the line that
connected that arm with the central platform with all four legs.
2.3.5. Anxiety in the dark and light (DL). The DL test is based on the conflict between
the inherent tendency of mice to explore a novel environment against their natural
avoidance of a brightly lighted open field. The DL apparatus consisted of a
polypropylene chamber divided in two compartments by a partition containing a small
opening. One chamber was open and illuminated while the other was closed and dark.
The behavioral test room was illuminated with a soft light. Each subject was placed in
the dark chamber. Tests were videotaped and the latency of the first entry into the lit
chamber, total time spent in the lit chamber and total number of crosses between
chambers, were recorded manually over 5 minutes. The same animal was first evaluated
in the EPM for 5 minutes and then immediately placed in the chamber for evaluation in
the DL during 5 more minutes.
2.4. Plasma corticosterone determination.
Mice received drug injections 60 minutes before being sacrificed by decapitation under
anesthesia. This time was chosen based on previous studies showing significant
increments in corticosterone levels between 30 and 100 minutes after caffeine
administration [8] and [29]. Blood samples were collected in heparinized (15 units/ml of
blood) Eppendorf tubes and centrifuged at 4000 rpm for 10 minutes. Supernatant was
taken and stored at -20°C until corticosterone determination. Plasma corticosterone
levels were measured spectophotometrically using a commercially available enzymatic
immunoassay kit (Rodents Corticosterone Enzyme Immunoassay System, OCTEIA
Corticosterone; Immunodiagnostic Systems LTD, Boldon, England). The ng/ml of blood
corticosterone concentration was determined using a logarithmic adjustment of the
standard curve.
2.5. c-Fos visualization and quantification.
Mice were anesthesized and perfused 90 minutes after receiving treatments. Brains were
collected and stored in 3.7% formaldehyde solution during 24 h and refrigerated in
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sucrose (30%), sodiumazide (2%) and PB 0.1M solution prior to slicing. Free floating
coronal sections (40 µm) were serially cut using a microtome cryostat (Weymouth, MA,
USA), rinsed in 0.01 M PBS (pH 7.4) and incubated in 0.3% hydrogen peroxide for 30
minutes to block endogenous staining. Sections were then rinsed in 0.01 M phosphate
buffer (PBS) (3 × for 5 minutes) and transferred into the primary antibody, anti-c-Fos
(Calbiochem, Germany) for 24 h incubation. Following the primary antibody treatment,
the sections were rinsed in PBS and incubated in the secondary antibody, anti-rabbit
HRP conjugate, envision plus (DAKO, Denmark) for 1.5 h. The immunohistochemical
reaction was developed using diaminobenzidine (DAB) as the chromagen (DAKO).
Processed sections were then mounted to gelatin-coated slides, air dried, and cover-
slipped using Eukitt® (Sigma Aldrich) as a mounting medium. The sections were
examined and photographed using a Nikon Eclipse E600 (Melville, NY, USA) upright
microscope equipped with an Insight Spot digital camera (Diagnostic Instruments, Inc).
Placements for the photographs were counterbalanced between right and left
hemispheres for all the animals and structures. Images of the regions of interest were
magnified at 20X and captured digitally using Stereo Investigator software. Cells that
were positively labeled for c-Fos were quantified with ImageJ software (v. 1.42,
National Institutes of Health sponsored image analysis program) in three sections per
animal, and the average value per mm2 was used for statistical analysis.
2.6. Statistics
Experiments used a between-groups design. Normally distributed and homogeneous
data were evaluated by a parametric two-way analysis of variance (ANOVA) followed
by non-orthogonal planned comparisons using the overall error term ([36] Keppel,
1991). Non-parametric data were analyzed with a Kruskal-Wallis one-way analysis by
ranks. The Mann-Whitney U test was used to compare between two groups for the
analysis of non-parametric data. A probability level of 0.05 or smaller was used to
indicate statistical significance. Effect size calculations (R2 values) were performed to
assess the magnitude of the effect for every drug in every parameter tested [36]. With
this type of effect size calculation, the magnitude of the treatment effect is independent
of the number of animals, and is expressed as the proportion of total variance accounted
for by treatment variance (for example R2 = 0.3 reflects 30% of the variance explained)
across experiments and measures (see Table. 2). Results are graphically depicted as
means ±SEM. Statistics were conducted using STATISTICA 7 software.
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3. Results
3.1. Effect of caffeine and theophylline on locomotor activity in the OF.
The two-way ANOVA (Treatment x Dose) showed a significant effect of the treatment
factor [F(1,67)= 6.33, p<0.05], a significant effect of dose [F(3,67)= 9.54, p<0.01], and
a significant treatment x dose interaction [F(3,67)= 6.36, p<0.05]. Planned comparison
analysis revealed a significant stimulant effect of 50.0 mg/kg theophylline (p<0.01) and
a depressant effect on locomotion of the highest dose of caffeine used (100.0 mg/kg)
(p<0.05), both compared with their respective vehicle treatment. Caffeine and
theophylline were significantly different from each other in their effects at the higher
doses, 50.0 and 100.0 mg/kg (p<0.01), as measured by planned comparisons.
3.2. Effect of caffeine and theophylline on locomotor activity in the RW.
The two-way ANOVA (Treatment x Dose) showed a significant effect of the treatment
factor [F(1,64)= 3.75, p<0.05], a significant effect of dose [F(3,64)= 16.05, p<0.01] and
a significant treatment x dose interaction [F(3,64)= 6.36, p<0.01]. Planned comparisons
analysis revealed that caffeine significantly decreased locomotion in the RW at all doses
used (25.0, 50.0 and 100.0 mg/kg) compared with vehicle (p<0.01), while theophylline
only showed this suppressant effect at the two highest doses (50.0 and 100.0 mg/kg)
compared with vehicle treatment (p<0.01) (see Fig. 1B). Thus, caffeine seems to be
more potent than theophylline at suppressing running in the RW.
3.3. Effect of caffeine and theophylline on rotarod performance.
The two-way ANOVA (Treatment x Dose) revealed that there was not an overall effect
of treatment on rotarod performance [F(1,46)= 0.09, n.s]. However, a significant effect
of dose [F(3,46)= 29.81, p<0.01], and a significant effect of treatment x dose interaction
[F(3,46)= 5.47, p<0.05] were observed. Planned comparisons revealed that caffeine at
doses of 50.0 and 100.0 mg/kg decreased time spent on the rotating rod (p<0.01) and
theophylline only showed this effect at the highest dose (100 mg/kg) (p<0.01). Caffeine
and theophylline were significantly different from each other at the dose of 50.0 mg/kg;
caffeine induced a greater suppressant effect than theophylline at this dose (p<0.01) (see
Fig. 1C). These results indicate that caffeine is more potent than theophylline at
suppressing motor performance in the rotarod.
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Fig. 1. Effect of caffeine and theophylline on A) horizontal locomotion in the OF (N=9-10 per group), B)
running in the RW (N= 7-8 per group), and C) performance in the rotarod (N=7-8 per group). Data are
expressed as mean (±SEM) number of counts during 10 minutes. *p<0.01**p<0.05 significantly different
from vehicle. ##p<0.01 #p<0.05 significant differences between treatments at the same dose.
3.4. Effect of caffeine and theophylline on plasma corticosterone levels.
Figure 2 shows data on plasma corticosterone levels. A two-way ANOVA (Treatment x
Dose) revealed a significant effect of treatment [F(1,43)= 19.25, p<0.01], a significant
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effect of dose [F(3,43)= 37.65, p<0.01], and a significant treatment x dose interaction
[F(3, 43)= 3.53, p<0.05].  Planned comparisons revealed that caffeine at all doses (25.0,
50.0 and 100.0 mg/kg) significantly increased plasma corticosterone levels (p<0.01).
This effect was also observed after theophylline administration at all doses employed
(25.0 mg/kg, p<0.05; 50.0 and 100.0 mg/kg p<0.01). Caffeine and theophylline were
significantly different from each other at the two lower doses (25.0 and 50.0 mg/kg).
Caffeine was more potent than theophylline at inducing corticosterone.
Fig. 2. Effect of caffeine and theophylline on plasma corticosterone levels (N=6-7 per group). Data are
expressed as mean (± SEM) nanograms of corticosterone per mililiter of plasma. **p<0.01 significantly
different from vehicle. ##p<0.01 significant differences between treatments at the same dose.
3.5. Effect of caffeine and theophylline in the EPM and in the DL.
For the anxiety experiments, only the two smallest doses of caffeine and theophylline
(25.0 and 50.0 mg/kg) were used in order to minimize the impact of ataxia and
incoordination on the anxiety measurements. Animals were evaluated first in the EPM
and immediately after were evaluated in the DL. For the EPM results, a non-parametric
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Kruskal-Wallis test of the median values for the dependent variable latency to enter into
one of the open arms showed a significant effect [H(5 df)= 20.2, p<0.01]. The Mann-
Whitney U test showed that caffeine at both doses (25.0 and 50.0 mg/kg) increased
latency to enter into the open arm compared to the vehicle group [U=22.0, and U=27.0,
p<0.01, respectively]. This effect was only observed with the highest dose of
theophylline (50.0 mg/kg; U=27.0, p<0.01), indicating an anxiogenic-like effect of
caffeine that was more potent than that of theophylline in this parameter (Fig. 3A). The
non-parametric Kruskal-Wallis test for the dependent variable time in open arms showed
a significant effect [H (5 df)=27.7, p<0.01]. Caffeine produced an anxiogenic effect as
measured by the reduction in time spent in open arms. Thus, Mann-Whitney U test
showed significant differences between both doses of caffeine (25.0 and 50.0 mg/kg)
and vehicle [U=16.0, and U=18.0, p<0.01, respectively]. However, only the highest dose
of theophylline (50.0 mg/kg) showed this significant decrement in time spent in open
arms in relation to its control group [U=21.0, p<0.01]. Comparisons between caffeine
and theophylline at the same dose revealed significant differences [U=47.5, p<0.05]
between both drugs at dose of 25.0 mg/kg. However, this difference disappeared with
the highest dose explored (50.0 mg/kg) in which both drugs reduced the time spent in
open arms (Fig. 3B), suggesting a more potent anxiogenic effect of caffeine than
theophylline. For the variable ratio of entries into open arms, the non-parametic Kruskal-
Wallis test of the median values showed a significant effect [H(5 df)= 25.1, p<0.01].
Mann-Whitney U test revealed that both doses of caffeine (25.0 and 50.0 mg/kg)
significantly reduced the ratio of entries into the open arms [U=16.0, p<0.01; U=25.0,
p<0.05, respectively] compared to vehicle. However, consistently with previous results,
this effect was only observed with the highest dose of theophylline (50.0 mg/kg)
[U=24.0, p<0.01]. Comparisons between caffeine and theophylline at the same dose
revealed significant differences [U=47.5, p<0.05] between both drugs at dose of 25.0
mg/kg. However, this difference disappeared with the highest dose explored (50.0
mg/kg) in which both drugs reduced the ratio of entries to open arm (Fig. 3C). Finally,
for the total arm entries a parametric test was performed. The two-way factorial
ANOVA (Treatment x Dose) showed a significant effect of the treatment [F(1,66)=3.77,
p<0.05] and a significant effect of dose factor [F(2,66)=4.80, p<0.05] as well as a
significant effect for the interaction [F(2,66)=4.02, p<0.05]. Planned comparisons
showed that caffeine reduced total arm entries at the highest dose (50.0 mg/kg)
compared to its vehicle (p<0.01) and compared to theophylline at the same dose
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(p<0.05). Consistently with the data obtained in the motor studies, this result indicates a
suppressor effect of caffeine on locomotor activity at the high dose (Fig. 3D).
Fig. 3. Effect of caffeine and theophylline on the EPM (N=11-13 per group). Data are expressed as mean
(±SEM) of A) latency (seconds) to enter an open arm, B) time (sec) spent in the open arms, C) ratio of
open arm entries, and D) total arm entries during 5 minutes. ##p<0.01 significant differences between
treatments at the same dose. **p<0.01 significant differences in ranks between treatments in A, or
**p<0.01 significantly different from vehicle in B, C and D.
The effects of caffeine and theophylline in the DL are shown in figure 4 A-C. Although
the results showed the same pattern as in the EPM, the non-parametic Kruskal-Wallis
test of the median values showed that none of the variables explored (latency to lit
compartment, time in lit compartment, and total number of crosses) were statistically
affected by drug treatment.
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Fig. 4. Effect of caffeine and theophylline on the behavior of mice in the DL. Data are expressed as mean
(±SEM) of A) latency (seconds) to lit compartment, B) time (seconds) in lit compartment, and C) crosses
during 5 minutes.
3.6. Effect of caffeine and theoplhylline on c-Fos immunoreactivity in different brain
areas.
CHAPTER 2
90
The c-Fos immunoreactivity levels were analyzed separately for every brain area. The
one-way ANOVA (Treatment x Dose) revealed an effect of treatment on c-Fos
immunoreactivity in the anterior cingulate (ACC) [F(2,16)= 16.36, p<0.01). The post
hoc test showed that only theophylline significantly increased c-Fos expression in ACC
compared to vehicle (p<0.01) and compared to caffeine (p<0.01). A significant effect of
treatment was also observed in the dorsomedial striatum (DMS) (F(2,16)= 3.46, p<0.05).
Theophylline induced higher levels of c-Fos expression than caffeine in this striatal
region (p<0.05). No statistically significant effects were observed in the other areas
explored (dorsolateral (DLS), and ventrolateral striatum (VLS), accumbens (Acb) shell
and core (see Table 1). These results suggest that theophylline seems to be more
efficacious than caffeine at inducing c-Fos in the ACC and DMS regions.
Vehicle Caffeine Theophylline
ACC
Acb Core
Acb Shell
DMS
DLS
VLS
22.8 ± 13.7
10.4 ± 3.0
5.9 ± 1.0
12.8 ± 3.3
6.8 ± 1.7
3.3 ± 1.3
34.2 ± 14.0
8.5 ± 3.8
9.5 ± 1.8
5.5 ± 1.5
6.9 ± 2.7
4.0 ± 1.1
132.8 ± 18.8**##
9.1 ± 1.9
9.6 ± 3.0
20.3 ± 5.7#
14.8 ± 7.2
3.5 ± 1.2
Table 1.  Effect of caffeine and theophylline administration on c-Fos immunoreactivity in several brain
areas (N=5-6 per group). Mean (±SEM) number of c-Fos positive cells per mm2. **p<0.01 significantly
different from vehicle, ##p<0.01 #p<0.05 significantly different from caffeine in the same structure.
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Fig. 5. Upper part: Diagram of coronal sections with bregma coordinates taken from Franklin and Paxinos
2007, showing location of the brain areas for c-Fos counting. Lower part: Photomicrographs of c-Fos
staining in ACC from representative animals in the vehicle, caffeine 50 mg/kg, and theophylline 50
mg/kg groups. Low power images (20x), scale bar = 250 μm.
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Table 2. Effect size calculations (R2 values). Marker of the magnitude of the effect for caffeine and
theophylline in the behavioral, endocrine and biochemical parameters explored.
4. Discussion
The present work offers a comparative study, between two of the most well known and
widely consumed methylxantines, caffeine and theophylline, at a range of doses that are
Dependent Variables Caffeine Theophylline
Open field 0.394 0.360
Running Wheel 0.375 0.499
Rotarod 0.823 0.545
Plasma corticosterone levels 0.886 0.689
Elevated plus-maze
Time in open arms
Latency to open arms
Ratio of open arms entries
Total arm entries
0.298
0.225
0.279
0.589
0.190
0.172
0.202
0.001
Dark and Light
Time in lit compartment
Latency to lit compartment
Crosses
0.038
0.156
0.074
0.040
0.052
0.040
C-Fos inmunochemistry
ACC
AcbCore
AcbShell
DMS
DLS
VLS
0.034
0.014
0.235
0.249
0.010
0.109
0.704
0.232
0.127
0.109
0.136
0.001
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not usually explored (i.e., moderate to high doses), using animal models of motor
performance and mood.
Evaluation of the motor stimulant actions of drugs is frequently conducted by analyzing
the locomotor activity of animals in an OF [37,38]. This paradigm can offer an index of
exploration induced by novelty when the animals are exposed to a chamber for the first
time, and it has been demonstrated that psychostimulant drugs potentiate reaction to
novelty in the OF, both in rodents as well as humans [39,40]. In our study the two
lowest doses of caffeine showed a tendency to stimulate locomotion, but the effect was
not statistically significant. Increases in locomotion with moderate doses of caffeine are
clearly seen in studies that habituate mice to the OF, and thus reduce basal activity [6].
In the present study with non-habituated animals, caffeine produced a biphasic effect
with a non-significant tendency to increase locomotion and clear suppression of
locomotion at the highest dose, in consonance with previous studies using also high
doses [6,24]. On the other hand, theophylline, under the same conditions, produced
significant stimulant effects at 50 mg/kg, and no suppressant effects. Previous data
show that theophylline at lower doses (10-20 mg/kg) than the ones used in the present
study also increase motor activity in mice [41,32]. Thus, theophylline- and caffeine-
treated groups at the two highest doses (50 and 100 mg/kg) were significantly different
from each other, indicating that theophylline is less potent than caffeine at suppressing
exploration. These results (see Fig. 1A) suggest that at this range of doses, theophylline
seems to be more efficacious at stimulating locomotion while caffeine is either more
efficacious or more potent at suppressing activity in a novel OF.
In research with rodents, one of the most common ways of studying voluntary and
vigorous physical activities is wheel running. This paradigm induces high levels of
locomotion [42,43], and is useful for the assessment of motor suppressant effects of
drugs. In our experiment, caffeine suppressed wheel running at all doses while
theophylline only showed this effect at the highest doses (50 and 100 mg/kg). These
results indicate again that theophylline is less potent than caffeine at reducing
spontaneous running behavior. Another relevant motor parameter is coordination and
balance. In the present study, those aspects of locomotion were assessed using a rotating
rod that forces the animal to move in order to avoid falling from the elevated rod. Thus,
this paradigm has an aversive component and also is a way to evaluate forced
locomotion. Once again, we observed a suppressant effect of caffeine at the two highest
doses (50 and 100 mg/kg) while theophylline only showed this effect at the highest
CHAPTER 2
94
dose. Thus, the effect size for caffeine in this parameter is greater than for theophylline
(see table 2). While low to moderate doses of caffeine (3-30 mg/kg) have demonstrated
not to produce motor incoordination in mice in the rotarod [22,44], the present results
on moderate to high doses of caffeine are in agreement with a study that evaluated the
stumbling frequency in the holeboard test as a measure of motor coordination after
moderate to high doses of caffeine (30-120 mg/kg), and demonstrated a dose-dependent
increase in stumbling frequency [25]. Our data on theophylline are also consistent with
a previous study showing that intraventricular administration of theophylline (150
µg/5µl) in mice did not affect endurance on the rotarod [45].
In addition to these behavioral effects, the present range of doses produced an increase
in corticosterone levels, indicating a strong endocrine stress response to administration
of these methylxantines. More importantly, caffeine reached higher levels of
corticosterone than theophylline at moderate doses (25 and 50 mg/kg), although these
differences disappeared at the highest dose (100 mg/kg). These results suggest that both
drugs are efficacious at inducing increments in corticosterone levels, but caffeine seems
to be more potent as also shown by the effect size analysis (see table 2). Previous
studies have showed dose-related increases in plasma corticosterone levels, associated
with changes in ACTH [8,29], after acute administration of caffeine in rats at a broad
range of doses [8,29,46,47]. However, there was a lack of information about
theophylline on this parameter.
Caffeine also has been demonstrated to induce anxiety in some humans (for a review
see [9]. In the present work, we confirmed that caffeine is an anxiogenic agent. In the
EPM, moderate (25 mg/kg) and high doses (50 mg/kg) of caffeine increased the latency
to enter into the open arm, and decreased the time spent and ratio of entries into the
open arms, causing a significant preference for the protected sections of the maze, an
index of its anxiogenic-like effects. These results are in accordance with previous
experiments in rats and mice using similar range of doses (15-100 mg/kg)
[30,31,48,49]. In contrast, theophylline only produced anxiogenic effects at the highest
dose used (50 mg/kg). The total number of entries into the different compartments was
only affected at the highest dose of caffeine, showing again a motor suppressant effect
of caffeine but not of theophylline. This difference is also observed in the effect size
calculations (see table 2). In our study, neither caffeine nor theophylline produced
statistically significant effects in the DL paradigm. However, there was a tendency of
caffeine to produce greater anxiogenic effects than theophylline. Conflicting results
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have been reported in the DL test after caffeine administration [48,50]. While caffeine
has previously demonstrated to have anxiogenic properties in the DL test at a range of
doses similar to those used above (25-100 mg/kg) [48], another study did not observed
this effect after caffeine administration (15-45 mg/kg) [50]. It is possible that in our
results the lack of clear effects is due to the experimental procedure. Animals were
evaluated in the DL immediately after being tested in the EPM, which could possibly
have masked the anxiogenic effects of both drugs in this paradigm. However, this serial
testing procedure has been previously used to assess anxiolytic and anxiogenic effects
of other drugs, and both effects were constant in both paradigms [51,52]. It is possible
then, that the anxiogenic reaction produced by methylxantines is not very strong, and
habituates easily. In summary, the overall results suggest that caffeine is more potent
than theophylline at inducing anxiety and at suppressing locomotion.
In spite of its anxiety inducing properties at medium to high doses, caffeine is orally
self-administered in rodents at medium to low doses. CD1 mice, independently of their
baseline anxiety levels, seem to consume caffeine at a low concentration that
nevertheless yielded a dose of 35 mg/kg per day [53]. Consumption of caffeine, at least
at lower doses (around 12 mg/kg per day) [55], seems to be regulated by A2A rather than
A1 adenosine receptors ([54,55], since A1 KO and WT counterparts seem not to differ in
terms of caffeine consumption [54], but A2A KO mice drink less caffeine than WT mice
[54]. It has also been demonstrated that rats prefer to drink only very low concentrations
of caffeine ([56]. Moreover, after pavlovian conditioning, rats develop preference vs.
avoidance to caffeine associated flavor solutions in a dose dependent manner: flavors
associated with low concentrations of caffeine produce preference and flavors
associated with high ones produce avoidance [56]. It has also been demonstrated that
high doses of caffeine such as the ones used in the present study (25-50 mg/kg)
associated to a place generate avoidance in rats [57,58], while only lower doses induce
place preference [57-59]. To our knowledge, there are no studies about the impact of
theophylline on these parameters.
Finally, the pattern of c-Fos expression has been used in past research as an index of
neuronal activation in different brain areas in which adenosine and dopamine receptors
are abundant [60,61]. Thus, in the present study we included dorsal and ventral areas of
the striatum as well as the two subregions of the Acb and an area of the frontal cortex;
the ACC. All these structures seem to be important for behavioral activation, exertion of
effort, habit formation, locomotion and voluntary movement in general [62,63], among
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other processes. In this case, our results show a greater efficacy of theophylline than
caffeine. Thus, c-Fos immunoreactivity after theophylline administration at a dose of 50
mg/kg is increased in ACC. The effect size for theophylline in ACC (R2=0.704) was the
biggest across all the structures, and was much larger than that of caffeine (R2=0.034).
Caffeine at this dose, did not induce c-Fos in any of the structures studied. Reports in
the literature show that, at least in rats, caffeine at high doses (50-100 mg/kg) produces
induction of c-fos expression or the amount of c-Fos protein in striatum and Acb
[27,64,65], as well as in ACC [66]. Thus, it is possible that a higher dose of caffeine
than the one used in the present study (e.g. 50 mg/kg) would induce c-Fos as well in
mice. The present results showing an effect of theophylline on c-Fos is relevant due to
the relative lack of studies on this methylxanthine. In mice, lower doses of theophylline
(15 mg/kg) than the ones used in the present work did not induce c-Fos
immunoreactivity in different areas of striatum or Acb [13,32]. However, a study in rats
showed that a high dose of caffeine and of theophylline (100 mg/kg) did induce c-fos
expression in the striatum [67]. Our results in mice indicate that the difference between
the two drugs is evident at a lower dose. The mechanism of action for methylxanthines,
specifically caffeine, on immediate early gene expression is not clear, but it has been
related to dopamine regulation [65]. Previous studies in rats have demonstrated that
dopamine D1, and to a lesser extent D2, receptor antagonists blocked potentiation of c-
fos expression by a high dose of caffeine (100 mg/kg) in different areas of striatum [65].
In turn, the effect of caffeine on c-fos induced by dopamine D1 and D2 receptor
blockade is probably regulated by the actions of caffeine on A1 and A2A receptors
respectively [65,68,69]. In most mammals, A2A receptors are highly concentrated in the
striatum, with very low concentrations in prefrontal cortex [4]. However, A1 receptors
are highly concentrated in prefrontal cortex as well as striatum [4]. Considering the
higher ratio of A1 versus A2A receptors in prefrontal cortex, it seems reasonable that the
present results (induction of c-Fos only in ACC) are probably due to theophylline
effects on A1 receptors. However, previous studies in rats, using A1 and A2A receptor
agonists alone or in combination, demonstrate that in order to produce changes in c-fos
expression in cingulate cortex, is necessary to have combined stimulation of both
receptors [70].
Taking all these results together, we have demonstrated that caffeine is more potent than
theophylline at suppressing voluntary physical activity, motor exploration and
coordination. In humans, one of the few experimental studies comparing both drugs
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found that subjects receiving a single dose of caffeine (6 mg/kg) or of theophylline (4.5
mg/kg), showed a delayed exhaustion time in a cycling task compared to placebo, and
there was not a significant difference between both drugs at these doses [71].
The average consumption of caffeine worldwide ranges from 100 mg to 400 mg per day
[72]. However, with the introduction of energy drinks (which can contain up to 500 mg
per unit) these levels are much higher in some consumers [2]. It has been reported that
most of the beneficial effects of caffeine show a linear dose–response relationship up to
about 300 mg, but at higher doses there is either a flattening of the curve, or impaired
performane [73]. However, there are clear individual differences in response to some
effects of caffeine, such as sleep disturbances or anxiogenic effects [74].
Thus, although caffeine is generally consumed with the purpose of potentiating an alert
state, or improving endurance and performance, our results suggest that at high doses it
can induce quite different actions. Our data do not support the idea that high doses of
caffeine can be used to potentiate endurance and performance, specially, when physical
activity is already performed at a high level (for a review see [75]).
The rank order in potency for the motor actions of methylxanthines has been established
from more potent to less as paraxanthine, caffeine, theophylline and theobromine
[67,76,77]. Behavioral and neurochemical reports confirmed this order [76-79].
However, there is a surprising lack of information about the less potent methylxantines.
The present study offers a necessary comparison between caffeine and theophylline in a
range of behaviors that can be affected after administration of these substances.
Moreover, these results could help to better understand the potential effects of two
nonselective adenosine receptor antagonists, caffeine and theophylline, that are being
widely consumed in food, coffee and tea, or as “energy” drinks [71], and that are being
proposed as possible therapeutic agents [80-84].
The separation between therapeutic efficacy and adverse side effects remains a challenge
in the discovery and development of novel adenosine-based medicines, but this also is
important for the naturally occurring ones. Although both methylxantines should have
similar properties at low doses, caffeine is more potent than theophylline at inducing
adverse effects at moderate and high doses; this would suggest that theophylline has a
wider therapeutic window than caffeine. The present study can help to establish a range
of doses that can induce undesirable side effects related to locomotion, anxiety and
physiological stress responses in animal models. Future translational research should
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assess the therapeutic window for each substance in disease animal models as well as
human studies.
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Abstract
Rationale. Caffeine and ethanol are frequently consumed in combination. Ethanol
increases adenosine levels, but caffeine is a non-selective adenosine A1/A2A receptor
antagonist. These receptors are highly expressed in striatum and olfactory tubercle,
brain areas involved in exploration and social interaction in rodents. Ethanol modulates
social interaction processes, but the role of adenosine in social behavior is still poorly
understood.
Objectives. These studies were undertaken to study the impact of caffeine and ethanol
and their combination on social behavior, and explore the involvement of A1 and A2A
receptors on those actions.
Methods. Male CD1 mice were evaluated in a social interaction three-chamber
paradigm, for preference of conspecific vs. object and for long-term recognition
memory of familiar vs. novel conspecific.
Results. Caffeine (7.5-60.0mg/kg) decreased social preference in a dose dependent
manner. Ethanol (0.25-1.5g/kg) showed a biphasic effect, blocking social preference at
high doses. However, ethanol reversed some impairments induced by caffeine (15.0-
30.0 mg/kg). CPT (A1 antagonist) did not modify social preference on its own, or in
combination with ethanol. MSX- (A2A antagonist) increased social preference, but did
not block totally ethanol-impairing effects on preference. Both, ethanol and caffeine, or
their combination, produced amnesic effects. MSX-3 blocked the amnesic effects of low
doses of ethanol but CPT did not.
Conclusions. Caffeine can reduce social interaction and preference possibly via A1
receptor antagonism but not A2A, since MSX3 potentiated rather than reduce social
preference. Low doses of ethanol can counteract caffeine reduction in preference.
Ethanol has a potent effect impairing recognition. However, adenosine antagonists do
not seem to have a strong effect on the prevention of memory loss.
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1. Introduction
Caffeine and alcohol are the most consumed psychoactive drugs worldwide. In recent
times, it has become common to consume high doses of caffeine in combination with
ethanol in order to reduce the intoxicating effects of the alcohol (Ferré and O’Brien
2011; López-Cruz et al. 2013; Correa et al. 2014). Caffeine and ethanol act on the
adenosine system in distinct ways that can result in opposite physiological and
behavioral effects. Caffeine is a non-selective adenosine antagonist that acts mainly on
A1 and A2A receptors (Fredholm 1999), whereas ethanol has been demonstrated to
increase the adenosinergic tone by inhibiting the endonucleotid transporter type-1, thus,
blocking adenosine uptake (Nagy et al. 1990; Krauss et al. 1993), and also by increasing
the synthesis of adenosine during ethanol metabolism (Carmichael et al. 1993).
Adenosine is a neuromodulator in the central nervous system (CNS) that plays an
important role in the regulation of synaptic transmission and neuronal excitability
(Sebastiao et al. 2009). Several subtypes of adenosine receptors are expressed in the
brain, with A1 and A2A being the most abundant. A2A receptors are expressed at high
levels, and almost exclusively, in the striatum and olfactory bulbs and tubercle
(Fredholm et al. 2001; Schiffmann et al. 1991), regions that are involved in the
regulation of motivated (Hauber and Sommer, 2009; Salamone and Correa 2002; 2012),
and social behaviors (Sano et al. 2008). However, A1 receptors have a widespread
distribution in the brain, with a somewhat higher concentration in hipoccampus
(Schwarzschild et al. 2006; Fuxe et al. 2003).
Caffeine was shown to decrease social interaction at high doses in mice (60 mg/kg)
(Hilakivi et al. 1989) and rats (20 and 40 mg/kg) (Baldwin and File, 1989; Baldwin et
al. 1989), effects that have been suggested to be related to its anxiogenic actions
(Baldwin et al. 1989; Hilakivi et al. 1989). However, other studies have shown that
caffeine increases the number of social contacts after similar doses (20 mg/kg) in rats
(Nadal et al. 1993). Ethanol consumption was shown to facilitate interactions with peers
and to alleviate anxiety (Kirchner et al. 2006; Varlinskaya and Spear, 2002). In rodent
models of social interaction, acute ethanol administration at low doses produces social
facilitation (Nadal et al. 1993; Varlinskaya and Spear, 2009; Procópio-Souza et al.
2011), but dose-related decrements in social interaction after high doses also have been
observed in mice (Hilakivi et al. 1989; Lister and Hilakivi, 1988). However, there are
almost no reports of interactions between these two drugs in this important aspect of
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motivated behavior (Hilakivi et al. 1989). In the only study so far, a high dose of
caffeine (30 mg/kg) that did not modify the time spent engaged in social interaction by
itself was able to reverse the impairment induced by a high dose of ethanol (2 g/kg)
(Hilakivi et al. 1989). The same lack of information applies to the impact of caffeine-
ethanol interactions in another important aspect of social behavior, long-term social
recognition memory. In the only interaction study on this type of memory, a low dose of
caffeine (5 mg/kg), blocked the retrograde memory impairments induced by a high dose
of ethanol (3 g/kg) in a social odor recognition test in rats (Spinetta et al. 2008). The
amnesic effect of ethanol is well known. Although ethanol at low doses was shown to
act as a short-term social memory enhancer in mice (Manrique et al. 2005), high doses
of ethanol can cause amnesia, or impaired retrieval of memory, after the drug wears off
(Goodwin 1995; Hartzler and Fromme, 2003). This effect of ethanol could be explained
by the fact that adenosine and adenosine receptor agonists impair short-term social
recognition memory in rats (Prediger and Takahashi, 2005). On the other hand, selective
A1 and A2A receptor antagonists can improve short-term social memory (Prediger and
Takahashi, 2005).
The present work evaluated the effect of a broad range of doses of caffeine, in
combination with ethanol, on social motivation as measured by preference towards a
conspecific versus a neutral object. Our procedure minimized anxiety induced by
aggression, avoiding whole-body contact. We also evaluated the impact of high doses of
caffeine on plasma corticosterone levels (a measure of physiological stress) and
assessed if a low dose of ethanol that improved caffeine-induced reductions in
preference was able to modulate those hormonal levels. In a second phase of the
behavioral test, long-term social recognition memory was studied 24 hours after the
preference test took place. In addition, the role of A1 and A2A receptors on social
motivation and memory were also evaluated using selective adenosine antagonists alone
or in combination with ethanol.
CHAPTER 3
112
2. Methods
2.1. Subjects
Adult male CD1 mice (30-45 g) were purchased from Janvier (France). Mice were
housed in groups of three per cage, with standard laboratory rodent chow and tap water
available ad libitum. They were maintained in the colony at 22 ± 1ºC with lights on
from 8:00 to 20:00 hours. All experimental procedures complied with the European
Community Council directive (86/609/ECC) for the use of laboratory animal subjects
and with the “Guidelines for the Care and Use of Mammals in Neuroscience and
Behavioral Research” (National Research Council 2003).
2.2. Drugs
Caffeine (Sigma-Aldrich, Spain) and MSX3 ((E)-phosphoric acid mono-[3-[8-[2-(3-
methoxphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]
propyl] ester disodium salt; synthesized at the laboratory of Dr. Christa E. Müller at the
Pharmazeutisches Institut, Universität Bonn, Germany) were dissolved in 0.9% w/v
saline. CPT (8-cyclopentyltheophylline; purchased from Sigma-Aldrich, Spain) was
dissolved in distilled water (pH=8). All these drugs were administered IP
intraperitoneally (IP) 30 minutes before testing. Ethanol (Panreac Quimica S.A., Spain)
was diluted to 20% (v/v) in physiological saline (0.9 % w/v) and administered IP 10
minutes before testing. Saline solution was used as vehicle. These doses of ethanol were
selected based on previous studies done in our laboratory with the same strain of mice
(Correa et al. 2008).
2.3. Behavioral apparatus and testing procedures
Social preference and social recognition tests. The effects of adenosine antagonists on
social preference were measured in a three-chambered social box (originally developed
by Crawley 2004). The general procedure was adapted from Chévere-Torres and
colleagues (2012). Every mouse had two consecutive habituation sessions in the
chambers: in the first one, they freely explored the empty social arena during 15
minutes, and immediately there was a second exploration session, that lasted 30 minutes,
in the presence of two wire cages, one in each of the side-compartments. After the 45
minute habituation period, different groups of animals received their corresponding
treatment and were placed in an individual cage during 10 or 30 minutes (depending of
drug). After this time, mice were placed in the center chamber of the social interaction
CHAPTER 3
113
apparatus and test started. During the test session (10 minutes), the three-chambered
arena contained a caged with a conspecific in one side, and in the other side there was a
small wire cage with an object. The center compartment was empty (see Figure 1 for a
schematic on the procedure). The placement of the conspecific or the object was
counterbalanced between animals. A trained experimenter who was unaware of the
experimental conditions, registered manually time spent sniffing each target (conspecific
versus object) as a measure of social preference. Vertical and horizontal locomotion
were also registered. Twenty-four hours after the social preference test, mice were
placed back in the central chamber and were subjected to a 10 minutes social recognition
test (Moy et al. 2004). No drugs were administered before this second test. During the
recognition test a novel mouse replaced the object, and the experimental mice were
given the choice to interact with the familiar conspecific (same conspecific used in the
social preference test the day before) versus a novel conspecific. Time sniffing each
conspecific was registered.
Figure 1. Schematic representation of social preference and social recognition tests settings and timeline.
Plasma corticosterone determination. Mice received caffeine (0.0, 15.0 or 30.0 mg/kg)
plus vehicle or the dose of ethanol that in experiment 3 had been more effective at
reversing the suppressant effects of caffeine on social preference (0.5 g/kg). Animals
received injections 80 and 60 min respectively before being sacrificed by decapitation
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under deep anesthesia. Animals were anesthetized with a 1.0 ml/kg IP injection of a
cocktail solution containing 10.0 ml of 100 mg/ml ketamine plus 0.75 ml of 20.0 mg/ml
xylazine (both from Phoenix Scientific, Inc., St. Joseph, MO, USA), 30 minutes before
decapitation. Blood samples were collected in heparinized (15 units/ml of blood)
Eppendorf tubes and centrifuged at 4000 rpm for 10 min. Supernatant was taken and
stored at -20°C until corticosterone determination. Plasma corticosterone levels were
measured spectrophotometrically using a commercially available enzymatic
immunoassay kit (Rodents Corticosterone Enzyme Immunoassay System, OCTEIA
Corticosterone; Immunodiagnostic Systems LTD, Boldon, England). Blood
corticosterone concentration (ng/ml) was determined using a logarithmic adjustment of
the standard curve.
2.4. Statistics
One-way ANOVA was used to analyze the effect of drug administration on the different
dependent variables; time sniffing conspecific, object, familiar and novel conspecific,
and vertical and horizontal locomotion. Two-way factorial ANOVA was used for the
interaction studies. When the overall ANOVA was significant, non-orthogonal planned
comparisons using the overall error term were used to compare each treatment with the
control group (Keppel, 1991). For these comparisons,  level was kept at 0.05 because
the number of comparisons was restricted to the number of treatments minus one.
Student's t-test for dependent samples was used to analyse “preference” (e.g.
conspecific vs. object, or familiar vs. novel conspecifics). A probability level of 0.05 or
smaller was used to indicate statistical significance. Statistics were done using
STATISTICA 7 software.
3. Results
Experiment 1: Effect of the non-selective adenosine A1/A2A antagonist caffeine on
social preference and locomotion: impact on long-term social recognition memory.
Mice (N=44) were injected with saline or caffeine (7.5, 15.0, 30.0 or 60.0 mg/kg) 30
minutes before the social interaction test started. The following day (24 hours later) no
drugs were administered and social recognition was evaluated as described before.
The one-way ANOVA revealed an overall effect of caffeine on time sniffing the
conspecific (F(4,39)=21.12, p<0.01). Planned comparison analysis showed a significant
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decrement on time spent sniffing the conspecific after caffeine administration at doses
of 15.0, 30.0 and 60.0 mg/kg (p<0.01). The one-way ANOVA for the effect of caffeine
on time sniffing the object (F(3.39)=4.03, p<0.01) was also significant, and the planned
comparisons revealed that the same doses of caffeine (15.0, 30.0 and 60.0 mg/kg)
decreased time sniffing the object compared to vehicle (p<0.05. p<0.01 and p<0.01,
respectively). The Student’s t-test for dependent samples was used to compare time
spent sniffing the conspecific with time spent sniffing the object. The vehicle treated
group spent more time exploring the conspecific than the object (t=5.24, p<0.01), and
this pattern of behavior was also preserved after the administration of moderate doses of
caffeine (7.5 and 15.0 mg/kg; t=6.28, p<0.01, t=3.84, p<0.01 respectively) but not after
the highest doses of caffeine (30.0 and 60.0 mg/kg; t=0.04, p=0.97 and t=2.15, p=0.06
respectively) (Fig 2. A)
Figure 2. Effect of caffeine on social preference and recognition tests. Data are expressed as mean
(±SEM) of time sniffing A) conspecific and object in the social preference test, B) familiar and novel
cosnpecifics in the social recognition test, and C) horizontal and D) vertical locomotion during the social
preference test. **p<0.01, *p<0.05 significant differences from vehicle for the same target. ##p<0.01
significant differences between time sniffing both targerts for the same dose of caffeine.
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The one-way ANOVA revealed an overall effect of caffeine on horizontal locomotion
(F(4,39)=7.90 p<0.01). Caffeine significantly increased horizontal locomotion at low to
intermediate doses (7.5 and 15.0 mg/kg; p<0.01) compared to vehicle, but did not have
a significant effect at higher doses. The one-way ANOVA for vertical locomotion
(F(4,39)=4.60 p<0.01) was also significant, but for this dependent variable, planned
comparisons revealed that the higher doses (30.0 and 60.0 mg/kg), significantly
decreased vertical locomotion in comparison with the vehicle treated group (p<0.05 and
p<0.01, respectively) (Fig 2. C and D). This increase in locomotion could be
influencing the reduction in time dedicated to targeted exploration, more importantly, to
conspecific exploration.
For the social recognition results, the one-way ANOVA revealed no significant effect of
the previous treatment with caffeine on time spent sniffing the familiar conspecific
(F(4,39)=1.37, n.s.). However, there was an overall effect of previous caffeine treatment
on time sniffing the novel conspecific (F(4,39)=3.83, p<0.01). Planned comparisons
revealed that the highest doses of caffeine (30.0 and 60.0 mg/kg) significantly decreased
time spent sniffing the novel conspecific compared with vehicle (p<0.05 and p<0.01,
respectively) (Fig 2.B). Student’s t-test for dependent samples showed that the vehicle
group spent more time sniffing the novel conspecific than sniffing the familiar one (t=-
3.40, p<0.01) and this was also observed in the group that received 15.0 mg/kg of
caffeine (t=-3.31, p<0.01), but not 7.5 mg/kg, 30.0 or 60.0 mg/kg (t=1.58, p=0.17;
t=0.16, p=0.87; t=-1.14, p=0.29, respectively) (Fig 2.B).
Experiment 2: Effect of ethanol on social preference and locomotion: impact on
long-term social recognition memory.
In this experiment mice (N=45) received saline or ethanol (0.25, 0.5, 1.0 or 1.5 g/kg) 10
minutes before been evaluated in the social preference test. The following day, the same
animals were tested for social recognition memory.
Ethanol treatment, as shown by the one-way ANOVA, had a significant effect on time
sniffing the conspecific (F(4,40)=20.12, p<0.01), and planned comparisons revealed
that ethanol at the lowest dose (0.25 g/kg) increased direct conspecific exploration
(p<0.01) in comparison with vehicle treatment, while higher doses decreased time with
conspecific (1.0 and 1.5 g/kg, p<0.05 and p<0.01 respectively). The one-way ANOVA
for time sniffing the object (F(4,40)=4.45, p<0.01) was also significant. However, only
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the highest dose of ethanol (1.5 g/kg) significantly reduced (p<0.01) time spent sniffing
the object compared to the vehicle treated group (Fig 3.A). When comparing time
exploring both stimuli in the same animals, Student t-test for dependent samples showed
that in the vehicle group there was a significant difference in time spent sniffing the
conspecific versus the object (t=-8.28, p<0.01), a pattern that was repeated at all doses
of ethanol (0.25 g/kg, t=-5.49, p<0.01; 0.5 g/kg, t=-5.75, p<0.01; 1.0 g/kg, t=2.61,
p<0.05; 1.5 g/kg t=-2.76, p<0.01) (Fig 3.A). Thus, independently of the ethanol dose
used, all groups explored more the conspecific than the object.
There were no significant effect of ethanol treatment on total crosses (F(4,40)=0.59,
n.s.) (Fig 3.C) and on vertical locomotion (F(4,40)=2.25, n.s.) (Fig 3.D).
Figure 3. Effect of ethanol in social preference and recognition tests. Data are expressed as mean (±SEM)
of time sniffing A) conspecific and object in the social preference test, B) familiar and novel cosnpecifics
in the social recognition test, and C) horizontal and D) vertical locomotion during the social preference
test. **p<0.01, *p<0.05 significant differences from vehicle for the same target. ##p<0.01 #p<0.05
significant differences between time sniffing both targerts for the same dose of ethanol.
One day after the social interaction test took place, social recognition was evaluated,
and the results of the one-way ANOVA showed an overall effect of previous exposure
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to ethanol on time sniffing the familiar conspecific (F(4.40)=2.08, p<0.05). Ethanol at
doses of 0.25 and 1.5 g/kg increased time sniffing the familiar conspecific (p<0.05 and
p<0.01 respectively) compared to the group previously treated with vehicle. A
significant effect of ethanol administered the previous day was also observed on time
sniffing the novel conspecific (F(4,40)=5.78, p<0.01). Only the lowest dose of ethanol
(0.25 g/kg) increased time sniffing the novel conspecific in comparison with the vehicle
group (p<0.01) (Fig 3.B). Student’s t-test for dependent samples showed significant
differences in the vehicle group between time spent sniffing familiar versus novel
conspecific. These animals spent more time sniffing the novel than familiar conspecific
(t=5.32, p<0.01), a pattern that was only observed on the group that had received the
lower dose of ethanol (0.25 g/kg, t=2.46, p<0.05), suggesting that ethanol, even at doses
that had no effect on social exploration the day before (0.5 g/kg), can impair social
recognition 24 hours after been administered.
Experiment 3: Effect of caffeine-ethanol coadministration on social preference and
locomotion: impact on long-term social recognition memory.
For experiment 3 mice (N=74) received and injection of saline or caffeine (15.0 or 30.0
mg/kg; 30 minutes before being tested) plus vehicle or a dose of ethanol (0.5 or 1.0
g/kg; 10 minutes before test), and were evaluated for social preference and locomotion.
The following day, the same animals were tested in the social recognition test.
Factorial ANOVA (caffeine x ethanol) on time sniffing the conspecific showed overall
effects of caffeine (F(2,65)=13.33, p<0.01), and ethanol (F(2,65)=9.97, p<0.01) and
also a significant interaction (F(4,65)=8.99, p<0.05). Planned comparisons confirmed
that when compared with the vehicle-vehicle group only the highest dose of ethanol
used in the present study (1.0 g/kg) reduced conspecific exploration (p<0.05), and that
the two doses of caffeine (15.0 and 30.0 mg/kg) selected for this experiment also
reduced social exploration (p<0.01). In terms of the interactions, the group that received
the lowest dose of caffeine (15.0 mg/kg) in combination with the lowest dose of ethanol
(0.5 g/kg) was significantly different (p<0.01) from the group that had received that
dose of caffeine but no ethanol, pointing to a reversal effect of ethanol on the caffeine-
induced impairment. However, the effect of this dose of caffeine was not reversed when
given in combination with the highest dose of ethanol (1.0 g/kg). As for the impairing
effect on conspecific exploration observed in the group that had received the highest
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dose of caffeine (30.0 mg/kg) plus vehicle, this effect was partially reversed by the two
doses of ethanol (p<0.05 and p<0.01 respectively). (Fig 4.A).
The factorial ANOVA (Caffeine x Ethanol) for the dependent variable time sniffing the
conspecific did not show a significant effect of caffeine (F(2,65)=1.31, n.s.), of ethanol
(F(2,65)=1.69, n.s.) or the interaction (F(4,65)=0.71, n.s.), (Fig 4.B).
Figure 4. Effect of caffeine plus ethanol interaction in the social preference test. Data are expressed as
mean (±SEM) of time sniffing A) conspecific, B) object, C) horizontal and D) vertical locomotion during
the social preference test. **p<0.01, *p<0.05 significantly different from the vehicle group in the same
dose of ethanol. ##p<0.01 #p<0.05 significantly different from the group that received the same dose of
caffeine plus ethanol 0.0 g/kg.
Factorial ANOVA (Caffeine x Ethanol) for total crosses as a measure of horizontal
locomotion revealed an overall effect of caffeine (F(2,65)=7.22, p<0.01), and ethanol
(F(2,65)=6.27, p<0.01), but no significant interaction (F(4,65)=0.77, n.s.), (Fig. 4.C). A
separate factorial ANOVA for vertical locomotion showed the same pattern of results. It
revealed an effect of caffeine (F(2,65)=4.23, p<0.05) and of ethanol (F(2,65)=7.74,
p<0.01), but no significant caffeine-ethanol interaction (F(4,65)=0.81, n.s.), (Fig. 4.D).
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The results for the impact of these pharmacological manipulations on social recognition
memory evaluated the day after the drug injection, and the preference test, are shown in
Table 1. The factorial ANOVA (Caffeine x Ethanol) showed an overall effect of
caffeine (F(2,65)=3.72, p<0.05), and of ethanol (F(2,65)=8.27, p<0.01) on time sniffing
the familiar conspecific. However, there was no significant caffeine x ethanol
interaction (F(4,65)=1.49, n.s.). The factorial ANOVA for variable time sniffing a novel
conspecific revealed a significant effect of caffeine (F(2,65)=3.43, p<0.05), but no
significant effect of ethanol (F(2,65)=2.37, n.s.), and a significant interaction effect
(F(2,65)=0.91, p<0.01). The Student’s t-test for dependent samples comparing time
spent sniffing familiar conspecific versus novel conspecific revealed that the group that
had received vehicle-vehicle injections the day before spent significantly more time
sniffing the novel conspecific than the familiar conspecific (t=4.96, p<0.01), and the
same was true for the animals treated with caffeine (15.0 mg/kg) plus saline (t=2.85,
p<0.05). However, caffeine 30 mg/kg plus saline impaired social recognition the day
after, since there was no difference between the time spent exploring the two
conspecifics (t=0.15, n.s.) as expected from the results in experiment 1. All doses of
ethanol employed (0.5 and 1.0 g/kg) impaired social recognition memory as it had been
observed in experiment 2 (t=0.47, n.s., t=-0.43, n.s., respectively). Moreover, combining
caffeine (15.0 or 30.0 mg/kg) with ethanol (0.5 or 1.0 g/kg) did not improve the
impairing effect produced by ethanol (caffeine 15 mg/kg plus ethanol 0.5 g/kg; t=-0.82,
n.s.; caffeine 15 mg/kg plus ethanol 1.0 g/kg, t=1.49, n.s.; caffeine 30.0 mg/kg plus
ethanol 0.5 g/kg, t=1.69, n.s.; caffeine 30.0 mg/kg plus ethanol 1.0 g/kg t=0.66, n.s.).
Time sniffing (sec)
Etoh (g/kg) 0.0 0.5 1
Caff
(mg/kg) Familiar Novel Familiar Novel Familiar Novel
0.0 87.5±9.1 136.4±12.1## 111.4±14.5 124.1±16.6 115.9±21.7 106±19.1
15.0 71.2±7.1 100.1±13.2# 120.6±27.3 98.1±12.5 72.1±10.5 102.3±21.7
30.0 33.0±11.1 31.9±21.1 103.6±11.8 137.2±21.9 83.3±11.2 91.1±12.7
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Table 1. Effect of caffeine-ethanol coadministration on social recognition memory. Data are expressed as
mean ± SEM of time in seconds sniffing the novel and the familiar conspecifics. ##p<0.01, #p<0.05
significant differences between time in familiar vs time in novel conspecific for the same treatment group.
Experiment 4: Effects of caffeine-ethanol co-administration on plasma
corticosterone levels.
Independent groups of mice (N=35) received one injection of saline or caffeine (15.0 or
30.0 mg/kg) plus a second injection of saline or ethanol (0.5 g/kg). Blood samples were
extracted 80 minutes after caffeine administration (60 minutes after ethanol
administration). Data are shown in Table 2. A two-way ANOVA (caffeine x ethanol)
showed a significant effect of caffeine treatment on plasma corticosterone levels
(F(2,24)=21.59, p<0.01). However, ethanol did not produce a significant effect
(F(1,24)=0.16, n.s), and there was not a significant interaction (F(2,24)=1.14, n.s). Thus,
ethanol did not modify the increase in corticosterone produced by caffeine, suggesting
that the effects seen in experiment 3 were not the result of a reduction on stress levels.
Plasma corticosterone levels (ng/ml)
Caffeine     /   Etoh (g/kg)
(mg/kg)
0.0 0.5
0.0 38.3 ± 11.6 36.8 ±17.8
15.0 76.4 ± 12.0 90.4 ± 9.0
30.0 128.3 ± 16.7 129.6 ± 14.5
Table 2. Effects of caffeine (0.0, 15.0 or 30.0 mg/kg) plus ethanol (0.0 or 0.5 g/kg) on corticosterone
levels. Data are expressed as mean (±SEM) plasma corticosterone levels (ng/ml).
Experiment 5: Effect of the selective adenosine A1 receptor antagonist CPT on
social preference and locomotion. Impact on long-term social recognition memory.
Mice (N=37) were injected with vehicle or CPT at doses of 3.0, 6.0, or 9.0 mg/kg 30
minutes before being tested in the social preference task. The following day (24 hours
later) the same animals were tested in the social recognition test.
The effect of CPT on time sniffing the conspecific was analyzed by a one-way
ANOVA, but revealed no significant effect (F(3,33)=2.13, n.s.). However, the one-way
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ANOVA on the effect of CPT on time sniffing the nonsocial target was significant
(F(3,33)=5.21, p<0.01). Planned comparison revealed that CPT significantly decreased
time spent exploring the object at all doses of CPT in comparison with the vehicle group
(p<0.01) (Fig. 5.A). Student’s t-test for dependent samples showed significant
differences in time sniffing the conspecific vs. the object in all the groups. Animals
spent more time sniffing the conspecific after saline (t=5.37, p<0.05), CPT 3.0 mg/kg
(t=11.25, p<0.01), CPT 6.0 mg/kg (t=6.38, p<0.01), and CPT 9.0 mg/kg (t=5.95,
p<0.01).
These doses of CPT did not affect horizontal (F(3,33)=1.03, n.s.) or vertical locomotion
(F(3,33)=1.42, n.s.) as analyzed by one-way ANOVA’s (Fig. 5.C and 5.D).
For the social recognition test, the one-way ANOVA’s did not show a significant effect
of CPT dose on time sniffing the familiar conspecific (F(3,33)=0.14, n.s.) or on time
sniffing the novel conspecific (F(3,33)=0.02, n.s.). Student’s t-test for dependent
samples showed significant differences between time spent sniffing the novel versus the
familiar conspecific in the vehicle group (t=-3.82, p<0.01), as expected when animals
recognized the previously explored conspecific, and this effect was also observed in the
animals that had received the highest dose of CPT 9.0 mg/kg the day before (t=-3.25,
p<0.05), but not the lower doses (CPT 3.0 mg/kg, t=-0.96, n.s.; and CPT 6.0 mg/kg t=-
0.79, n.s.) (Fig 5.B).
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Figure 5. Effect of CPT in the social preference and recognition tests. A) conspecific and object in the
social preference test, B) familiar and novel cosnpecifics in the social recognition test, and C) horizontal
and D) vertical locomotion during the social preference test. **p<0.01 significant differences from
vehicle for the same target. ##p<0.01 #p<0.05 significant differences between time sniffing both targerts
for the same dose of CPT.
Experiment 6: Effect of CPT–ethanol co-administration on social preference and
locomotion: impact on long-term social recognition memory.
Mice (N=60) received and injection of vehicle or CPT 6.0 mg/kg 20 minutes before the
test and a second injection of vehicle or ethanol (0.5 or 1.0 g/kg) 10 minutes before the
social preference test started. The following day, the same animals were tested in the
social recognition test with no drug been administered.
A factorial ANOVA (CPT x Ethanol) showed an overall effect of ethanol
(F(2,41)=5.33, n.s.), but no significant effect of CPT (F(1,41)=0.32, n.s) or CPT-ethanol
interaction (F(2,41)=1.60, n.s.) on time sniffing the conspecific. (). The factorial
ANOVA for time sniffing the object did not reveal a significant effect of CPT
(F(1,41)=0.43, n.s.), of ethanol (F(2,41)=1.46, ns), or of the interaction (F(2,41)=2.21,
n.s.) either (Fig 6.A).
For the social recognition test the factorial ANOVA (CPT x Ethanol) did not show a
significant effect of CPT (F(1,41)=1.06,  n.s.), of ethanol (F(2,41)=0.97, n.s.), or of the
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interaction (F(2,41)=0.05, n.s.) on time sniffing the familiar conspecific (Fig 6.B) The
factorial ANOVA for the variable time sniffing the novel conspecific, did not show an
overall effect of CPT (F(1,41)=0.38, n.s), ethanol (F(2,41)=1.78,  n.s.) or CPT-ethanol
interaction (F(2,41)=1.11,  n.s.)
Figure 6. Effect of CPT plus ethanol interaction on the social preference test. Data are expressed as mean
(±SEM) of time sniffing A) conspecific, B) object, C) horizontal and D) vertical locomotion during the
social preference test.
Student’s t test for dependent samples showed significant differences between time
sniffing the novel vs. familiar conspecific in control group (t=4.7, p<0.01). Ethanol as
well as happened in the experiment 2 impaired social recognition at all doses employed
(0.5 g/kg, t=0.47, n.s. and 1 g/kg, t=0.14, n.s). CPT (6 mg/kg) as occurred in experiment
6 also impaired social memory since t-student test for dependent samples did not
showed differences between time sniffing novel vs. familiar conspecific in this
treatment group (t=0.79, n.s). None of the doses of ethanol co-administered with CPT (6
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mg/kg) reverted such effect (0.5 g/kg; t=0.99, p=0.35 and 1.0 g/kg; t=0.14, p=0.89)
(Table 3).
Time sniffing (sec)
Etoh (g/kg) 0.0 0.5 1.0
CPT
(mg/kg)
Familiar Novel Familiar Novel Familiar Novel
0.0 74.1±4.5 139.4±12..4## 122.6±12.4 124.1±16.6 99.0±22.0 102.5±12.4
6.0 100.1±20.5 123.5±25.3 111.0±14.6 172.3±27.8 119.6±23.3 105.0±27.8
Table 3. Effects of CPT-ethanol combination on social recognition memory. Data are expressed as mean
±SEM of time in seconds sniffing novel and familiar conspecifics. ##p<0.01 significant differences
between time in familiar vs time in novel conspecific for the same dose of CPT and ethanol.
Experiment 7: Effect of the selective adenosine A2A receptor antagonist MSX-3 on
social preference and locomotion. Impact on long-term social recognition memory.
Different groups of mice (N=36) received an acute administration of vehicle or MSX-3
at dose of 1.5, 3.0, 6.0 mg/kg, 30 minutes before the social interaction test. The same
animals were tested 24 hours later in the social recognition test.
The one-way ANOVA revealed an overall effect of MSX-3 on time spent sniffing the
conspecific (F(3,32)=4.58, p<0.01), and planned comparison showed that all doses
increased significantly time sniffing the social target (MSX-3 1.5 mg/kg, p<0.05; MSX3
3.0 mg/kg and MSX-3 6.0 mg/kg, p<0.01) compared with the vehicle treated group. The
one-way ANOVA for the dependent variable time spent exploring the object was also
significant (F(3,32)=3.63, p<0.05). MSX-3 significantly decreased the time exploring
the object at all doses employed (MSX-3 1.5 mg/kg, p<0.05; MSX3 3.0 mg/kg and
MSX-3 6.0 mg/kg, p<0.01) when compared with the vehicle group. Student t-test for
dependent samples demonstrated that there were significant differences in time spent
sniffing the conspecific versus the object in the vehicle group (t=12.96, p<0.01), but
also in all the MSX-3 treated groups (MSX-3 1.5 mg/kg, t=7.96, p<0.01; MSX-3 3.0
mg/kg, t=10.33 p<0.01, and MSX-3 6.0 mg/kg, t=6.87 p<0.01) (Fig 7.A).
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The impact of MSX-3 on locomotion is shown in Fig 7.C. and 7.D. The ANOVA for
the effect of MSX-3 on horizontal locomotion was significant (F(3,32)=3.66, p<0.05),
and planned comparisons showed a significant effect of all doses of MSX-3 on total
crosses between compartments as a measure of horizontal locomotion (MSX-3 1.5
mg/kg and MSX-3 3.0 mg/kg, p<0.05; and MSX-3 6.0 mg/kg, p<0.01). However, the
one-way ANOVA for vertical locomotion was not significant (F(3,32)=1.83, n.s.).
Figure 7. Effect of MSX3 in social preference and recognition tests. Data are expressed as mean (±SEM)
of time sniffing A) conspecific and object in the social preference test, B) familiar and novel cosnpecifics
in the social recognition test, and C) horizontal and D) vertical locomotion during the social preference
test. **p<0.01, *p<0.05 significant differences from vehicle for the same target. ##p<0.01 #p<0.05
significant differences between time sniffing both targerts for the same dose of MSX3.
For the social recognition test, the one-way ANOVA’s revealed no significant effect of
MSX-3 on time spent sniffing the familiar conspecific (F(3,32)=1.83, n.s.), and also no
significant effect of this drug on novel conspecific exploration (F(3,32)=0.61, n.s.) (Fig
7.B). Student’s t-test for dependent samples showed significant differences between
time spent sniffing novel versus familiar conspecific in the vehicle group (t=-4.71,
CHAPTER 3
127
p<0.01), as expected, and this pattern was also observed in the MSX-3 1.5 mg/kg, (t=-
2.64, p<0.05) and the MSX-3 6.0 mg/kg groups (t=-2.42, p<0.05). The intermediate
dose of MSX-3 3.0 mg/kg almost reach significant levels (t=-2.13, p=0.06). Thus MSX-
3 administered the day before did not affect social recognition memory.
Experiment 8: Effect of MSX3-ethanol co-administration on social preference and
locomotion. Impact on long-term social recognition memory.
Mice (N=50) received a dose of vehicle or of the lowest dose of MSX-3 (1.5 mg/kg)
that was effective in experiment 7. MSX-3 was administered 20 minutes before test, and
10 minutes before the social preference test a second injection of vehicle or ethanol (0.5
or 1.0 g/kg) was administered. The following day, the same animals were tested for
social long-term memory.
A factorial ANOVA (MSX-3 x ethanol) revealed an overall effect of MSX-3
(F(1,43)=40.65, p<0.01), and ethanol (F(2,43)=3.36, p<0.05) on time sniffing the
conspecific. However, there was not a significant interaction effect with this variable
(F(2,43)=0.34, n.s.) (Fig 8.A). The factorial ANOVA for time sniffing the object did not
reveal a significant effect of MSX-3 (F(1,43)=1.45, n.s.), or ethanol (F(2,43)=0.49,
p=0.61), and no significant interaction (F(2,43)=2.23, n.s.) either (Fig 8.B).
Total crosses between compartment as a measure of horizontal locomotion were overall
affected by MSX-3 (F(1,43)=21.18, p<0.01), but not by ethanol (F(2,43)=2.42, n.s.),
and there was not a significant interaction either (F(2,43)=0.30, n.s.). The one-way
ANOVA for vertical locomotion revealed a significant effect of ethanol (F(2,43)=3.99,
p<0.05), but no effect of MSX3 (F(1,43)=2.27, n.s.), and no significant interaction
(F(2,43)=0.11, n.s.).
CHAPTER 3
128
Figure 8. Effect of MSX3 plus ethanol interaction in the social preference test. Data are expressed as
mean (±SEM) of time sniffing A) conspecific, B) object, C) horizontal and D) vertical locomotion during
the social preference test.
As for the impact of these drugs on recognition of the conspecific presented during the
preference test, the factorial ANOVA (MSX-3 x Ethanol) for time sniffing the familiar
conspecific showed a significant effect of ethanol (F(2,43)=6.97, p<0.01), but did not
show an effect of MSX-3 (F(1,43)=0.02, n.s.), and no MSX-3 x ethanol interaction on
this variable (F(2,43)=2.14, n.s.) (Table 4). Another factorial ANOVA for the variable
time sniffing the novel conspecific, did not reveal an effect of MSX-3 (F(1,43)=0.14,
n.s.), it did not show a significant effect of ethanol although it was close to significance
(F(2,43)=2.73, p=0.08), and the interaction was not significant (F(2,43)=0.43, n.s.).
When comparing the behavior of every group of animals in the exploration of the
known and novel conspecific, the control group that had been treated with vehicle-
vehicle the day before spent significantly more time sniffing the novel conspecific vs.
the familiar conspecific as expected if the animal recognizes the known conspecific
(t=4.71, p<0.01). This result was also observed in animals treated with MSX-3 1.5
mg/kg plus vehicle (t=2.64, p<0.05), and with MSX-3 1.5 mg/kg plus the lowest dose of
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ethanol 0.5 g/kg (t=2.52, p<0.05). However, the group treated with MSX-3 1.5 mg/kg
plus the highest dose of ethanol 1.0 g/kg showed memory impairment since the time
spent exploring both conspecifics was not different (t=-0.93, n.s.). There were no
differences between time sniffing the novel conspecific vs. novel conspecific either in
mice that had received vehicle plus ethanol 0.5 g/kg (t=0.62, n.s.) or vehicle plus
ethanol 1.0 g/kg (t=-0.21, n.s.). Thus, it seems that MSX-3 had a preventive effect only
when the dose of ethanol was low.
Time sniffing (sec)
Etoh (g/kg) 0.0 0.5 1.0
MSX3
(mg/kg) Familiar Novel Familiar Novel Familiar Novel
0.0 75.1±4.9 138.3±14.0## 105.6±11.9 118.7±13.3 120.0±24.6 114.6±19.8
1.5 84.1±10.9 160.1±24.8# 68.7±7.8 109.3±12.3# 142.6±20.0 117.8±12.2
Table 4. Effects of MSX3-ethanol combination on social recognition memory. Data are expressed as
mean ±SEM of time in seconds sniffing novel or familiar conspecifics. ##p<0.01, #<p0.05 significant
differences between time in familiar vs time in novel conspecific for the same dose of MSX3 and ethanol.
4. Discussion
In the present study, we characterize the impact of two of the most commonly
consumed drugs of abuse, caffeine and alcohol, on motivation for social contact as
manifested by social preference or avoidance, and also on consolidation of social
memories. We evaluated the possibility of a common mechanism of action for both
drugs via the adenosine system. Thus, we hypothesized that low to intermediate doses
of alcohol could lead to an increase in adenosine levels that would counteract the effect
of caffeine, which acts as a non-selective A1 and A2A antagonist. For that purpose, the
effects of selective A1 and A2A receptor antagonists were also assessed alone or in
combination with ethanol.
Our results show that the suppressing effects of high doses of caffeine on social
approach and preference can be counteracted by low doses of ethanol, but this reversal
effect reaches a ceiling when ethanol starts to mildly impair social approach and
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preference on its own. Ethanol at the low dose did not improve social approach by
reducing the physiological stress response induced by caffeine, which increased plasma
corticosterone levels at these doses. However, since there is not a clear direct
relationship between endocrine measures of stress and behavioral anxiety measures
(Marquez et al. 2006), we cannot rule out anxiety as the cause of these changes in social
preference and approach. In fact, social interaction has been mostly used to evaluate
anxiety in rodents, because it was found that anxiolytics increase time spent in active
social interaction while anxiogenic drugs decrease social contact independently of any
change in activity (File and Hyde 1979; Guy and Gardner, 1985). Thus, the reduction in
social preference observed after caffeine administration could be explained by an
increase in anxiety, since doses ranging from 25 to 100 mg/kg have been demonstrated
to have a potent anxiogenic effect in this strain of mice as seen in the elevated plus
maze (López-Cruz et al. 2013). It is also possible that anxiolysis induced by ethanol
could be playing a role in potentiating social interaction as suggested by previous
researchers (Nadal et al. 1993; Hilakivi et al, 1993). However, it cannot be the only
explanation for this effect since doses of ethanol that induced anxiolysis in this strain of
mice (0.5 and 1.0 g/kg) in an elevated plus maze (Correa et al. 2008) were not able to
reverse social preferences to normal levels. Moreover, in the present study we used a
procedure developed to minimize anxiety in the experimental mouse by eliminating the
possibility of physical aggression since the target mouse was enclosed in a wire cage
(Crawley, 2004; Moy et al. 2007). Thus, in this paradigm it is possible to assess
preference or avoidance for social interaction based on free choice. Furthermore, none
of the pharmacological manipulations used in the present series of studies produced a
significant avoidance for the compartment where the conspecific was located (data not
shown). The effects of caffeine and ethanol alone or in combination on social behavior
do not seem to be mediated by their effects on locomotion either, because the range of
doses used do not clearly impair locomotion, and an increase in locomotion induced by
the lowest doses of caffeine (7.5 and 15.0 mg/kg) seem to be unrelated to social
exploration.
Although a strength of the present study was the use of a broad range of doses for all
drugs, including the studies of drug interaction (most of the previous studies have used a
single dose approach), it is not clear that the effect of high doses of caffeine were
mediated by its actions on adenosine A1 and A2A receptors, since neither of the selective
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adenosine receptors reduced social interaction at the doses tested. Because in the present
paradigm the experimental mouse has to explore a broad area that separates the two
targets (conspecific and object), we selected doses of caffeine and selective adenosine
antagonists based on results from previous work showing no impairing effects on
ambulation and rearing in an open field (López-Cruz et al. 2013; Pardo et al. 2013), in
order to avoid the possibility of mediating variables related to motor function. Thus, the
A1 antagonist CPT did not produce a significant change in social approach and
preference, although mice spent more time in the conspecific compartment at the low
doses (data not shown), and there was no interaction with ethanol on these parameters.
It is possible, however, that higher doses of CPT could mimic the effects of caffeine on
social preference. On the other hand, the A2A receptor antagonist MSX-3 did have a
significant effect, increasing preference for the social target and reducing it for the
object. It is also worth noting that although general exploration (crossings between the 3
compartments) increased, MSX-3 did not disturb focused social exploration. Moreover,
there was no significant interaction between MSX-3 and ethanol on any of these
parameters; the improving effect of MSX-3 on preference was maintained at the same
level independently of the dose of ethanol (0.5 or 1.0 g/kg) that the animals received.
Consistently, high levels of social interaction have been observed in A2A receptor KO
mice, and these animals were not affected by a dose of ethanol (1.0 g/kg) that impaired
social interaction (López-Cruz et al. submitted). Interestingly, A2AKO mice showed an
anxiogenic profile, which again argues against a straight relationship between anxiety
and social interaction (López-Cruz et al. submitted).
A decrease in exploring a familiar conspecific when a new one is also present has been
interpreted as an index of social recognition (Thor and Holloway, 1982; Moy et al.
2004; Crawley, 2004), which some authors consider to be also an index of preference
for novelty seeking (Costa et al. 2014). Whatever the interpretation, it is required that
the animal consolidates a memory for the familiar conspecific. Adenosine seems to
modulate short-term social memory in rats by acting on both A1 and A2A receptors, with
adenosine receptor agonists and antagonists respectively disrupting and enhancing
social recognition memory (Prediger and Takahashi, 2005). Thus, the selective A1
agonist CCPA and the A2A agonist DPMA disrupted juvenile recognition in adult rats
(Prediger and Takahashi, 2005). This impairment of short-term social memory induced
by adenosine agonists was reversed by caffeine, the A1 antagonist DPCPX, and the A2A
CHAPTER 3
132
antagonist ZM24138 (Prediger and Takahashi, 2005). Moreover, acute administration of
caffeine or selective A2A antagonists reversed the disruption of social recognition
memory in ageing rats (Prediger et al. 2005a) and also in spontaneously hypertensive
rats (Prediger et al. 2005b) in which some alterations in the adenosinergic
neurotransmission have been reported (Matias et al. 1992; Cunha et al. 1995; Lopes et
al. 1999; Davies et al. 1987). However, all these studies evaluated short-term social
memory and not long-term social memory.
If the recognition test is carried 24 hours after the first presentation it can be considered
as a test of long-term memory processes. The development and consolidation of long-
term potentiation seems to be also modulated by adenosine receptor-dependent
mechanisms in the hippocampus (Tanaka et al. 1990; de Mendonca and Ribeiro 1994;
Hauber and Bareiss, 2001). Data from the present study indicates that caffeine at high
doses impaired recognition on the following day, especially at those doses (30.0 and
60.0 mg/kg) that had reduced relative preference for social interaction the day before.
Thus, mice explored familiar and novel conspecifics equally, which could be explained
by the fact that animals had explored the conspecific much less time the day before than
animals under control conditions. It is possible that the ability of caffeine to improve
memory at low doses could be seen under different experimental conditions. In fact,
theophylline has been demonstrated to facilitate long-term spatial reference memory in
retention sessions, but not in working memory, both of which are tasks that are highly
dependent on hippocampus (Hauber and Bareiss, 2001). Thus, when the nature of the
task involves optimal performance during basal conditions is very difficult to improve
performance.
It is well know that ethanol can produce amnesic effects and impair retrieval of
memories after the drug wears off (Goodwin 1995; Hartzler and Fromme 2003; Gulick
and Gould, 2007; 2009). Ethanol-induced memory impairments can be produced by
disruption of attention, and also by affecting neural mechanisms involved in memory
consolidation such as the adenosinergic system (Tanaka et al. 1990; Gulick and Gould,
2007; 2009). In experiment 2, ethanol, even at doses that did not impair social
interaction (0.5 g/kg), impaired social recognition 24 hours later. In spite of been a
situation of low performance, caffeine (15.0 or 30.0 mg/kg) co-administration was not
able to block the amnesic effects of ethanol. A previous study in rats explored the effect
of caffeine-ethanol interaction on long-term memory using social odors (Spinetta et al.
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2008). In that study ethanol was administered immediately after exposure to the social
odor, and a recognition test was performed 24 hours later (Spinetta et al. 2008).
Caffeine, at a low dose that did not have an effect on its own (5 mg/kg), was able to
prevent the disruptive effects of ethanol (1.0 g/kg) on memory consolidation (Spinetta et
al. 2008). It is possible that in our study lower doses of caffeine could have improved
ethanol-induced deficits. The behavioral effects induced by methylxantines at low doses
are likely to be mediated by an nonselective adenosine A1/A2A receptor blockade,
while higher doses might involve additional mechanisms such as inhibition of
phosphodiesterases (Nehlig et al. 1992; Hauber and Bareiss, 2001).
As for the role of selective adenosine receptor antagonists, it appears that although CPT
did not affect social interaction, it mildly impaired long-term social recognition at low
doses, an effect that was not observed at high doses. CPT was not able to reverse the
ethanol-induced impairment of recognition memory. In contrast, the selective A2A
antagonist MSX-3, which increased preference for the conspecific when administered
alone, did not impair social recognition, and was able to block the amnesic effect of the
lower dose of ethanol (0.5 g/kg). Thus, in our studies a selective A2A antagonist was
able to improve social memory under conditions of suboptimal performance (ethanol
amnesic effects), but not under optimal performance (i.e., non-treated animals). This
improvement in memory might be due to actions on processes involved in learning,
such as attention and wakefulness, but may also be related to direct actions on learning
and memory.
Although it is clear that normal social interaction is required for normal retrieval of
social memories, the data from the present studies indicate a relative independence
between social preference and social long-term memory processes. The results available
at the present moment also suggest that A1 receptors do not seem to regulate social
motivation and social recognition, since blocking their tonic activity has very little
effect. A1 receptor antagonists appear to play only a modest role in the regulation of
dopamine-dependent aspects of motivated behaviors (Nunes et al. 2013; Salamone and
Correa 2012). Moreover, because selective A1 and A2A antagonists did not mimic the
effects of caffeine, it is possible that blockade of both receptors is necessary for
producing a caffeine-like action. Alternately, it is possible that at high doses caffeine
may not be acting solely as an adenosine antagonist. Thus, although an increase in
adenosine levels could be mediating ethanol effects, the usefulness of highly caffeinated
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drinks in counteracting ethanol-induced impairments on these normal social processes is
questionable.
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Abstract
Social interaction paradigms evaluate the natural preference of animals for exploring
other conspecifics and the ability to differentiate between familiar versus novel ones.
Anxiety is one of the factors that can induce avoidance of social interaction. It has been
demonstrated that blockade of adenosine A2A receptors can potentiate motivation for
natural reinforcers, but can also induce anxiety. However, the role of adenosine
receptors in motivation for social interaction has not been widely explored. In the
present study, A2A knockout (A2AKO) and wild-type (WT) mice were assessed for
social and anxiety-related behaviors. c-Fos immunoreactivity was evaluated as a
measure of neuronal activation in brain areas involved in motivational and emotional
processes. Although A2AKO mice showed an anxiogenic profile, they displayed higher
levels of sociability than WT mice. WT mice displayed a typical pattern of social
recognition 24 hours later, but not A2AKO mice, which explored equally both
conspecifics. There were no differences between strains in aggressiveness or social odor
preferences. c-Fos immunoreactivity in A2AKO mice was higher in anterior cingulate
and amygdala compared to WT mice. An anxiolytic dose of ethanol eliminated
differences between strains in social preference, and impaired conspecific recognition in
WT mice. In conclusion, A2AKO mice tend to engage more in social exploration and are
less sensitive to social novelty. In these animals, there seems to be a dissociation
between baseline and ethanol-related anxiety and motivation for social interaction.
Thus, A2A receptors appear to be potential targets for the improvement of pathologies
related to social function.
Key words: social preference, social recognition, adenosine, anxiety, aggressive
behavior, c-Fos, marble-burying test.
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Introduction
Adenosine is a central nervous system (CNS) neuromodulator that in the brain acts
mainly via the activation of high affinity A1 and A2A G-protein coupled receptors
(Fredholm et al., 2001). While A1 receptors are widely distributed in the brain, A2A
receptors are predominantly localized and highly concentrated in the basal ganglia.
Nucleus accumbens and caudate/putamen have a high concentration of adenosine A2A
receptors (Ferré et al., 2004; Jarvis and Williams, 1989; Vontell et al., 2010), and
considerable evidence indicates that those adenosine receptors interact with dopamine
receptors in the regulation of the activational component of motivated behaviors such as
actively seeking natural reinforcers (i.e.: food or sucrose) (Salamone and Correa, 2009).
Adenosine A2A receptors are also highly concentrated in the olfactory tubercle (Vontell
et al., 2010), and to a much lesser extent, in amygdala (Fredholm et al., 2001;
Schiffmann et al., 2007), both important regions for the regulation of social behaviors in
rodents (Sano et al., 2008).
Although adenosine has been demonstrated to modulate processes involved in social
interaction such as exploration (Florio et al., 1997), arousal (Dunwiddie & Worth,
1982), anxiety (Correa & Font, 2008), and memory (Zarrindast & Shafaghi, 1994), the
role of adenosine and adenosine A2A receptors in seeking social interaction has not been
widely explored. In some studies, caffeine, a non- selective adenosine receptor
antagonist (A1/A2A) has been shown to decrease social interaction in rodents at high
doses, which has been interpreted as an axiogenic effect (Daldwin et al., 1989; Hilakivi
et al., 1989). However, lower doses seem to potentiate social contact (Nadal et al.,
1993). Anxiolytic drugs such as ethanol (Correa et al., 2008), which increases the brain
adenosinergic tone (Nagy et al., 1990), has also been demonstrated to increase social
interaction at low doses (Nadal et al., 1993) but decrease it at high doses (Hilakivi et al.,
1989).
On the other hand, caffeine and selective adenosine antagonists for A1 and A2A
receptors improve short-term social memory in rats (Prediger & Takahashi, 2005),
while ethanol impairs social recognition in mice (Manrique et al., 2005). Thus, it is not
clear how adenosine regulates social motivation or social memory, and if adenosine
modulation of anxiety can reduce social exploration in rodents.
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In the present study, we focused on the impact of A2A receptor deletion (A2A receptor
knockout, A2AKO) on motivation for social exploration, as well as social memory, in
mice. These A2AKO mice have been shown to be more aggressive, and more anxious,
and they display lower levels of locomotion than their wild type (WT) counterparts
(Ledent et al., 1997; Berrendero et al., 2003). However, their patterns of social behavior
have not been previously explored. Thus, the present work evaluates the performance of
A2AKO mice on tests of social preference, recognition, and anxiety. The impact of an
anxiolytic dose of ethanol on social behaviors was also explored in these animals.
Because perseverative behavior, aggressiveness or odor detection problems could
regulate social behavior patterns in rodents (Liebenauer & Slotnick et al., 1996;
Bortolato et al., 2011; Doty, 1986), these processes were also evaluated. Finally,
expression of the immediate early-gene product c-Fos as a measure of neuronal
activation was evaluated in different A2A receptor containing regions, as well as areas
that are important for the regulation of motivation and emotion.
Materials and methods
Subjects
Male mice lacking the A2A adenosine receptor and WT littermates (N=9 and 10
respectively) were generated from a CD1 background by C. Ledent at Universite Libre
de Bruxelles (Belgium), as previously reported (Ledent et al., 1997). All animals
weighted 30-40 g at the beginning of the study and were housed in groups of 3 or 4
animals per cage with water and food available ad libitum. The colony was kept at
temperature of 22 + 2 ºC with lights on from 8:00-20:00h. All animals were under a
protocol approved by the Institutional Animal Care and Use committee of Universitat
Jaume I, and all experimental procedures complied with European community Council
directive (86/609/EEC).
Drugs
Ethanol (Panreac Quimica S.A., Spain) was diluted to 20% (v/v) in physiological saline
(0.9 % w/v) and administered intraperitoneally (IP) 10 minutes before testing. Saline
solution was used as vehicle. The dose of ethanol used (1.0 g/kg) was based in previous
studies with the same strain (Correa et al., 2008).
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Behavioral apparatus and testing procedures
The behavioral test room was illuminated with a soft light, and external noise was
attenuated. All tests were videotaped and dependent variables were later registered by a
trained observer unaware of the experimental condition.
Anxiety in the dark and light box (DL)
The DL test is based on the conflict between the inherent tendencies of mice to explore
a novel environment vs. their natural avoidance of a brightly lit open field. The DL
apparatus consisted of a polypropylene chamber divided in two compartments by a
partition containing a small opening. One compartment was open and illuminated while
the other was enclosed and dark. Initially each subject was placed in the dark
compartment. Latency to enter the lit compartment, latency to go back into the dark
compartment, total time spent in the lit compartment and total number of crosses
between chambers were recorded manually over 5 min.
Anxiety in the elevated plus maze (EPM)
The EPM consists of two open and two enclosed arms arranged in a plus conﬁguration.
This anxiety paradigm measures the avoidance that rodents show to elevated open
spaces. Animals were placed in the central platform facing a closed arm and assessed
during 5 minutes. Time spent in the open arms, ratio of entries into the open arms to
total arm entries, and latency to enter the open arms as measures of anxiety were
evaluated. Total number of entries in the four arms was recorded as an index of
locomotion. An entry into an arm was recorded when the animal crossed the line that
connected that arm with the central platform with all four legs.
Marble-burying task
Burying behavior in rodents involves the displacement of bedding material in an effort
to cover an object as a defensive mechanism against potentially threatening objects
(Pinel & Treit 1978), and it can be extended in time as a sign of perseverative or
repetitive behavior (Thomas et al., 2009). Mice were placed individually in clean cages
containing fresh bedding (5-6 cm deep) on top of which were placed 25 black marbles
arranged in five evenly spaced rows of five marbles each. Testing lasted 5 minutes.
Number of non-buried marbles at the end of this period was recorded.
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Olfactory preference test
Although contact is important, olfaction is a key component of social interaction in
mice (Bluthe & Dantzer, 1993). Animals were compared in their preference between a
non-social odor and a social odor. The social odor was obtained by rubbing a cotton ball
off the body of an unknown mouse. The non-social odor consisted of a drop of a floral
essence in a cotton ball. This experiment took place in the three-chamber box used for
the social preference and novelty experiments. Testing lasted 10 minutes and time spent
sniffing each target (social vs. non-social odor) was registered by a trained observer
unaware of the experimental condition.
Social preference and social recognition tests.
Sociability was measured in a three-chambered social box (Crawley, 2004), and the
general procedure was adapted from Chévere-Torres and colleagues (2012). Mice
received two habituation sessions in the social arena in two consecutive sessions. In the
first session, they freely explored the empty social arena during 15 minutes, and then a
second exploration session (30 minutes) was allowed to be in the presence of two wire
cages, one in each of the chamber sides. After these two habituations (45 minutes total),
the social preference test lasted 10 minutes and started by placing the animal in the
empty middle compartment. Mice were allowed to explore the three-chambered arena,
which in one chamber contained a caged with a conspecific, and in the opposite side
chamber a cage with an object (Fig 4A). The placement of the conspecific or object was
counterbalanced between animals. Time spent sniffing each target (conspecific vs.
object) and time spent in each compartment were evaluated as measures of social
preference. Vertical and horizontal locomotion in all compartments were also registered
as indices of motor behavior. The following day (24 hours after social preference test)
mice were placed in the central chamber and were evaluated during 10 minutes in a
“social novelty test”. During this test a novel caged mouse replaced the object. Thus,
mice were given the choice to interact with a familiar conspecific (same conspecific
used in the social preference test) versus a novel conspecific (Fig 4B). The same
parameters were registered. The index of social recognition is based upon comparing
the time spent investigating the novel mouse vs. the more familiar one (Moy et al.,
2004).
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Fig 4. Schematic illustration of social preference (A) and social novelty tests (B).
Aggressive behavior
Since our social interaction paradigm avoids body contact, aggressive behavior was
evaluated by registering tail rattle frequency during the social recognition test (10
minutes). Tail rattling was defined as rapid vibrations of the tail, which has been
classified as reflecting threat behavior during aggressive encounters (Krsiak, 1979).
c-Fos visualization and quantification
Mice were anesthetized and perfused after the social preference and novelty tests.
Brains were collected and stored in 3.7% formaldehyde solution during 24 h and
refrigerated in sucrose (30%), sodiumazide (2%) and PB 0.1M solution prior to slicing.
Free floating coronal sections (40 µm) were serially cut using a cryostat (Microm HM
560, Weymouth, MA, USA), rinsed in 0.01 M PBS (pH 7.4) and incubated in 0.3%
hydrogen peroxide for 30 minutes to block endogenous staining. Sections were then
rinsed in 0.01 M phosphate buffer (PBS) (3 × for 5 minutes) and transferred into the
primary antibody, anti-c-Fos (Calbiochem, Germany) for 24 h incubation. Following the
primary antibody treatment, the sections were rinsed in PBS (3 × for 5 minutes) and
incubated in the secondary antibody, anti-rabbit HRP conjugate, envision plus (DAKO,
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Denmark) for 1.5 h. The immunohistochemical reaction was developed using
diaminobenzidine (DAB) as chromogen (DAKO). Processed sections were then
mounted to microscope slides (Menzel-Gläser, Superfrost ® Plus, Thermo scientific), air
dried, and cover-slipped using Eukitt® (Sigma Aldrich) as a mounting medium. The
sections were examined and photographed using a Nikon Eclipse E600 (Melville, NY,
USA) upright microscope equipped with an Insight Spot digital camera (Diagnostic
Instruments, Inc). Images of the regions of interest were magnified at 20X and captured
digitally using Stereo Investigator software. Cells that were positively labeled for c-Fos
were quantified with ImageJ software (v. 1.42, National Institutes of Health sponsored
image analysis program) in three or four sections per animal, and the average value per
mm2 was used for statistical analysis.
Statistical analysis
Normally distributed data with homogeneity of variance were evaluated by Student's t-
test for independent samples, and Mann-Whitney U test was used to analyse non-
parametric data. Student's t-test for dependent samples was used to analyse “preference”
(e.g. conspecific vs. object). A probability level of 0.05 or smaller was used to indicate
statistical significance. Statistics were done using STATISTICA 7 software.
Results
Experiment 1: Anxiety in the DL test.
Statistical analysis revealed that KO mice spent significantly less time in the lit
compartment (t=-2.56, p<0.05), and had a higher latency to enter into the lit
compartment (U=27,0, p<0.05) compared to their WT counterparts (Figs. 1A and B).
Latency to go back to the dark compartment did not reach statistical significance
(U=50.0, n.s.) (Fig. 1C). There were no differences between strains in the total number
of crosses between compartments (t=-0.84, n.s.) (Fig. 1D).
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Fig 1. WT and KO mice performance in the elevated plus-maze. Data are expressed as mean
(±SEM) of time spent in the open arms (A), latency to enter in one of the open arms for the first
time (B), ratio of open arm entries versus total entries (C) and total crosses between arms (D).
**p<0.01, *p<0.05 significant differences between strains.
Experiment 2: Anxiety in the EPM test.
Also in this test, KO mice displayed an anxiogenic profile in comparison with their WT
counterparts. They spent significantly less time in the open arms (t=-2.84, p<0.05), and
had a lower ratio of entries into the open arms compared to WT mice (t=-2.15, p<0.05)
(Fig. 2A and C). No differences in latency to enter into an open arm for the first time
(U=49.0, n.s.) (Fig. 2B) or in total number of crosses (Fig. 2D) were observed between
the strains in this paradigm (t=0.98, n.s.). Thus, in both paradigms, locomotion does not
seem to be the source of differences in anxiety.
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Fig 2.WT and KO mice performance in the dark and light box. Data are expressed as mean (±SEM) of
time in lit compartment (A), latency to enter the lit compartment (B), latency back to the dark
compartment (C) and number of crosses between compartments. **p<0.01, *p<0.05 significant
differences between strains.
Experiment 3: Anxiety-perseverative behavior in the marble burying test.
The Mann-Whitney U test showed no differences between WT and KO mice in number
of non-buried marbles in 5 minutes (U=116.5, n.s.), although there was a non-
significant tendency of the KO mice to bury more marbles than WT in the same period
of time (Fig. 3A).
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Experiment 4: Odor preference tests.
The Student's t-test showed that both strains of mice, KO and WT, spent significantly
more time exploring social odors than non-social odors (t=-8,44, p<0.01, t=-5.83,
p<0.01, respectively). Although there was a tendency for the KO mice to spend more
time sniffing social odors than the WT mice, this effect did not reach statistical
significance (t=-1.78, n.s.) (Fig. 3B).
Experiment 5: Social preference test.
In the social preference test, when comparing preference between stimuli for each
strain, the Student's t-test for dependent samples showed that both types of mice spent
Fig 3. WT and KO mice performance in
the marble burying test, and the odor
preference test. Data are expressed as mean
(±SEM) of number of non-buried marbles
(A), and time sniffing the cottons with the
social and non-social odors (B). #p<0.05
significant differences in time spent
exploring the different odors in the same
strain.
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significantly more time sniffing a conspecific than an object; KO (t=7.36, p<0.01) and
WT (t=3.23, p<0.05). They also remained in the compartment with the conspecific
longer than in the object compartment; KO (t=3.80, p<0.01) and WT (t=2.44, p<0.05).
Thus both WT and KO mice showed a clear social vs. non-social preference. In
addition, Student's t-test for independent samples comparing both strains for each
stimuli indicated that KO mice spent more time sniffing the conspecific compared to
their WT counterparts (t= -2.32, p<0.05), and they also spent more time in the
compartment with the conspecific than their WT counterparts (t=-2.03, p<0.05). There
were no significant differences between strains in relation to object exploration (t=0.26,
n.s). However, a Student's t-test for independent samples showed that KO mice spent
less total time in non-social compartments (object plus middle compartments) than WT
mice (t=-3.01, p<0.05). These results suggest that KO mice allocate more time into
social exploration than WT mice. There was not a significant effect of the strain on
horizontal (t=1.18, p= n.s) and vertical locomotion (t=0.82, p= n.s). For all these data
see Fig. 5A to 5D.
Fig 5. WT and KO mice performance in the social preference test. Data are expressed as mean (±SEM) of
time sniffing the conspecific or the object (A), time spent in the compartments were the conspecific or the
object are located (B), total time spent in non-social compartments (middle plus object) (C), and total
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horizontal and vertical locomotion (D). *p<0.05, **p<0.01 significant differences between strains.
#p<0.01, ##p<0.05 significant differences in the same strain.
Experiment 6: Social recognition test, and aggressive behavior.
In the social recognition test, WT mice spent more time sniffing a novel conspecific
than a familiar one (t=-2.81, p<0.05), and the tendency was the same in the variable
time in compartments (novel versus familiar conspecific), though it did not reach
statistical significance (t=-1.84, n.s.). Thus, control mice displayed a normal recognition
pattern. However, in KO mice, there were no differences either in time sniffing familiar
versus novel conspecific (t=0.42, n.s.), or in time spent in those compartments (t=0.96,
n.s.) (Fig. 6A and B). When comparing between strains, the Student’s t-test showed that
KO mice spent more time sniffing the familiar conspecific (t=-2.33, p<0.05), and
remained more time in the familiar conspecific compartment (t=-2.61, p<0.05) in
comparison with WT mice, showing again a higher level of social exploration. The
Mann-Whitney U test did not show differences between WT and KO mice in threat
behavior evaluated as the number of total tail-rattling behaviors during the social
recognition test; neither during interaction with familiar conspecifics, nor with novel
mice (U=26.00, n.s., U=20.5, n.s.) (Fig. 6C). No differences in total crosses and rearing
were observed between strains (t=2.08, n.s.; t=1.78, n.s., respectively) (Fig.6D).
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Fig 6. WT and KO mice performance in the social novelty test. Data are expressed as mean (±SEM) of
time sniffing the familiar or the novel conspecifics (A), time spent in compartments (B), number or tail
ratling bouts during conspecific exploration (C), and total horizontal and vertical locomotion (D).
*p<0.05, significant differences between strains. #p<0.05 significant differences in the same strain.
Experiment 7: c-Fos immunoreactivity in different brain areas.
Fig 7. Left part: Sagital plane of the mouse brain with bregma coordinates: 1.94 mm (A), 1.18 mm (B)
and -1.34 mm (C). Right part: Diagram of coronal sections with bregma coordinates (A, B and C)
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showing location of the brain areas for c-Fos counting taken from Franklin and Paxinos, 2007. Lower
part: Photomicrographs of c-Fos immunoreactivity staining in ACg and ACo from representative WT and
KO animals. Images at 20x, scale bar = 250 μm.
Differences in c-Fos immunoreactivity between WT and KO mice were assessed in
brain areas rich in A2A receptors, some of which are traditionally implicated in social
exploration. These data are shown in Table 1 and Fig. 7. When analyzing data for c-
Fos immunoreactivity in brain regions such as all prefrontal cortex, all striatum and all
amygdala, there were no significant differences between strains either in cortical or in
striatal regions (t=-1.66, n.s., t=-1.17, n.s. respectively). However, in amygdala KO
mice showed higher c-Fos immunoreactivity than their WT counterparts (t=-2.47,
p<0.05).
Separate analysis for every specific brain area showed significant differences in c-Fos
staining between WT and KO mice in ACg. KO mice showed significantly more c-Fos
immunoreactivity than WT in this region (t=-2.24, p<0.05). However no differences
between strains were observed in the other cortical regions explored, PrL and IL (t=-
0.88, n.s; t=-0.72, n.s, respectively). There were no differences in c-Fos
immunoreactivity in regions of dorsal striatum; DMS and DLS (t=0.44, n.s. and t=0.75
n.s., respectively), or ventral striatum; AcbC and AcbSh (t=0.95, n.s. and t=1.00, n.s.,
respectively). Although KO mice showed almost double c-Fos staining in the OT, this
difference did not reach statistical significance (t=-1.64, n.s). The same pattern was
observed in specific amygdala regions, in which no differences were seen between WT
and KO in c-Fos expression in individual nuclei; BLA, CeA, MeA, or ACo (t=-0.54,
n.s; t=-0.44, n.s; t=-1.50, n.s; t=1.49, n.s, respectively).
CHAPTER 4
157
Strain
Brain area WT KO
Prefrontal Cortex
ACg 61.5 ± 14.9 100.0 ± 8.6*
PrL 21.7 ± 3.2 32.4 ± 11.8
IL 23.2 ± 5.3 33.3 ± 13.0
Striatum
DMS 53.8 ± 13.7 38.6 ± 12.8
DLS 23.7 ± 5.9 21.3 ± 4.6
AcbSh 21.7 ± 4.3 21.7 ± 6.8
AcbC 27.4 ± 5.7 27.9 ± 7.1
Olfactory system
OT 7.6 ± 2.8 14.5± 3.2
Amygdala *
BLA 9.1 ±1.8 18.24 ± 5.2
CeA 18.6 ± 6.9 23.52 ± 8.7
MeA 34.5 ± 12.3 58.80 ± 9.4
ACo 26.9 ± 4.9 54.5 ± 17.8
TABLE 1. c-Fos immunoreactivity in several brain areas of WT and KO mice (N=5-6 per group). Mean
(±SEM) number of c-Fos positive cells per mm2. *p<0.05 significant differences between strains. ACg
anterior cingulated cortex; PrL, prelimbic cortex; IL, infralimbic cortex; DMS, dorsomedial striatum;
DLS, dorsolateral striatum; AcbSh, nucleus accumbens shell; AcbC, nucleus accumbens core; OT,
Olfactory tubercle; BLA, basolateral nucleus of amygdala; CeA, central nucleus of amygdala; MeA,
medial nucleus of amygdala; ACo, anterior cortical nucleus of the amygdala.
Experiment 8: Effect of an anxiolytic dose of ethanol on social preference.
After receiving an anxiolytic dose of ethanol (1.0 g/kg) both strains behave similarly in
the social preference test (Fig. 8A and B). A Student’s t-test for dependent samples
showed that both strains spent significantly more time sniffing a conspecific than an
object; WT (t=6.84, p<0.01) and KO (t=4.01, p<0.01). In addition, WT mice remained
in the compartment with the conspecific longer than they did in the object compartment
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(t=3.51, p<0.01). This tendency was also observed in KO mice, however it did not reach
statistical significance (t=1.72, n.s.). When comparing both strains, the Student’s t-test
for independent samples showed no differences between WT and KO mice after
receiving ethanol, neither in time sniffing the conspecific (t=0.35, n.s.), nor in time
exploring the object (t=-1.45, n.s.). Both strains also were not different in time spent in
compartments (conspecific and object, t=0.41 n.s., t=-1.34, n.s., respectively). Time in
non-social compartments (middle plus object compartment, Fig. 8C) was not different
between both strains after ethanol administration (t=0.01, n.s.). Thus, both strains
showed a clear but equal social preference after ethanol administration. Horizontal
locomotion after receiving ethanol was significantly lower in KO than in WT (t=2.60,
p<0.05), but no differences were observed in vertical locomotion (t=1.49, n.s) (Fig. 8D).
Fig 8. WT and KO mice performance in the social preference test after receiving 1.0 g/kg of ethanol. Data
are expressed as mean (±SEM) of time sniffing the conspecific or the object (A), time spent in the
compartments were the conspecific or the object are located (B), total time spent in non-social
compartments (middle plus object compartments) (C), and total horizontal and vertical locomotion (D).
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Experiment 9: Effect of an anxiolytic dose of ethanol administered before the
preference test on social recognition the following day.
Ethanol produced recognition memory impairments in both strains of mice, since both
WT and KO mice spent the same amount of time (or even more) with the familiar
conspecific compared to the novel one. Thus, Student’s t-test for dependent samples
revealed that WT mice spent significantly more time sniffing the familiar conspecific
than the novel conspecific (t=2.91, p<0.05, Fig. 9A), and there was no differences in
time in compartments (familiar vs. novel) (t=0.82, lllln.s., Fig. 9B). KO mice spent
similar time sniffing novel and familiar conspecifics (t=1.11, n.s.), and they spent more
time in the familiar conspecific compartment than in the novel conspecific compartment
(t=2.74, p<0.05), which suggests a lack of recognition. When comparing between
strains, KO mice spent significantly more time sniffing the novel conspecific than did
the WT mice (t=-2.91, p<0.01), although there were no differences in time spent in the
novel conspecific compartment (t=0.15, n.s.). There were no differences between strains
in time sniffing the familiar conspecific (t=-0.90, n.s.), however, KO mice spent
significantly more time than their WT counterparts (t=-2.43, p<0.05) in that
compartment. Thus, KO mice had a tendency to spend more time with both conspecifics
compared to WT animals. Finally, a dose of ethanol administered 24 hrs before seemed
to have an impact on vertical locomotion (t=2.02, p<0.05) in KO mice, however
horizontal locomotion was not affected (t=1.74, n.s).
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Discussion
The present study evaluated anxiety and social behavior patterns in A2AKO mice. The
results demonstrate that the lack of A2A receptors induces an anxiogenic pattern of
behavior that does not seem to impair social behaviors. Thus A2AKO mice, in
comparison with WT mice, were more anxious in the DL box, delaying the first
entrance into the lit compartment, and spending less time there. The same pattern of
results was observed in the EPM, in which A2AKO mice spent less time in the open
arms and had a lower ratio of entries to the open arms compared with total entries. Our
results in the anxiety paradigms are in agreement with previous studies (Ledent et al.
1997; Berrendero et al. 2003). In spite of been more anxious, A2AKO mice are more
Fig 9. WT and KO mice performance in the
social novelty test after receiving 1.0 g/kg
of ethanol. Data are expressed as mean
(±SEM) of time sniffing the familiar or the
novel conspecifics (A), time spent in
compartments (B), and total horizontal and
vertical locomotion (C). *p<0.05 significant
differences between strains. #p<0.05
significant differences in the same strain.
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sociable than WT mice; they spent more time exploring or in proximity to conspecifics.
Traditionally, social interaction paradigms in rodents have been used as models of
anxiety (File & Hyde, 1978; File & Seth, 2003). Thus, increases in social interaction
after drug administrations have been interpreted as reflecting anxiolytic actions,
whereas a specific decrease in social interaction has been considered as being due to an
anxiogenic effect (File & Seth, 2003). However, this correspondence between anxiety
levels and social interaction is not always clear (Egashira et al., 2007), as it has been
shown by the present results.
Social preference and social novelty tests in the three-chamber social paradigm provide
information about central aspects of social behavior, such as social motivation or
sociability, as well as novelty seeking or recognition of conspecifics. Sociability in this
case is defined as propensity to spend time with another conspecific compared to time
spent alone (Moy et al., 2004) or with an object in our case. Preference for social
novelty is defined as propensity to spend time with a novel conspecific and can be
interpreted in terms of novelty seeking (Costa et al., 2014), or also of recognition and
memory of the already know animal (Moy et al., 2004; Crawley, 2004). In our study,
A2AKO mice showed poor recognition of a familiar mouse, allocating equal amounts of
time exploring both conspecifics. This lack of social recognition could not be explained
by deficits in spatial memory, since A2AKO mice have previously been shown to have
better results in spatial memory tasks such as the Y test in comparison with WT mice
(Wang et al. 2006). Although greater exploration of a novel versus familiar conspecific
is a normal pattern of social recognition in rodents (Moy et al., 2004), it is possible that
since these mice seem more sociable they do not show distinctive preferences when the
two stimuli are conspecifics.
Lower horizontal and vertical activity has been previously reported for A2AKO mice in
an open field (Ledent et al. 1997; Chen et al. 2007; Berrendero et al. 2003; Pardo et al.
2013). However, in the present study, no significant differences in baseline locomotion
were observed between A2AKO mice and their WT counterparts in any of the
paradigms. Thus, differences between WT and A2AKO mice in this social task do not
seem to be influenced by differences in motor parameters leading to less exploration of
the chambers.
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A number of factors could be influencing this potentiated sociability observed in the
A2AKO mice. More aggressive tendencies, avoidance of non-social odors, or repetitive
and perseverative behaviors when checking other conspecifics, all could underlie an
apparent increase in sociability. For that reason we explored those behaviors. In the
marble test, A2AKO mice did not differ from WT controls, although the KO animals did
show a tendency to bury marbles in 5 minutes. Pharmacological studies established this
paradigm as a model of anxiety-related behavior (Broekkamp et al., 1986), although it
also has been suggested as test for preservative or repetitive behavior (Thomas et al.,
2009). Is possible that our conditions generated high levels of anxiety in both strains in
this paradigm, making difficult to observe clear differences in burying behavior. Odor
cues are known to be important for rodents in different contexts (Schellinck & Brown,
1998) and many behavioral tasks designed for mice depend on these cues. Olfactory
deficits could interfere with performance in our social tests and produce false positive
results. Thus, accurate assessment of olfaction is critical for proper interpretation of
mice behaviors within the social domain (Yang and Crawley, 2009). In addition, A2A
receptors are highly concentrated in the olfactory tubercle and olfactory bulbs (Kaelin-
Lang et al., 1999; Vontell et al., 2010). In experiment 4 of the present study, when a
social odor (rubbed in a cotton ball) was presented concurrently to a non-social odor
(floral odor in a cotton ball) in the three-chambered box, all animals spent more time
exploring the social odor, and no differences in non-social odor exploration were
observed between WT and A2AKO mice. There was a tendency for A2AKO to spend
more time than WT sniffing social cues, which could suggest a stronger sociability in
KO mice, though this effect was not significant. Previous studies have demonstrated
that A2AKO mice displayed an increased number of attacks and tail rattles, as well as a
decreased latency to attack the intruder in the resident-intruder test of aggression
(Ledent et al., 1997). However, no differences between WT and A2AKO mice were
observed in our experiment when evaluating the number of tail rattles as a measure of
basal levels of threat behavior towards the cage enclosed conspecific, possibly because
our setting did not potentiate aggressive behaviors.
Analyses of the c-Fos immunoreactivity data indicated that A2AKO mice showed greater
neuronal activation in brain regions that are important for the regulation of social
behavior. Amygdala is a region in which adenosine A1 and A2A receptors have been
identified (Brass et al., 1986; Svenningsson et al., 1997, 1999; Rosin et al., 1998), and
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this region, especially the medial nucleus, has been implicated in processing social
information in humans (Critchley et al., 2000) and in rodents (Young et al., 2002). In
our study, there was greater c-Fos immunoreactivity in A2AKO mice compared with WT
mice in the amygdala. OT is an area rich in A2A receptors that also is very important for
social behavior in rodents (Wesson et al., 2011), which receives inputs from the
accessory and main olfactory systems (Ubeda-Bañona et al., 2007; Martinez-Marcos,
2009). Although there was a tendency for the number of c-Fos positive cells in the OT
to be higher in A2AKO compared to WT animals, there was not a significant difference.
However, A2AKO mice did show significantly higher levels of c-Fos immunoreactivity
in ACg compared to WT animals. ACg is an important prefrontal area that is involved
in the regulation of aspects of motivation (Schweimer et al., 2005). Allocating more
time into social exploration (as the KO mice did) indicates increased preference, which
is an index of the directional component of motivation. ACg has also been implicated in
enhancing stimulus discrimination (Schweimer et al., 2005).
Previous studies using WT and A2AKO mice with the same CD1 background as the ones
used in the present study have shown how A2AKO mice have increased sensitivity to the
anxiolytic effects of low doses of ethanol (Houchi et al. 2008). Thus, we tried to assess
if a low dose of ethanol that has been shown to be anxiolytic in CD1 mice in previous
studies (Correa et al., 2008) can regulate social interaction in A2AKO mice. Although
ethanol did not change social exploration in WT mice, it did eliminate differences
between WT and A2AKO animals. Since ethanol increases adenosine levels (see López-
Cruz et al., 2013), it is possible that an ethanol-induced increase in adenosine tone can
counteract the effects of reduced A2A receptor transmission in KO animals, possibly by
acting on A1 receptors. An increase in adenosine after receiving ethanol can also explain
a reduction in locomotion in A2AKO mice seen in the social test. Thus, our studies with
A2AKO mice do not support the idea of a simple and direct relationship between anxiety
and social interaction in these mice, since ethanol reduced social exploration in A2AKO
mice but it induced anxiolysis in these animals (Houchi et al. 2008). In addition, ethanol
disrupted social recognition the following day in both strains, with a bigger impact on
WT animals that spent less time with the novel animals than the familiar ones. A2AKO
mice spent equal time with both conspecifics, suggesting that they had a higher
preference for social contact overall.
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Thus, the present results suggest that the A2A receptors are potential targets for the
regulation of social function, an aspect of behavior that seems to be affected in a variety
of neuropsychiatric disorders (Landau et al., 1991; Mueser et al., 1991). Future studies
should investigate pharmacological antagonists with different selectivity profiles for A1
and A2A receptors in order to elucidate the role of the adenosine system in socially
motivated behaviors. Moreover, since A2A receptors are localized in regions that also
are rich in neuropeptides such as oxytocin and vasopressin, which are important for the
establishment of social attachment (Tobin et al., 2010; Ferguson et al., 2011), A2A
receptors could be also important for modulating the actions of those neuropeptides.
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CHAPTER 5:
Does caffeine have a therapeutic role in depression?:
relevance for the treatment of motivational symptoms.
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Abstract
Major depressive disorder is one of the most common and debilitating psychiatric
conditions. Some of its motivational symptoms, such as anergia (lack of self-reported
energy) and fatigue, are resistant to traditional treatments with serotonin uptake inhibitors,
so new pharmacological targets are being investigated. Limited epidemiological data
indicate that caffeine consumption has an impact in some aspects of depressive
symptomatology. In animal studies, drugs that act on adenosine receptors are being
assessed for their effects on the modulation of behavioral functions related to depression.
Caffeine is a non-selective adenosine antagonist that binds to both A1 and A2A receptors,
and has been shown to modulate behavior in classical animal models of depression. This
review focuses on the effects of caffeine and selective adenosine antagonists on different
aspects of depression in humans, as well as in animal models. The effects of caffeine on
motivational symptoms of depression such as anergia and psychomotor slowing receive
particular attention. In that regard, the ability of caffeine to reverse the anergia induced by
dopamine antagonism or depletion is of special interest. In conclusion, it appears that
caffeine and adenosine antagonists could have potential as therapeutic agents for the
treatment of motivational dysfunction in depression.
KEYWORDS: caffeine, depression, adenosine, anergia, fatigue, amotivation, anxiety.
CHAPTER 5
174
Major Depression Disorder: symptomatology and current treatment
Major depression disorder (MDD) is one of the most debilitating psychiatric disorders
in the world (World Health Organization, 2004), and the most commonly diagnosed
(American Psychiatric Association, 2013). The Diagnostic and Statistical Manual
(DSM) in its last edition (DMS-V) defines this disorder as a set of symptoms that
include depressed mood, decreased interest or pleasure in almost all activities nearly
every day, appetite changes (changes in body weight), sleep disturbances, feelings of
worthlessness or guilt, diminished ability to concentrate or indecisiveness, psychomotor
agitation or retardation and fatigue or loss of energy (American Psychiatric Association,
2013).
Symptoms such psychomotor retardation, fatigue and loss of energy are related to the
activational component of motivation. Motivated behavior is directed towards or away
from particular stimuli, but it also is characterized by a high degree of activity, effort,
vigor, and persistence (Salamone and Correa, 2002). People with depression commonly
show profound activational impairments, such as lassitude, listlessness, fatigue and
anergia (low self-reported energy) that affect their motivation (Tylee et al., 2002; Stahl,
2002). In fact, among depressed people, energy loss and fatigue are the second most
commonly reported symptoms, only behind depressed mood itself (Tylee et al., 1999),
and depressed patients with anergia are more common than patients with anxiety related
symptoms (Tylee et al., 2002). Furthermore, in a factor analytic study of depressed
patients, “lack of energy” was a factor that correlated highly with problems such as
energy/fatigability, inability to work, and psychomotor retardation, loading most
strongly onto a second order general depression factor (Gullion and Rush 1998).
Moreover, many people with major depression have fundamental deficits in reward
seeking, exertion of effort, and effort-related decision making that do not simply depend
upon any problems that they may have with experiencing pleasure (Treadway et al., 2012).
Lack of energy is the symptom most highly correlated with impaired social function in
depressed patients, and is closely related to various work-related problems such as days
in bed, days of lost work, and low work productivity (Swindle, 2001). In addition, this
cluster of symptoms can be highly resistant to treatment (Stahl, 2002), and they are the
best predictors of lack of remission after antidepressant drug treatment (Stahl, 2002;
Gorwood et al., 2014).
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Treatments for the motivational and activational symptoms in depression.
The severity of effort-related motivational symptoms in depression is related to
problems with social function, employment absence, and treatment outcomes (Tylee et
al. 1999; Stahl 2002). Patients with high scores in psychomotor retardation also have
longer duration of illness, an earlier age of onset, and more depressive episodes (Calugi
et al., 2011; Gorwood et al., 2014). These symptoms are a predictor of delayed response
to treatment with either interpersonal psychotherapy or selective serotonin (5-HT)
reuptake inhibitor pharmacotherapy (Frank et al., 2011), often remaining as residual
symptoms even in patients in remission (Stahl, 2002; Fava et al. 2014; Gorwood et al.,
2014).
Most of the present treatment strategies for MDD focus on drugs that block the
inactivation (i.e., inhibitors of enzymatic breakdown or uptake) of the monoamine
neurotransmitters 5-HT and norepinephrine (NE). The classical antidepressants include
monoamine oxidase inhibitors (MAOIs), which affect one of the major catabolic
enzymes for monoamines (Quitkin et al., 1979), and drugs that inhibit uptake of one or
more monoamines (Feighner, 1999; Richelson et al., 1982; Yildiz et al., 2002).
Although 5-HT and NE reuptake inhibitors have become the most frequently prescribed
medications for MDD, they fail to induce symptom remission in 40%-60% of all
patients (Rush and Trivedi, 1995; Fava et al., 2014), and it is widely accepted that at
least 20% of all depressed patients do not respond adequately to most antidepressant
drugs (Crown et al., 2002). Many common antidepressants, including 5-HT transport
inhibitors such as fluoxetine, are relatively ineffective at treating anergia and fatigue,
and in fact, can induce or exacerbate these symptoms (Padala et al. 2012; Stenman and
Lilja 2013; Fava et al. 2014).
Interestingly, some clinical studies suggest that drugs that inhibit dopamine (DA)
transport, such as the catecholamine uptake inhibitor bupropion, are relatively more
effective than 5-HT uptake inhibitors for treating effort-related motivational symptoms
(Rampello et al. 1991; Stahl 2002; Demyttenaere et al. 2005; Pae et al. 2007).
Furthermore, a recent paper (Bell et al. 2013) reports that individual differences in
behavioral traits can differentiate between depressed patients that are more responsive
to bupropion (i.e., motivated, achievement-oriented, active, exercise-oriented people)
vs. fluoxetine (people with mood problems, irritability, and rumination). Stimulant
drugs that are not considered to be antidepressants in the classical sense, such as
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methylphenidate and modafinil, have been shown to increase energy and motivation in
depressed patients (Zisook et al., 2006). Thus, clinical studies, together with preclinical
investigations (e.g. Salamone et al. 2006, 2007; Salamone and Correa, 2012;
Argyropoulos and Nutt, 2013; Yohn et al., 2015ab), have led to the suggestion that DA
systems and related circuits are particularly involved in effort-related motivational
symptoms.
In addition to DA, another possible therapeutic target for the anergia component of
depression is the adenosinergic system. In the present review, we focus on studies that
assessed the effect of caffeine and selective adenosine antagonists on different aspects
of depression in humans, as well as in animal models of depression, with special
emphasis on motivational/psychomotor symptoms.
Caffeine consumption, depression and related mood symptoms.
Caffeine is a naturally occuring methylxanthine that acts mainly as a non-selective A1
and A2A adenosine receptor antagonist (Fredholm et al., 1999). This methylxantine is
found in common beverages including coffee, tea, soft drinks, and products containing
cocoa, as well as a variety of medications and dietary sources (Barone and Roberts
1996; Andrews et al., 2007). Thus, caffeine ranks as one of the most commonly
consumed dietary ingredients throughout the world (Heckman et al., 2010). Daily intake
of caffeine among consumers in US is about 280 mg, and higher intakes are estimated
in some European countries (Gilbert, 1984; Barone and Roberts, 1996). Caffeine is
typically consumed in order to increase alertness, arousal, activation and self-reported
energy (Malinauskas et al., 2007; Smith et al., 2002). Its consumption has been related
to changes in cognitive performance and mood in the normal population (Smith et al.,
2002), as well as in people with fatigue (Childs and de Wit, 2001).
There are very few studies on the relation between caffeine consumption and
depression-related symptoms, and in many cases, its use is related to self-medication
patterns. Some of these studies focus on the role of caffeine as a drug that prevents
depression, while others discuss caffeine as a possible treatment for existing depression.
Thus, in a longitudinal study in women free from depressive symptoms at baseline, high
levels of caffeine consumption (>550 mg/day) were negatively correlated with the
appearance of depressive symptoms (Lucas et al., 2011). In fact, the relative risk for
depression was higher for those women with lower caffeine consumption (<100
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mg/day; Lucas et al., 2011). However, in women with multiple sclerosis, high doses of
caffeine (>400 mg/day) increased the prevalence of MDD (Patten et al., 2000).
Moreover, in non-clinical samples, although caffeine consumption at moderate doses
was related to decreases in suicide risk (Kawachi et al., 1996; Tanskanen et al., 2004),
excessive consumption (750 mg/day) was correlated with a higher risk of suicide
(Tanskanen et al., 2004; Kawachi et al., 1996). Thus, from the present studies, it seems
that intermediate levels of caffeine consumption (300-550 mg/day) may produce
beneficial effects in non-clinical populations, but not in people with some neurological
pathologies. Higher doses appear to have negative effects, even in non-clinical
populations.
Multiple reports have lent support to the idea that depressed people could use caffeine
as self-medication. It has been reported that psychiatric patients show a relatively high
degree of caffeine consumption compared to the normal population (Greden et al, 1978;
Scott et al, 1989; Rihs et al., 1996, Leibenluft et al., 1993). This appears to be
particularly true in patients that have experienced depressive symptoms (Leibenlugt et
al., 1993). Different profiles of patients (i.e. with alcohol dependence, seasonal affective
disorder and people with MDD) have been shown to have higher levels of caffeine
consumption after experiencing depressive symptoms (as shown by the Halmilton
Rating Scale for depression; Leibenluft et al., 1993; Halmilton et al., 1967). Among
youth with depression, there is higher caffeine consumption that in the general
population (Whalen et al., 2008). Moreover, the degree of caffeine consumption seems
to be a predictor of improvement of somatic symptoms and hostility in depressed
patients medicated with fluoxetine (Worthington et al., 1998), suggesting that caffeine
could be an effective co-treatment for some of the symptoms of depression.
Impact of caffeine on energy/fatigability and behavioral activation in humans.
A wide range of studies have demonstrated that caffeine can increase alertness and
subjectively reported energy, and also can reduce fatigue (Lieberman et al., 2001; Yu et
al., 1991; Johnson et al., 1990; Smith et al., 1992; 1997). Caffeine has also been
demonstrated to increase feelings of efficiency, self-confidence, motivation to work
(Fredholm et al., 1999), to increase the desire to socialize (Griffiths et al.,
1990; Silverman et al., 1994; Griffiths and Mumford, 1995), and to improve
psychomotor performance (Rees et al., 1999). The behavioral effects of caffeine can be
CHAPTER 5
178
influenced by baseline arousal levels and also by the nature of the task requirements. It
has been argued that the effects of caffeine on fatigue should be most clearly evident in
situations of low baseline arousal or high fatigue, or in tasks placing high demands on
controlled processing (Bachrach, 1966; Liberman et al., 1986; Weiss and Laties, 1962).
In fact, beneficial effects of caffeine have been observed in people in low states of
alertness, such as after benzodiazepines administration (Johnson et al., 1990), sleep loss
(Bonnet et al., 1995), when the person is suffering from a common cold (Smith et al.,
1997), or when the experiment is done in the early morning (Smith, 1992). In addition, a
broad range of studies have reported effects of caffeine withdrawal on different markers
of motivation using descriptors such as fatigue, decreased energy or vigor, lethargy,
amotivation for work, etc. (for a review see Juliano and Griffiths, 2004). For example,
in controlled studies, after 10 days of high levels of caffeine consumption (1,250
mg/day), withdrawal results in increased subjective ratings of headache, sleepiness,
laziness and fatigue, as well as decreased alertness, activation and vigor (evaluated with
the Profile of Mood State, POMS) (Griffiths et al., 1986). Abstinence from intermediate
doses in daily coffee and cola consumers (average of 579 mg/day) increased ratings of
drowsy/sleepy, fatigue/tired, lazy/sluggish/slow-moving, and decreased ratings of
active/energetic/excited, and motivated to work, as well as performance in psychomotor
tasks (Liguori and Hughes, 1997). Even at low doses (100 mg/day, in a controlled
study), caffeine withdrawal increased ratings of lethargy, fatigue, tiredness, and
sluggishness, and decreased ratings of energy, motivation and urge to work (Griffiths et
al., 1990). Silverman et al. (1992) reported that caffeine withdrawal in non-depressed
moderate caffeine users increased fatigue and decreased self-reported vigor, and also
increased the number of people with abnormally high scores on the Beck Depression
Inventory.
Effect of caffeine and adenosine antagonists on classic animal models of
depression.
Preclinical studies have attempted to elucidate the effect of caffeine and selective
adenosine antagonists on classic animal models of depression (El Yacoubi 2001). Two
of the classic tests for the assessment of antidepressant properties of different
substances in rodents are the forced swim test (FST) and the tail suspension test (TST).
In the FST, animals are placed in an inescapable cylinder filled with water, and after an
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extended period of swimming, eventually become immobile (Porsolt et al., 1977; Petit
de Mouliere et al., 2005). The TST is based on the observation that a mouse suspended
by the tail shows alternate periods of agitation and immobility (Sterú et al., 1985).
Classical antidepressants reduce immobility time in these paradigms, which have
become the classical models for evaluating the antidepressant effects of drugs or
showing depressive symptoms induced by behavioral manipulations (Armario and
Nadal 2013).
There are a number of stress-based models used to study behavioral processes related to
depression. Learned helplessness has been considered as one of the factors leading to
the development of depression in vulnerable individuals that suffer stressful life events
(Abelaira et al., 2013). Learned helplessness can be produced in animal models in which
the depressive-like state is induced either by chronic uncontrollable and unpredictable
stressors (CUS), typically electrical foot-shock, and subsequently fails to escapable
shock (Overmier and Seligman, 1967). In addition to deficits in escape and avoidance,
animals that develop learned helplessness show decreases in weight gain, increased
immobility in the FST or TST, and reduced locomotion, all symptoms associated to
some degree with depression (Maier and Seligman, 1976). More recently, the chronic
mild stress (CMS) model was developed.  CMS is induced by irregular exposure to a
combination of different types of stressors over a period of weeks (Katz et al., 1981;
Willner, 2005). These conditions reduce sucrose consumption in rodents (Willner,
2005). After the administration of substances with antidepressant properties, animals
exposed to CUS or CMS consume normal levels of sucrose (Willner, 2005), and display
escape-directed behaviors, reducing time of immobility (Porsolt et al., 1977; Steru et al.,
1985).
All these tests and manipulations have been used to study the potential therapeutic
properties of caffeine and selective adenosine antagonists or genetic deletion of
adenosine receptors in rodents. In one of the seminal papers, Porsolt and colleagues
(1978) demonstrated that an acute dose of caffeine reduced immobility time in the FST
in Sprague-Dawley rats. In later studies, this effect has been confirmed using other
strains of rats and mice, after acute or repeated administration of a broad range of doses
and using diverse animal tests (see table 1). Consistent with the effects of caffeine,
selective adenosine A2A receptor antagonists have also been effective in these tests.
Thus, SCH 58261 and istradefinille (KW6002), reduced total immobility time in both
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the TST and the FST in mice (El Yacoubi, 2001). SCH 58261 also reduced immobility
time in a selectively bred ‘helpless’ CD1 mice strain in the TST (El Yacoubi, 2001).
Moreover, A2A receptor knockout (A2AKO) mice showed reductions in immobility time
compared to wild type (WT) animals in both tests (El Yacoubi, 2001).
Using the learned helplessness model for inducing depressive symptoms, it has been
demonstrated that acute doses as well as chronic administration of caffeine can reduce
the impact of CUS. Thus, caffeine prevented as well as reversed CUS-induced
behavioral and physiological signs of depression such as decreased weight gain,
increased corticosterone levels, escape behavior impairments in a shuttle box, increased
immobility time in the FST and TST, increased anxiety, and decreased sucrose
consumption, locomotion and spatial reference memory (see table 1). In agreement with
these findings, mice that received the selective A2A receptor antagonist istradefylline, as
well as constitutive A2AKO mice, were protected from the CUS-induced behavioral
impairments in the FST, TST, and memory tests (Kaster et al., 2015), suggesting a key
role for A2A receptors in acute and chronic stress-induced depressive effects.
Based on these results some researchers have focused on adenosine receptor
antagonists, including caffeine, as tools to reverse behavioral impairments induced by
pharmacological manipulations of the adenosine system (Pechlivanova et al., 2012;
Minor et al., 2008; 1994; Woodson et al., 1998; Kulkarni and Mehta, 1985; Hunter et
al., 2003). Thus, a high dose of adenosine (100 mg/kg, intraperitoneally; IP), or its
analog 1-chloroadenosine (2.0 mg/kg, IP) induce immobility in the FST in mice, and
caffeine and theophylline (8.0 mg/kg, IP), reversed this effect (Kulkarni and Metha,
1985). Theophylline is a psychoactive methylxanthine found in tea and other
substances, and is also a metabolite of caffeine that acts as a non-selective adenosine
antagonist for A1/A2A receptors (Gu et al., 1992). In contrast, Kaster and colleagues
(2004) used low doses of adenosine administered via two different routes of
administration (IP: 1-10 mg/kg, and intracerebroventricular, ICV: 0.1-10 ug/site), and
observed antidepressant-like effects in the FST and TST. Moreover, the A1 adenosine
receptor agonist, adenosine N6-cyclohexyladenosine (CHA) (0.05-1.0 mg/kg, IP), and
the A2A agonist N6-[2-(3,5-dimethoxyphenyl)- 2-(methylphenyl)ethyl]adenosine
(DPMA) (1.0-5.0 mg/kg, IP) also decreased the immobility time in this test (Kaster et
al., 2004). In addition, pretreatment with non-effective doses of caffeine (3.0 mg/kg,
IP), the A1 antagonist DPCPX, and the A2A antagonist ZM241385, inhibited the
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antidepressant effect induced by a low dose of adenosine in the FST (Kaster et al.,
2004). These authors also observed that a higher dose of adenosine (50.0 mg/kg, IP) did
not have antidepressant effects (Kaster et al., 2004). As a whole, these studies suggest
that adenosine might elicit antidepressant actions only at low doses (1.0-10.0 mg/kg,
IP), having no effect at intermediate doses (50.0 mg/kg) and depressant-like effects at
higher doses (100 mg/kg) (Kulkarni and Metha, 1985).
Figure 1. Adenosine synthesis and metabolism. Abbreviations: ADA, adenosine deaminase;
AK, adenosine kinase; A1R and A2AR, adenosine A1 and A2A receptors, cNT: cytosolic endo-
nucleotidase; ENT, equilibrative nucleoside transporter; eNT, exo-nucleotidase.  (Adapted from
Ruby, 1999).
Consistent with the results from studies using high doses of IP adenosine, increases in
central adenosine transmission have been also associated with escape deficits in the
inescapable shock paradigm (Minor et al., 1994a; Woodson et al., 1998; Kurlarni and
Mehta, 1985; Minor and Hanff, 2015). Thus, it has been demonstrated that ICV
administration of NBTI (S-(4-nitrobenzyl)-6-theoinosine), an equilibrative nucleoside
transport (ENT) blocker that increases extracellular adenosine levels by blocking its
reuptake, impaired escape latency in rats (Jacobson et al., 1992; Noji et al., 2004; Minor
et al., 2008). Moreover, ICV administration of erytrho-9(2-hydroxy/3/nonyl adenine
(ENHA), a selective adenosine deaminase (ADA) inhibitor which blocks adenosine
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metabolism, mimicked the effect of inescapable shock (Woodson et al., 1998). Low
doses of caffeine reversed the escape deficits induced by EHNA (Woodson et al., 1998).
The reversal effects of caffeine appear to be specific to actions on adenosine receptors,
and not as a general psychomotor stimulant effect, since amphetamine exacerbated the
behavioral impairments induced by inescapable shocks. Moreover, the amphetamine-
induced impairment was reversed by caffeine and theophylline (Minor et al., 1994b),
and also by the A2A antagonist CSC, but not by the selective A1 adenosine antagonist
DPCPX (Minor et al., 2008). Injections of glutamate into prefrontal cortex have been
shown to impair escape performance (Petty et al., 1985), and later work reported that
caffeine can reverse these glutamate-induced escape deficits (Hunter et al, 2003). This
pattern of results is consistent with studies showing that increases in glutamate are
counterbalanced by an increase in adenosine production and release (Deckert and
Gleiter, 1994).
Caffeine has also been used to enhance the effect of monoaminergic antidepressants
(especially 5HT and NE uptake inhibitors) that are been used in clinical practice and
also have been shown to reduce immobility in classical animal tests of depression. Thus,
caffeine administered at doses that do not have an effect on their own can potentiate the
effects of desipramine, imipramine, duloxetine, fluoxetine and paroxetine on FST
performance (Robles-Molina et al., 2012; Kale et al., 2014; Szopa et al., 2016). In
addition, a low dose of caffeine can also enhance the behavioral and neurochemical
effects of bupropion, which blocks catecholamine uptake (Kale et al., 2014).
Impact of caffeine on behavioral activation and effort-related processes:
preclinical studies
In the animal literature, as with the human data, there are studies showing how caffeine
and selective adenosine antagonists affect the willingness to work depending on the
demands of the task. Caffeine and theophylline produced rate-dependent effects on lever
pressing to obtain palatable food in rats (Randall et al., 2011). Caffeine (5.0-20.0 mg/kg,
IP) and theophylline (10.0-40.0 mg/kg, IP) increased responding on the schedule that
generated low baseline rates of responding (a fixed interval 240 seconds (FI-240 sec)
schedule). In contrast, caffeine and theophylline decreased responding on a fixed ratio
20 (FR20) schedule that typically generates high rates of responding (Randall et al.,
2011) (see table 2). The A2A antagonists MSX-3 and istradefylline increased FI-240 sec
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lever pressing but did not suppress FR20 lever pressing in the dose range tested. In fact,
there was a tendency for istradefylline to increase FR20 responding at a moderate dose.
A1 antagonists failed to increase lever-pressing rate, and actually DPCPX decreased
FR20 responding at higher doses. These results suggest that the work potentiating
effects of methylxantines are mediated by their actions on adenosine A2A receptors,
while their A1 receptor antagonist action could be mediating the suppressant effects.
Progressive ratio (PR) schedules, which require gradually increasing work output, have
been also employed to explore the effect of caffeine on motivation to work for sucrose
or food reinforcement in rats and monkeys (Sheppard et al., 2012; Retzbach et al., 2014;
Buffalo et al., 1993). Acutely and chronically moderate doses of caffeine elevated PR
lever pressing for sucrose (Sheppard et al., 2012; Retzbach et al., 2014). Caffeine had
no effect on inactive lever presses suggesting that this increase was not due to an
increase in general motor activity (Retzbach et al., 2014). However, in rhesus monkeys
intravenous (IV) caffeine decreased percent of task completed, and breakpoint in a PR
for palatable food (Buffalo et al., 1993), possibly because this dose directly
administered in the blood stream resulted in higher levels in the brain. Thus, it seems
that low-to-moderate doses of caffeine increase behavioral output in tasks that evaluate
willingness to work for a reinforcer, while high doses decrease responding.
Caffeine modulation of DA-related postsynaptic signaling.
As described above, caffeine is a non-selective adenosine receptor antagonist. In the
brain, adenosine acts upon both A1, and A2A G-protein-coupled receptors (Fredholm et
al., 2011; Jackobson and Gao, 2006). The distribution of adenosine receptors within the
brain (Fredholm et al., 2011) allows a wide range of effects, including modulation of
other neurotransmitter systems (Cuhna-Reis et al., 2007). Thus, adenosine A2A receptors
are highly expressed in DA rich areas such as neostriatum and accumbens (Acb)
(Shiffmann et al., 1991; deMet et al., 2002). In fact, it has been demonstrated that in
these areas, there is a functional interaction between DA D2 and adenosine A2A
receptors (see Figure 2), which are co-localized on enkephalin-containing medium spiny
neurons, form hetromeric complexes, and converge onto the same signal transduction
pathways in an antagonistic manner (Ferré, 2008; Ferré et al., 1997, 2008; Fink et al.,
1992; Fuxe et al., 2003). Similarly, A1 and D1 receptors antagonistically interact in
substance P-containing medium spiny neurons (Ferré et al., 1997; 2008).
CHAPTER 5
184
Figure 2. Impact of caffeine on the functional interaction between adenosine and DA
receptors. A1R and A2AR: adenosine A1 and A2A receptors, D1: DA type 1 receptor, D2: DA
type 2 receptor (adapted from Ferré 2008).
The behavioral significance of this interaction has frequently been studied in the context
of neostriatal motor functions and pathologies (Correa et al., 2004; Ferré et al., 1997;
Collins et al., 2010; Pinna et al., 2007; Simola et al., 2004, 2006; Wardas et al., 2001).
Thus, selective A2A receptor antagonists are been tested in clinical trials for pathologies
involving DAergic dyfunctions such as Parkinson disease (LeWitt et al., 2008), and
positive results indicate that they can be used as adjuvant therapies (Hung and
Schwarzschild, 2014). In fact, istradefylline is currently approved in Japan for use in
treating Parkinson’s disease. Caffeine’s actions on A1 and A2A adenosine receptors
(Ferré, 2008), has promoted its study as an alternative preventive or therapeutic tool for
Parkinsonian symptoms (Prediger, 2010). Moreover, within the last few years, the
motivational significance of DA-adenosine receptor interactions has become apparent
with regard to processes such as behavioral activation and effort-related decision-
making, which could have significance for the treatment of depression and other
pathologies (Salamone et al., 2006; 2009; 2010). The next two sections will review the
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literature related to DA-adenosine interactions in pathological symptoms related to
effort-based decision-making.
Effort-related decision-making in depression: Clinical significance and animal
models.
Activational aspects of motivation (i.e., vigor, persistence, work output) are highly
adaptive because they enable organisms to overcome obstacles or work-related response
costs that separate them from significant stimuli (Salamone and Correa, 2002, 2012; van
den Bos et al., 2006). An important feature of adaptive behavior, in the face of work-
related challenges, is effort-related decision making. Frequently, organisms must make
cost/benefit analyses in which they weigh the value of a stimulus relative to the cost of
obtaining it, and such decisions involve effort-relateed costs (Salamone and Correa,
2002, 2012; Salamone et al., 2007). These processes are important for both normal and
pathological aspects of motivation.  For example, people with MDD show a reduced
likelihood of selecting high effort activities in human tasks of effort-related decision
making (Treadway et al. 2012; Yang et al., 2014).
Extensive animal research has demonstrated that Acb DA is a key mediator of effort-
based decision-making processes (for a review see Salamone and Correa, 2012). In
preclinical studies, animals are given a choice between a more valued reinforcer that can
only be obtained by engaging in a more demanding-higher effort activity vs. a low
effort/low value option. Interference with DA transmission produces a shift in effort-
related choice behavior, biasing animals towards instrumental behaviors that involve
less effort or lower activity. One such procedure is a T-maze task that provides an
effort-related challenge by having a vertical barrier in the arm with the higher reward
density (HD) vs. an arm that contains a lower density of reward (LD) and has no barrier
(Salamone et al. 1994; Cousins et al. 1996; Mott et al., 2009; Pardo et al., 2012). With
this procedure, rodents choose to climb the barrier to get more reward in 90% of the
trials, once they have been trained (Cousins et al. 1996; Pardo et al., 2012). In operant
tasks animals are given a choice between lever pressing for the more preferred reward
(in FR5, FR7, or PR schedules) vs. approaching and consuming a less preferred
reinforcer that is concurrently freely available in the chamber (Salamone et al. 1991;
Randall et al. 2012; Pardo et al., 2015). When tested on the concurrent FR5/free reward
choice task, untreated rats typically spend most time pressing the lever for the preferred
reward and eat little of the freely available food or fluids (Salamone et al., 1991, 2002;
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Pardo et al., 2015). In contrast, rats tested on the PR/chow free feeding choice task show
more individual variability, and tend to disengage more readily from the PR lever
pressing component because of the increasing work requirement (Randall et al., 2012,
2014). Research with these concurrent choice tasks has shown that interference with DA
transmission via DA depletions or DA receptor antagonism typically biases rodents
towards the low effort-low reward option (Salamone et al., 1991; 2009; Worden et al.,
2009; Pardo et al., 2012; Randall et al., 2012, 2014; Yohn et al., 2015a,b,2016a,b).
Using these effort-related choice procedures it has been demonstrated that the
catecholamine depleting agent and vesicular transport inhibitor (VMAT-2) tetrabenazine
(TBZ) can shift effort-based decision making across multiple behavioral tasks (Nunes et
al., 2013; Randall et al., 2014; Yohn et al., 2015a,b, 2016a,b; Pardo et al., 2015). TBZ has
been shown to deplete monoamines, with its greatest impact being upon striatal DA
(Pettibone et al., 1984; Tanra et al., 1995; Nunes et al., 2013). TBZ is used as a
therapeutic drug to treat Huntington’s disease patients, but it also induces side effects
that include symptoms of depression, including fatigue, in humans (Frank 2010; Guay
2010).  Because of its neurochemical and behavioral effects, TBZ is a useful tool for
animal models of depression, and TBZ has previously been employed in studies that use
the FST and TST rodent models of depression (Preskhorn et al. 1984; Kent et al. 1986;
Wang et al. 2010). Recent studies have demonstrated that the effort-related effects of
TBZ are attenuated by the catecholamine uptake blocker bupropion, which is a
commonly used antidepressant, and also by the selective DA uptake blocker GBR12909
(Nunes et al., 2013; Randall et al., 2014; Yohn et al., 2016a). In contrast, other classical
drugs for the treatment of depression, such as the 5-HT uptake inhibitors fluoxetine and
citalopram and the NE uptake inhibitor desipramine, failed to reverse the effects of
TBZ, and higher doses even led to further behavioral impairments (Yohn et al.,
2016a,b).
In addition to DA, adenosine also is involved in effort related decision-making
processes (Farrar et al., 2007, 2010; Hauber and Sommer, 2009; Nunes et al., 2010;
Salamone et al., 2007, 2009). Microinjections of the adenosine A2A agonist CGS 21680
into the Acb produced effects on instrumental behavior and effort-related choice that
resembled those produced by Acb DA antagonism or depletion (Font et al., 2008;
Mingote et al., 2008). In addition, considerable evidence indicates that DA D2 and
adenosine A2A receptors interact to regulate effort-related functions (Salamone and
Correa, 2009, 2012). Thus, adenosine A2A antagonists such as MSX-3, MSX-4, and
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istradefylline were able to reverse the shift in effort-based choice that was induced by
administration of the D2 antagonists haloperidol and eticlopride (Farrar et al., 2007,
2010; Salamone et al., 2009; Mott et al., 2009; Worden et al., 2009; Nunes et al., 2010;
Pardo et al., 2012; Santerre et al., 2012). Moreover, A2A KO mice were resistant to the
effects of haloperidol on performance of the T-maze barrier task (Pardo et al., 2012). In
contrast, adenosine A1 antagonists DPCPX and CPT were ineffective at reversing the
effort-related effects of either the D1 antagonist ecopipam or the D2 antagonist
eticlopride (Salamone et al., 2009; Nunes et al, 2010; Pardo et al., 2012, 2015).
The effects of caffeine and theophylline on effort-related choice behavior after the
administration of D2 antagonists have also been reported in rats tested on the concurrent
FR5/chow feeding choice task. Caffeine (5.0, 10.0 and 20.0 mg/kg, IP) partially
attenuated the effects of haloperidol, increasing the lever pressing and decreasing chow
intake in haloperidol-treated rats (Salamone et al., 2009). Similarly, theophylline (10.0
and 15.0 mg/kg) reversed the effects induced by D2 antagonism in mice tested on the T-
maze barrier task (Pardo et al., 2012). Furthermore, using the T-maze task, our
laboratory recently conducted an experiment in CD1 male mice assessing the impact of
caffeine (0.0, 2.5, 5.0 or 10.0 mg/kg, IP 30 min before test) on arm selection before and
after DA depletion via TBZ (0 or 4.0 mg/kg, IP 120 min before test). Although a single
dose of caffeine (10.0 mg/kg) significantly reduced latency to get access to the food in
the first 10 trials in the phase in which there was no barrier (t-test for dependent
samples; (t=2.2, p<0.05), it did not increase HD arm selection or food consumption (see
figure 3).
Figure 3. Impact of caffeine (10.0 mg/kg, IP 30 minutes before test) on performance in a T
maze in which the high density (HD) and the low density (LD) arms had no barrier. Data for the
10 first trials. A) Average latency to reach the food (seconds) *p<0.05 different from saline. B)
Number of HD arm selection. C) Number of total pellets consumed.
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Caffeine was effective at reversing the reduction in HD arm selection (repeated
measures ANOVA for HD arm selection; F(3,28)=8.32, p<0.01) and the concurrent
increase in LD arm selection (F(3,28)=7.53, p<0.01) when there was a 14 cm barrier in
the HD arm and animals had received a dose of TBZ that shifted behavior towards the
low effort option. Thus, a dose of 5.0 mg/kg of caffeine reversed the impairing effect of
the DA depleting agent TBZ on selection of the high effort choice (see figure 4).
Figure 4. Impact of TBZ (4 mg/kg, IP administered 120 minutes before test) on HD arm (A)
and LD arm (B) selection and reversal with different doses of caffeine in a T maze with a 14 cm
barrier in the HD arm. Mean + SEM of number of trials in which animals choose HD or LD arm
(**p<0.01 different from VEH/VEH. ##p<0.01 different from TBZ/VEH.)
Furthermore, several recent papers have reported that the adenosine A2A antagonist
MSX-3 can reverse the effort-related effects of TBZ across multiple tasks (Nunes et al.,
2013; Randall et al., 2014; Yohn et al., 2015a). Taken together with the results of
studies showing that A2A but not A1 receptor antagonists can reverse the effort-related
effects of D2 antagonism, these results suggest that the ability of caffeine to reverse the
effects of DA antagonism and depletion may depend largely upon blockade of A2A
receptors.
Mental fatigue associated with high attentional demands can also be overcome by the
use of psychostimulants such as amphetamine or caffeine (Peeling and Dawson, 2007;
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Silber et al., 2006). In cost/benefit decision-making tasks involving the evaluation of the
cost involved in high attention-demanding tasks, rats can choose between engaging in
hard trials (difficult visuospatial discrimination) leading to more reward versus easy
trials leading to less reward (Cocker et al., 2012). Under basal conditions, animals chose
high effort/high reward trials more than low-effort/low reward trials. However, there are
substantial individual differences in baseline performance. Amphetamine increases the
selection of high effort/high reward trials in animals that usually do not choose this
option under baseline conditions, but it decreases the selection of the high cognitive
demand trials in animals that usually choose them. A high dose of caffeine (20.0 mg/kg)
decreased choice of high effort/high reward trials in animals that usually choose them as
did amphetamine, but caffeine did not increase the selection in the ones that usually did
not choose them (Cocker et al., 2012). Thus, it appears that cognitive arousal and
attention are components of this task that are not improved by caffeine, which, on the
other hand, seems to benefit selection of responses that require high levels of physical
effort.
Translational studies in humans have employed tasks that evaluate effort-based decision
making processes in normal humans as well as psychiatric patients. The effort
expenditure for rewards task (EEfRT; Treadway et al., 2009), is based on the operant
lever pressing and T-maze choice tasks described above (Salamone et al., 1991, 1994,
2002). In the human version of this task, subjects choose on each trial between a high
cost/high reward option (HC/HR) and low cost/low reward option (LC/LR) to obtain
different monetary rewards. The HC/HR trials required 100 button presses with the non-
dominant little finger within 21 seconds, and subjects were eligible to win higher
amounts that varied per trial between $1.24-4.30. In contrast, the LC/LR option only
required 30 button presses with the dominant index finger during 7 seconds, and
subjects could win $1.00 for each successfully completed trial. The rewards were not
guaranteed if they completed the task, thus some trials were “win” trials while others
were “no win” trials. Participants were provided with probability cues during the choice
session, leading to three levels of probability of a win trial: high (88%), medium (50%),
and low (12%). Based on these percentages, participants could choose between the
HC/HR trial and the LC/LR trial. Patients with MDD were significantly less likely to
make HC/HR choices relative to controls, and this result was not related with
depression-related differences in psychomotor speed (Treadway et al., 2012). The
probability of reward was an important factor, as the impairment in MDD patients was
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greater when reward probability, and thus baseline selection of the high effort option,
was highest (Treadway et al., 2012). The effects of caffeine on this task in depressed
patients has not been explored, but it was assessed in nonpathological human subjects
(Wardle et al., 2014).  A single dose of caffeine (200 mg) significantly increased the
speed of responses compared to placebo, but did not have an effect on percentage of
HC/HR choices (Wardle et al., 2014). In fact, caffeine decreased effortful choices in
high cardiovascular responders (subjects with high arterial pressure in response to
caffeine) (Wardle et al., 2014). These results are different from previous human studies
reporting that a major psychomotor stimulant, amphetamine, was able to increase
HC/HR choice (Wardle et al., 2011), and also with studies showing that, during
exercise, caffeine decreases the perception of effort in humans (Doherty and Smith,
2005) and improves performance particularly during endurance testing (Doherty and
Smith, 2004).
Conclusions and further directions
Although many available treatments for MDD provide relief for some individuals with
depressed mood, no single therapeutic option provides a full and permanent recovery
for all the symptoms of MDD in the majority of patients (McClintock et al., 2011).
Clinicians have come to emphasize the importance of effort-related motivational
symptoms in depression (Tylee et al., 1999; Stahl 2002; Demyttenaere et al,. 2005;
Salamone et al., 2006), because even among patients in remission, anergia and
psychomotor retardation are pervasive symptoms (Gorwood et al., 2014). Thus, novel
pharmacological targets are being investigated in clinical and preclinical studies. There
are promising results shown in human epidemiological studies, as well as research with
animal models, characterizing the potential effect that caffeine and selective adenosine
receptor antagonists could have on these symptoms. It is worth noting that the
epidemiological studies have reported mixed outcomes in humans depending on the
amount of caffeine consumed. Thus, whereas some studies reveal a relation between
caffeine consumption and decreased risk for developing depression (Lucas et al., 2011),
and different reports demonstrate the use of caffeine as a self-medication among
depressed patients (Leibenlugt et al., 2003), other studies show a relation between high
levels of caffeine consumption and increased risk of suicide (Tanskanen et al., 2004).
Thus, it seems clear that more controlled studies are needed to explore the effect of
caffeine on the wide variety of symptoms observed in patients with MDD.
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Systematic studies on the effects of caffeine in animal models of depression and anergia
have shown the efficacy of this methylxanthine at improving parameters related to
initiation and maintenance of behavior in order to escape an aversive situation, but also
in order to pursue valued reinforcers and achieve goals (Pechilivanova et al., 2012;
Hunter et al., 2003; Minor et al., 2008; Woodson et al., 1998; Kulkarni and Metha et al.,
1985; Salamone et al., 2006; Randall et al., 2011). As with the human data, these
actions are dependent on the dose, since high doses not only fail to improve depression-
like symptoms, but can in fact promote anxiety (Correa and Font 2008; López-Cruz et
al., 2014). Both in humans and in animal studies, the therapeutic actions of caffeine also
seem to be dependent on the basal state; for example it seems to be effective when
subjects are under a state or fatigue, tiredness or sleepiness (Bonnet et al., 1995;
Johnson et al., 1990; Smith 1992), or when the DAergic system is compromised
(Salamone et al., 2009; present data), and such effects are less evident when humans
and rodents are assessed under “normal” conditions. Other methylxantines such as
theophylline, and several A2A selective antagonists, have also been shown to reverse
motivational impairments induced by DA antagonism or depletion in animal models of
anergia (Salamone et al., 2009; Farrar et al., 2009; Mott et al., 2009; Pardo et al., 2012).
Adenosine A2A receptors appear to be involved in these processes, probably through
their interaction with DA D2 receptors in the Acb, a striatal region that is highly
involved in the activational component of motivation (for a review see Salamone and
Correa, 2012).
Consistently, it has been demonstrated in human studies that the rank order of clinical
effectiveness in depressed patients with psychomotor retardation paralleled the
specificity of antidepressants as DA-mimetic agents (Rampello et al., 1991).
Antidepressants such as bupropion have been demonstrated to have therapeutic effects
on motivational symptoms in humans (Pae et al., 2005) and to stimulate effort-related
behavioral output in animals (Randall et al., 2014). In animal studies, caffeine has been
shown to improve the effects of antidepressants such as bupropion, duloxetine and
desipramine (Kale et al., 2014; Robles-Molina et al., 2012; Szopa et al., 2016). These
studies have helped to identify caffeine as a potential enhancer of antidepressant
pharmacotherapy (for a review, Kale et al., 2010). This suggestion is consistent with the
clinical trials for antiparkinsonian effects showing that A2A antagonists can be a useful
adjuvant in the treatment of motor symptoms (Hung and Schwarzschild, 2014).
However, determination of the predominant symptomatology in individual patients may
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be an important key to therapeutic success. In patients affected by anxious depression,
preferential inhibition of 5-HT reuptake may be a more effective selective inhibition of
DA reuptake (Rampello et al., 1995), and caffeine in those types of depressed patients
may actually worsened the anxiety symptoms.
Table 1. Effect of caffeine in classical animal tests of depression.
Caffeine dose Animal
model
Species/strain Behavioral effects Reference
15-20 mg/kg,
IP. Acute
FST Sprague-
Dawley rats
Decreased immobility Porsolt et al.,l.,
1978
Kitada et al., 1981
1 mg/kg,
IP. Repeated
3 times
FST Wistar Rats Decreased immobility Enríquez-
Castillo, et al.,
2008
10 mg/kg,
5 mg/kg
IP. Acute
FST, TST Swiss mice Decreased immobility.
Potentiated antidepressant effect
of bupropion and duloxetine
Kale et al., 2014
10-50 mg/kg,
5 mg/kg
IP. Acute
FST Albino Swiss
mice
Decreased immobility.
Potentiated antidepressant effect
of imipramine, desipramine,
fluoxetine, paroxetine,
escitalopram and reboxetine.
Spoza et al.,
2016
3.1-30 mg/kg,
0.31-1 mg/kg,
IP. Acute
FST Balb-c mice Decreased immobility.
Potentiated antidepressant effect
of desipramine
Robles-Molina
et al., 2012
3 mg/kg,
IP. Acute
FST, TST Swiss mice Reversed: immobility induced
by adenosine
Kaster et al.,
2004
8 mg/kg,
IP. Acute
FST Wistar mice No effect on its own.
Reversed: immobility induced
by adenosine and 2-
chloroadenosine.
Kulkarni and
Mehta et al.,
1985
7 mg/kg,
IP. Acute
FST Sprague
Dawley Rats
Reversed: immobility induced
by reserpine
Minor et al.,
2015
8 mg/kg,
Oral. 4 weeks
CUS
induction
Wistar Rats Reversed: immobility in FST,
weight loss, hypolocomotion,
anxiety, decreased sucrose
consumption, and core
temperature
Pechlivanova et
al., 2012
7 mg/kg,
IP. Acute
CUS
induction
Sprague
Dawley Rats
No effect on its own
Reversed: escape deficits
induced by glutamate injection
in prefrontal cortex.
Hunter et al,
2003
7 mg/kg,
IP. Acute
CUS
induction
Sprague
Dawley Rats
Reversed: escape deficits
induced by ENT blocker
Minor et al.,
2008.
10 mg/kg,
IP. Acute
CUS
induction
Sprague
Dawley Rats
Reversed: escape deficits
induced by ICV administration
of EHNA
Woodson et al.,
1998
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1 g /L ,
Orally.
6 weeks
(before and
after CUS)
CUS
induction
C57BL/6 mice Prevented: immobility in FST
and TST, weight loss, increased
levels of corticosterone,
reduction in sucrose preference,
and decreased spatial reference
memory
Kaster et al., 2015
Table 2. Effect of caffeine in behavioral activation and effort-based decision making tests.
Caffeine dose Animals model Species/
strain
Behavioral effects Reference
5-20 mg/kg,
10-40 mg/kg,
IP. Acute
FI-240
FR20
Sprague
Dawley
Rats
Increased lever pressing
Decreased lever pressing
Randall et
al., 2011
6.25-25.0 mg/kg,
IP Acute.
FR2
PR
Sprague
Dawley
Rats
Increased lever pressing for
visual stimuly and sucrose
Sheppard et
al., 2012
5 mg/kg,
IP. Chronic
10 days
FR4 Sprague
Dawley
Rats
Increased lever pressing for
sucrose.
Retzbach et
al., 2014
10 mg/kg,
IV. Acute
PR Rhesus
Monkey
Decreased breakpoint for
palatable food.
Buffalo et
al., 1993
5-20 mg/k,
IP. Acute
FR5/Free chow
concurrent choice
Sprague
Dawley
Rats
Increase lever pressings and
decrease free chow intake in
haloperidol-treated rats
Salamone et
al., 2009
20 mg/kg,
IP. Acute
Cognitive effort
task (rCET)
Long
Evans
Rats
Decreased choice of high
effort/high reward trials in
“workers”. No increase in
“slackers”.
Cocker et al.,
2012
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CHAPTER 6:
Caffeine reverses the shift in preference from high to low
effort reinforcing activities induced by dopamine depletion:
relation to DARPP32 phosphorylation patterns.
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Abstract
The mesolimbic dopamine (DA) system plays a critical role in behavioral activation and
effort-based decision-making. DA depletion produces anergia (shifts to low effort
options) in effort-based tasks. Caffeine, the most consumed stimulant in the world, acts
as an adenosine A1/A2A receptor antagonist, and DA D1 and D2 receptors are co-
localized with adenosine A1 and A2A receptors. In the present work, we evaluated the
effect of caffeine on anergia induced by the VMAT-2 inhibitor tetrabenazine (TBZ),
which produces DA depletions. Anergia was evaluated in a three-chamber T-maze task
in which animals can chose between running on a wheel (RW) vs. sedentary activities
such as consuming sucrose or sniffing a neutral odor. Independent groups of animals
were evaluated for voluntary motor activity in the RW and sucrose consumption. DA
tissue levels after TBZ were evaluated with HPLC. TBZ-caffeine interactions were
evaluated on DARPP-32 phosphorylation patterns as an intracellular marker of DA
receptor activity in striatum. In the T-maze, control mice spent more time running and
much less consuming sucrose, and also did very little sniffing. TBZ (4.0 mg/kg)
reduced DA tissue levels and also shifted preferences, reducing selection of the
reinforcer that involved vigorous activity (RW), but increasing consumption of a
reinforcer that required little effort (sucrose), at doses that had no effect on independent
measures of appetite or locomotion in the RW. This suggests that DA depletion
produced anergia, but did not affect the primary motivating effects of sucrose. Caffeine
at doses that had no effect on their own reversed TBZ effects on the T-maze and the
RW. Caffeine also suppressed TBZ-induced pDARPP-32(Thr34) expression, suggesting
a role for D2-A2A interaction.
Key words: Decision-making, motivation, behavioral activation, dopamine, adenosine,
sucrose, running wheel
Running title: Caffeine reversal of dopamine depletion-induced anergia
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1. Introduction
Motivated behavior is directed towards or away from particular stimuli, but it also is
characterized by a high degree of activity, effort, vigor, and persistence (Salamone and
Correa, 2002; 2012). These activational aspects of motivation are highly adaptive, because
they enable organisms to overcome the work-related obstacles that separate them from
significant stimuli (Salamone and Correa, 2002, 2012). Activation-related dysfunctions,
such as anergia, and fatigue, are an important and debilitating set of symptoms seen in
major depression, Parkinson disease (PD), schizophrenia and other pathologies (Caligiuri
and Ellwanger, 2000; Salamone and Correa, 2012; Friedman et al. 2007; Tellez et al. 2005;
Tylee et al. 1999; Demyttenaere et al. 2005). Thus, it has been demonstrated that early
Parkinsonian patients have subjective reports of lack of energy (Friedman et al. 2007;
Nomoto et al. 2014), and reduced selection of high-effort activities (Elbers et al. 2009), and
people with depression show a decrease -n selection of high effort/high reward options
when compared with healthy controls (Treadway et al. 2012).
Several lines of evidence have identified dopamine (DA), particularly in nucleus
accumbens (Nacb), as a critical component of the brain circuitry regulating behavioral
activation and effort-related processes (Salamone and Correa, 2002, 2012; Mai et al.
2012). Interference with DA transmission can affect allocation of effort on tasks that
assess effort-based choice behavior, biasing individuals towards lower effort
alternatives (Salamone et al. 2007; Floresco et al. 2008; Hauber and Sommer, 2009). In
these tasks animals have the option of vigorously working (lever pressing or climbing a
barrier) to get access to preferred reinforcers versus approaching and consuming a less
preferred food or sucrose solution that requires less effort to obtain (Salamone et al.
1991, 1994, 2002; Randall et al. 2012; Pardo et al. 2012, 2015; Mott et al. 2009; Yohn
et al., 2015). The catecholamine depleting agent and vesicular transport inhibitor (VMAT-
2) tetrabenazine (TBZ) used to treat Huntington’s disease patients, has demonstrated to
deplete monoamines, with its greatest impact being upon striatal DA (Pettibone et al.
1984; Tanra et al. 1995; Nunes et al. 2013). TBZ’s main side effects include fatigue,
Parkinsonism, and depression (Frank, 2009, 2010; Guay, 2010). TBZ also has been
demonstrated to induce shifts in behavior towards low effort/low reward options in
effort-based decision-making tasks in rodents (Pardo et al. 2015; Yohn et al. 2015;
Nunes et al. 2013).
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In addition to DA, the neuromodulator adenosine appears to be involved in the
regulation of the activational component of motivated behaviors (Salamone and Correa
2009; Pereira et al. 2011). DA and adenosine receptors are co-localized (D2-A2A and D1-
A1), and they converge onto the same signal transduction pathways, having opposite
effects on the adenylyl cyclase-related signal transduction cascade (Ferré et al. 2004).
Striatal areas such as neostriatum and Nacb are very rich in these types of adenosine
receptors (Demet et al. 2002; Ferré et al. 2008, 2004). Thus, adenosine antagonists are
been proposed as therapeutic agents to counteract symptoms induced by DA
dysfunctions (Jenner 2014). In human patients with PD, istradefylline (a A2A antagonist)
has been demonstrated to reduce feelings of fatigue, depression and listlessness
(Nomoto et al. 2014). Thus far, istradefylline is the only adenosine A2A antagonist that
is approved for clinical use, and it is available in Japan. Caffeine is a natural
methylxantine that acts mainly as a non-selective adenosine A1 and A2A receptor
antagonist (Fredholm et al. 1999). In humans, caffeine has been shown to increase
subjectively reported energy, and motivation to work, and to reduce fatigue and improve
psychomotor performance (Lieberman et al. 2001; Yu et al. 1991; Johnson et al., 1990;
Smith et al. 1992; 1997; Fredholm et al. 1999; Rees et al. 1999). It has been argued that
the most powerful therapeutic effects of caffeine would be expected in situations of high
fatigue (Liberman et al. 1987; Weiss and Laties, 1962).
The present studies investigated the impact of TBZ, caffeine and their combination on a
novel T-maze task developed to assess preferences between active versus sedentary
sources of reinforcement (adapted from Correa et al. 2016). This T-maze task does not
involve work in order to get access to a reinforcer, as previous tasks developed in our
laboratory (Pardo et al. 2012; Yohn et al. 2015), but instead offers the choice to freely
engage in wheel running, or to consume palatable pellets containing 50% sucrose or, as
a third alternative, to sniff into a hole with a neutral non-social odor. In addition, we
evaluated the impact of TBZ and caffeine even at higher doses in independent groups of
animals that were not in a choice situation and only had access to pellets or to a RW.
Striatal levels of DA after TBZ administration were evaluated, and markers of D1 or D2
receptor activity (phosphorylated forms of DARPP-32; pDARPP-32(Thr34) and
(Thr75) were quantified by western blot after these manipulations.
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2. Methods
2.1. Subjects.
CD1 adult male mice (N=119) purchased from Janvier, France S.A. were 15-17 weeks
old (30-45 g) at the beginning of the study. Mice were housed in groups of three or four
per cage, with standard laboratory rodent chow and tap water available ad libitum. The
colony was kept at a temperature of 22 2 ºC with lights on from 08:00 to 20:00 h. All
animals were under a protocol approved by the Institutional Animal Care and Use
Committee of Universitat Jaume I, and all experimental procedures complied with
European Community Council directive (86/609/ECC). All efforts were made to
minimize animal suffering, and to reduce the number of animals used.
2.2. Drugs.
Tetrabenazine (TBZ) [(R,R)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-
pyrido[2,1-a]isoquinolin-2-one] (CIMYT Quimica SL, Spain), was dissolved in a 20%
dimethylsulfoxide (DMSO) solution mixed with saline and pH adjusted with 1 N HCl to
bring the final solution to pH 5.5. DMSO (20%v/v) was used as its control. TBZ was
administered 120 min before testing. Caffeine (Sigma-Aldrich, Spain) was dissolved in
0.9% w/v saline. Saline solution was used as its vehicle control. Caffeine was
administrated 30 min before test. All solutions were administered intraperitoneally (IP).
2.3. Behavioral and biochemical procedures
Three-choice running wheel T-maze task. The T-maze apparatus consisted of a
central corridor with two opposed arms. Each arm provided a different type of stimuli
(for details, see Fig 1). In one of them sweet pellets (TestDietTM, 50% sucrose, 45 mg
each) were available, in another arm there was a RW, and in the third arm there was a
hole with a cotton ball soked with a neutral non-social odor. Training as well as test
sessions lasted 15 minutes. Mice were trained 5 days a week. Training phase 1: to avoid
neophobia to the sweet tasting pellets, animals were enclosed in that arm with the food
during 5 sessions. Training phase 2: during 2 more weeks animals were exposed, one 15
min session a day to the T-maze with free access to the three stimuli. Test phase: This
phase lasted during 4 more weeks. For each week there were 4 baseline sessions plus a
testing session in which animals either received drug injections. Sessions were
videotaped and a trained observer unaware of the drug condition register manually
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accumulated time spent in the RW, consuming the sucrose pellets, or sniffing the hole,
and crosses into the arms or time spent in the arms of the T-maze. These measures were
taken based on previous studies (Correa et al., 2016). Time was selected as the main
dependent measure because it allowed us to evaluate the three conditions with the same
units. Time allocation is a useful measure of preference, relative reinforcement value,
and response choice (Baum and Rachlin, 1969). Testing sessions started two hours after
light period onset. The behavioral test room was illuminated with a soft light, and
external noise was attenuated.
Figure 1. Schematic representation of the 3-choice RW T-maze task settings and experiments
timeline.
Sweet pellets intake. Mice were individually placed in testing chambers (32 x 15 x 13
cm) identical to their home cages, during a 30 min session per day, 5 days/week. The
testing chambers contained a glass plate with 30 pellets (45 mg each, with a 50%
sucrose composition). At the end of the session, mice were immediately removed from
the chamber, returned to their respective home cages, and number of pellets consumed
was determined. Each animal was exposed to this procedure for 4 weeks before testing
started.
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Running Wheel (RW) locomotion. The automated RW (Ugo Basile) consisted of a
cage (32 x 15 x 13 cm) with a wheel (11 cm in diameter) inserted on top. Locomotor
activity was registered by an electrical counter connected to the wheel. A completed
turn of the wheel was registered as 4 counts. Animals placed in the cage had free access
to the wheel. Animals were trained during 3 weeks to achieve a stable baseline of
locomotion (30 min sessions per day).
High Performance Liquid Chromatography (HPLC) for DA level determination.
Brain samples were extracted after TBZ administration. Mice were anesthetized with
carbon dioxide for 30 s and decapitated. Brains were quickly removed and frozen on a
Leitz Wetzlar microtome. Coronal sections 750 μm thick were cut through the striatum.
A 16-gauge stainless-steel tube was used to dissect bilateral cylindrical samples from
the ventral striatum. These tissue samples were then placed in 200 μl of 0.1 N perchloric
acid, and then homogenized, centrifuged, and frozen. The supernatant was subsequently
analyzed for DA content using HPLC with electrochemical detection (ESA Coulochem
II system). The electrochemical parameters were as follows: channel 1= − 100 mV,
channel 2 = +200 mV, and guard cell = +350 mV. Each liter of mobile phase contained
27.6 g sodium phosphate monobasic, 8.0% of methanol 750 μl of 0.1M EDTA, and
2875 μl of 0.4M sodium octyl sulfate dissolved in deionized ultrapure H2O with a final
pH of 4.5. The flow rate was 1.0 ml/min.
Western blotting. Striatal tissue samples were homogenized in ice cold lysis buffer
[137mM NaCl, 20mM Tris-HCl (pH 8.8), 1% NP40, 10μg/ml of aprotinin, leupetin,
0.5mM orto sodium vanadate and 0.1mM PMSF, protease inhibitors]. Homogenates
were centrifuged at 13.000 rpm for 15 minutes at 4°C. Aliquots of supernatants were
collected and used for Bradford quantification of total protein and others stored at -80ºC
until analyses. Every sample was boiled for 5 minutes. Equal amounts (30μg) of
striatum protein samples were separated by 12.5% SDS-PAGE and transferred to
nitrocellulose membrane for 90 minutes at 30 volts. Membranes were block with 5%
Bovine Serum Albumin (BSA) in TBS-Tween 0.1% for one hour and later incubated
with polyclonal rabbit anti- DARPP32 (1:1000, Cell Signalling), DARPP32-Thr75
(1:500, Cell Signalling and DARPP32-Thr34 (1:500, Cell Signalling) overnight at 4°C.
After rinses with TBST 0.1%, membranes reacted with goat anti-rabbit peroxidase
conjugated secondary antibody and developed by enhanced chemiluminescence (1:40
ThermoScientific). Filters were probed with anti-Actin monoclonal antibody (1:500;
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Abcam) as an internal standard for protein quantification. The film signals were scanned
and levels of the band density were blind processed and quantified by densitometry with
ImageJ software. Every sample was replicated at least twice to ensure the
reproducibility of the method.
2.4. Experiments
Behavioral experiments used a within-groups design, in which each mouse received all
treatments once per week over consecutive weeks. No dose sequence was repeated
across different animals in any of the experiments.
Experiment 1. Impact of TBZ, caffeine and their combination on preference
between concurrently available reinforcers in the T-maze
Experiment 1.1. Effect of TBZ on T-maze preferences. Mice (N=9) received vehicle
or TBZ (1.0, 2.0 and 4.0 mg/kg) 120 minutes before the test.
Experiment 1.2. Effect of caffeine on T-maze preferences. A different group of mice
(N=9) was injected with caffeine (1.25, 2.5 and 5.0 mg/kg) or saline 30 minutes before
test started.
Experiment 1.3. Reversal of TBZ induced effects in the T-maze by different doses
of caffeine. After being trained as described above, mice (N=8) received two injections:
DMSO plus saline, TBZ (4.0 mg/kg) plus saline, and TBZ (4.0 mg/kg) plus caffeine
(1.25, 2.5 and 5.0 mg/kg). TBZ was injected 120 min before test started, while caffeine
was injected 30 min before test.
Experiment 2. Impact of TBZ, caffeine and their combination on independent tests
of sucrose consumption or locomotion in the RW.
Experiment 2.1. Effect of caffeine and TBZ on sucrose consumption. Mice (N=8)
were exposed to sucrose pellets daily during 6 weeks (30 minutes session). When the
animals reached a stable level of intake, they were injected with TBZ at doses of 2.0,
4.0 and 8.0 mg/kg or DMSO 120 minutes before test. Another group of mice (N=9) was
injected with caffeine at doses of 1.25, 2.5, 5.0 and 10.0 or saline 30 minutes before the
intake test.
Experiment 2.2. Effect of caffeine and TBZ on locomotion in the RW. After RW
training, mice (N=9) received TBZ (1.0, 2.0, and 4.0 mg/kg) or DMSO 120 minutes
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before the locomotion test. A second group of mice (N=10) received injections of
caffeine (2.5, 5.0 and 10.0 mg/kg) or saline 30 minutes before testing. A third group of
mice (N=9) received a combination of treatments: DMSO plus saline or TBZ (8.0
mg/kg) plus saline or TBZ (8.0 mg/kg) plus caffeine (2.5, 5.0 and 10.0 mg/kg). Caffeine
or saline vehicle was injected 30 min before the RW test while TBZ or DMSO vehicle
were administered 120 min before the test began.
Experiment 3. Effect of TBZ on DA tissue levels in striatum. Mice (N=8 per
condition) were injected with DMSO or TBZ (4 or 8 mg/kg). The striatum was
extracted 120 min after drug administration. Samples were processed and analyzed with
HPLC in order to quantify DA tissue levels.
Experiment 4. Effect of TBZ and caffeine co-administration on DARPP-32,
pDARPP-32(Thr75) and pDARPP-32(Thr34) levels in striatum. Mice (N=6-8 per
condition) were injected with DMSO plus saline or TBZ (8 mg/kg) plus saline or with
TBZ (8 mg/kg) plus caffeine (10.0 mg/kg) before brain extraction. Striatum samples
were analyzed by western blotting for DARPP-32, pDARPP-32(Thr75) and pDARPP-
32(Thr34).
2.5. Statistical Analyses.
All the behavioral experiments followed a within-subjects design, and were analyzed
with repeated measures analysis of variance (ANOVA). Behavioral data on the
interaction between TBZ and caffeine were analyzed using a two way-factorial
ANOVA. When the overall ANOVA was significant, non-orthogonal planned
comparisons using the overall error term were used to compare each treatment with the
vehicle control group (Keppel, 1991). For these comparisons,  level was kept at 0.05
because the number of comparisons was restricted to the number of treatments minus
one. Biochemical studies were analyzed with one-way ANOVA. All data were
expressed as mean ± SEM, and significance was set at p<0.05. STATISTICA 7 software
was used for statistical analyses of the data.
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3. Results
Experiment 1. Impact of TBZ, caffeine and their combination on preference
between concurrently available reinforcing activities in the T-maze
Experiment 1.1. Effect of TBZ on T-maze preference. Repeated measures ANOVA
revealed an overall effect of TBZ dose on time spent running in the RW (F(3,24)=6.83,
p<0.01), and time spent eating (F(3,24)=2.94, p<0.05), but no significant effect on time
sniffing the neutral odor (F(3,24)=1.43, n.s.) (Fig 2A-C). Planned comparisons showed
a significant decrement in time running in the RW after TBZ injection at doses of 2.0
and 4.0 mg/kg compared with the vehicle group (p<0.01). There was also a significant
increase in the time eating after the highest dose of TBZ (4.0 mg/kg) compared with the
vehicle condition (p<0.01) (Fig 2A and B). The repeated measures ANOVA did not
yield a significant effect of TBZ on total crosses as a measure of locomotion
(F(3,24)=0.52, n.s.) (Fig 2D). Thus none of these doses of TBZ produced an impairment
on locomotion.
Figure 2. Effect of TBZ in the 3-choice RW T-maze task. Data are expressed as mean (±SEM)
of time (seconds) spent interacting with each stimuli (A, B and C) or number of crosses between
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the compartments where the stimuli were located (D), during a 15 minutes session. A) Time
with RW, B) time eating C) time sniffing the non-social odor, and D) number of crosses
between the 3 compartments. **p<0.01 significantly different from vehicle.
Experiment 1.2. Effect of caffeine on T-maze preference. Repeated measures
ANOVA for caffeine treatment showed no significant effects in any of the 3 variables:
time running in the RW (F(3,24)=0.18, n.s.), time spent eating (F(3,24)=0.92, n.s.) and
time sniffing the neutral odor (F(3,24)=0.81, n.s.) (Fig 3A-C). There was not an effect
of caffeine on total crosses (F(3,24)=0.10, n.s.) either (Fig 3D).
Figure 3. Effect of caffeine in the 3-choice RW T-maze task. Data are expressed as mean
(±SEM) of time (seconds) spent interacting with each stimuli (A, B and C) or number of crosses
between the compartments where the stimuli were located (D), during a 15 minutes session. A)
Time with RW, B) time eating C) time sniffing the non-social odor, and D) number of crosses
between the 3 compartments.
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Experiment 1.3. Reversal of TBZ-induced effects in the T-maze by caffeine.
Repeated measures ANOVA showed an overall effect of treatment on time running in
the RW (F(4,28)=4.57, p<0.01) and on time eating (F4,28)=3,63, p<0.05), but not on
time sniffing (F(4,28)=0.71, n.s.) (Fig 4A-C). Planned comparisons revealed a
significant decrease in time running in the RW after administration of TBZ/VEH
compared with control condition (VEH/VEH) (p<0.01), and this decrement was
reversed by the two highest doses of caffeine that were co-administered with TBZ (2.5
mg/kg, p<0.05, and 5.0 mg/kg, different from TBZ/VEH, p<0.01) (Fig 4A). Planned
comparisons revealed that TBZ/VEH administration increased the time spent eating
compared with control group (VEH/VEH) (p<0.05). This increase was reversed by the
co-administration of caffeine at all doses (1.25, 5.0 mg/kg p<0.01 and 2.5 mg/kg,
p<0.05) (Fig 4B). Repeated measures ANOVA did not reveal an effect of treatment on
total crosses between compartments (F(4,28)=0.51, n.s.) (Fig 4D).
Figure 4. Effect of TBZ plus caffeine in the 3-choice RW T-maze task. Data are expressed as
mean (±SEM) of time (seconds) spent interacting with each stimuli (A, B and C) or number of
crosses between the compartments where the stimuli were located (D), during a 15 minutes
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session. A) Time with RW, B) time eating C) time sniffing the non-social odor, and D) number
of crosses between the 3 compartments. **p<0.01, *p<0.05 significantly different from VEH-
VEH. ##p<0.01, #p<0.05 significantly different from TBZ-VEH.
Experiment 2. Impact of TBZ, caffeine and their combination on independent tests
of sucrose consumption and locomotion in the RW.
Experiment 2.1. Effect of TBZ and caffeine on sucrose consumption. Repeated
measures ANOVAs did not show significant overall effects of treatment with TBZ (0,
1.0, 2.0 and 4.0 mg/kg) or caffeine (0.0, 1.25, 2.5 and 5.0 mg/kg) on total intake of
sweet pellets. Thus the ANOVA for TBZ (F(3,24)=2.38, n.s.), and for caffeine
(F(3,21)=1.33, n.s.) did not yield significant effects, indicating that they had no effect
on pellet consumption when there was no alternative reinforcer (see Fig 5A and B).
Figure 5. Effect of TBZ (A) and caffeine (B) on sucrose pellets consumption. Data are
expressed as mean (±SEM) of number of pellets consummed during 30 minutes.
Experiment 2.2. Effect of TBZ and caffeine on locomotion in the RW. Repeated
measures ANOVA indicated a significant effect of TBZ treatment (F(3,24)=7.44,
p<0.01) on locomotion (Fig 6A). Planned comparisons revealed that TBZ at the highest
dose used in the present experiment (8.0 mg/kg) significantly decreased locomotion
compared with the vehicle group (p<0.01). However, the repeated measures ANOVA
did not reveal a significant effect of caffeine treatment (F(3,27)=1.44; n.s) on
locomotion in the RW, even at higher doses (Fig 6B). In the third experiment the
highest dose of TBZ that had suppressed locomotion (8.o mg/kg) was used to study the
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potential of caffeine to reverse TBZ-induced locomotor suppression. Repeated measures
ANOVA across conditions (VEH/VEH, TBZ/VEH, TBZ-Caffeine 2.5, 5.0 or 10.0
mg/kg) yielded a significant effect on RW locomotion (F(4,32)=3.44, p<0.01). Planned
comparisons indicated that TBZ (8.0 mg/kg) suppressed locomotion compared to
control group (VEH/VEH) (p<0.01). All doses of caffeine (2.5, 5.0 and 10.0 mg/kg)
reversed the locomotor suppression induced by 8.0 mg/kg TBZ. Thus, TBZ/VEH was
significantly different from all the TBZ plus caffeine conditions (2.5, 5.0 mg/kg,
p<0.05, and 10.0 mg/kg, p<0.01) (Fig 6C).
Figure 6. Effect of TBZ (A), caffeine (B) and their combination (C) on locomotion in the RW.
The dose of TBZ used in C was 8 mg/kg.  Data are expressed as mean (±SEM) of counts in the
RW during 30 minutes. **p<0.01 significantly different from vehicle. ##p<0.01, #p<0.05
significantly different from TBZ-VEH.
Experiment 3. Effect of TBZ on DA tissue levels in striatum. The one way between-
groups ANOVA revealed an overall significant effect of treatment on DA tissue levels
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in the striatum (F(2,28)=5.16, p<0.05). Planned comparisons revealed a significant
reduction in DA tissue levels after administration of TBZ at doses of 4.0 and 8.0 mg/kg
compared with control group (p<0.05 and p<0.01, respectively) (Fig 7).
Figure 7. Effect of TBZ (4 or 8 mg/kg) on DA levels in striatum. Data are expressed as mean
(±SEM) of ng per mg of DA in tissue. **p<0.01, *p<0.05 significantly different from vehicle.
Experiment 4. Effect of TBZ and caffeine coadministration on DARPP-32,
pDARPP-32(Thr75) and pDARPP-32(Thr34) levels in striatum. One way ANOVA
showed an overall effect of treatment on DARPP-32 levels (F(2,19)=3.70, p<0.05). The
post hoc analysis showed a significant increase of DARPP-32 in the TBZ plus saline
treated group compared with control group (p<0.05) and with the TBZ plus caffeine
group (p<0.05) (Fig 8A). A one way ANOVA for pDAPPP-32(Thr75) levels did not
show an overall effect of treatment on this marker (F(2,12)=1.86, p=1.19) although a
non significant increment was observed after TBZ treatment (Fig 8B). Finally, the one
way ANOVA revealed a significant effect of treatment on pDARPP-32(Tr34)
(F(2,10)=43.9, p<0.01). The post hoc analysis showed a significant increase of this
marker after TBZ treatment (p<0.05) compared to control, and compared to the group
that also received caffeine (p<0.05), indicating a reversal of TBZ effects by caffeine
(Fig 8C).
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Figure 8. (A) Diagram showing effect of DA depletion on DARPP-32 phosphorylation patterns.
Effect of TBZ-caffeine interaction on DA-related markers of signal transduction. The doses
used were: TBZ 8.0 mg/kg and caffeine 10 mg/kg. Data are expressed as mean (±SEM) of
density units of DARPP-32 (B), pDARPP-32(Thr75) (C) and pDARPP-32(Thr34) (D).
**p<0.01, *p<0.05 significant differences from VEH-VEH. ##p<0.01, #p<0.05 significant
differences from TBZ-VEH group.
4. Discussion
The present study assessed the impact of the VMAT-2 inhibitor TBZ on the choice
between voluntary engagement in vigorous and highly preferred physical activity vs.
other sources of reinforcement that could be obtained with little effort, such as sucrose
consumption. TBZ was administered at doses that were shown to reduce tissue levels of
DA in ventral striatum. In the first experiment, mice were evaluated in a T-maze in
which they could freely distribute their time between running on a RW or consuming or
exploring other reinforcers that require minimal behavioral activation (sucrose pellets or
non-social odor). Under basal conditions, mice spent most of the time running (60%),
and much less time eating (2%) or sniffing the neutral odor (0.1%). Consistent with this
finding, previous studies have demonstrated that running has a high motivational value,
since animals work to unlock a wheel (Collier et al. 1990; Iversen, 1993; Belke and
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Heyman, 1994), to turn on a motorized wheel (Kavanau, 1967) or to gain access to areas
containing a wheel (Sherwin, 1996; Sherwin and Nicol, 1996). In addition, wheel
running, as well as the after effect or running, can be used as the motivational stimulus
for the establishment of conditioned place preference (CPP) (Lett et al. 2000; Torst and
Hauber, 2014).
After TBZ administration choice behavior was altered; time spent running was reduced,
but time consuming sucrose was actually increased, which demonstrates a shift to a low
effort option. No changes were observed in time sniffing the neutral odor. This set of
results is consistent with previous studies in a similar two-options T-maze, in which the
D2 antagonist haloperidol shifted relative preference from RW to sucrose pellets in mice
(Correa et al., 2016). Haloperidol has previously been demonstrated to shift behavior in
mice towards low effort alternatives in a T-maze barrier task in which animals have to
climb a barrier in order to get a higher quantity of food in every trial (Pardo et al. 2012).
TBZ was previously shown to reduce selection of high effort/high reward options in
rats, using effort-based decision-making paradigms such as the T-maze barrier task
(Yohn et al. 2012), operant tasks with concurrent lever pressing for preferr5ed highly
palatable food versus free feeding standard chow (Salamone et al. 2012; Nunes et al.
2013), or lever pressing for high concentrations of sucrose versus free access to low
sucrose concentrations (Pardo et al. 2015). Furthermore, TBZ also has been shown to
have these effects when injected into Nacb core, reducing lever pressing for the
palatable food and increasing chow intake (Nunes et al. 2013). However, free
consumption of foods or sweet solutions, preferences between different types or
amounts of foods, or facial expressions that reflect hedonic reactivity after sucrose
intake, were not affected in rats after TBZ administration (Nunes et al. 2013; Pardo et
al. 2015; Yohn et al. 2015), demonstrating that DA depletion does not simply affect
primary food motivation. Similarly, in the present results from experiment 3, even
higher doses of TBZ than the ones used in the T-maze did not change sucrose
consumption when animals had no alternative option present during the testing session.
Thus, as previously demonstrated, DA depletion with TBZ does not affect primary
motivation for food or sucrose when little work is involved (Nunes et al. 2013; Pardo et
al. 2015). Furthermore, although the after effect of running can contribute to the
establishment of emotional Pavlovian memories, as seen by the development of CPP,
this after effect is not DA-dependent (Trost and Hauber, 2014), and it does not seem to
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be playing a role in the present results, since mice did not change the amount of time
that they spent in the RW compartment (data not shown) even after the administration
of doses of TBZ that reduced time spent running on the wheel. It is also important to
emphasize that the present results are not merely due to motor incapacity, because the
higher dose of TBZ used in the T-maze (4.0 mg/kg) did not impair voluntary
locomotion in a RW when there was no other reinforcer available (experiment 2.2).
The non-selective adenosine antagonist caffeine when administered alone did not
change the relative preference of mice in this T-maze test, even when given at high
doses (up to 10.0 mg/kg). However, caffeine (2.5 and 5.0 mg/kg) was able to reverse the
change in relative preference induced by TBZ (4.0 mg/kg), shifting preferences by
increasing time in the RW and decreasing time spent eating sucrose in TBZ-treated
animals. Furthermore, caffeine (1.25-10 mg/kg) reversed the suppression of RW
locomotion induced by a high dose of TBZ (8.0 mg/kg) that also significantly reduced
DA tissue levels. Consistent with the present results, previous studies showed a similar
interaction between DA antagonists or depletions and adenosine receptor antagonism or
deletion (Farrar et al. 2007; Mott et al. 2009; Worden et al. 2009; Correa et al. 2016;
Yohn et al. 2013; 2015). Thus, A2A KO mice were resistant to the effects of the D2
antagonist haloperidol in the two-option T-maze paradigm (Correa et al., 2016). A2A KO
mice did not shift time allocation from RW towards sucrose after haloperidol
administration, as did the wild type mice (Correa et al. 2016). These KO mice were also
resistant to the effect of haloperidol in a simple RW (Pardo et al., 2013), and in the T-
maze barrier choice task (Pardo et al., 2012). Theophylline, which is another
methylxantine, was able to palliate the anergia-like effect induced by haloperidol in the
T-maze barrier task in mice (Pardo et al., 2012). In rats, the selective adenosine A2A
antagonist MSX-3 was shown to reverse the effects of the D2 antagonist haloperidol and
TBZ in several different types of effort-based decision making paradigms (Farrar et al.,
2007; Nunes et al., 2013; Yohn et al., 2015; Pereira et al., 2011).
TBZ significantly increased postsynaptic intracellular DA markers, including DARPP-
32 and one of its phosphorylated forms, pDARPP-32(Thr34). These TBZ-induced
increases in markers of DA-related signal transduction were significantly reversed by
caffeine. In contrast, the induction of pDARPP-32(Thr75) expression by TBZ did not
reach significance. These results suggest that there is a substantial action of TBZ on
neurons containing D2 receptors (Nunes et al. 2013). DA D2 and adenosine A2A
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receptors are co-localized on enkephalin-containing medium spiny neurons (MSNs),
while D1 and A1 receptors are co-localized on substance P-containing MSNs (Nunes et
al. 2013; Ferré, 2008; Ferré et al. 2004). D2 and A2A receptors are capable of forming
heteromers, and also converge onto the same signal transduction mechanisms, having
opposite effects on intracellular signaling cascades (Fuxe et al. 2003; Ferré, 2008).
Reductions in D2 receptor transmission have been shown to increase expression of
pDARPP-32(Thr34) (Svenningsson et al. 2004; Bateup et al. 2008; Yger and Girault,
2011; Bonito-Oliva et al. 2011; Santerre et al. 2012; Nunes et al., 2013; see Fig 8).
Previous studies in rats using immunohistochemical techniques have demonstrated that
TBZ increased both phosphorylated forms of DARPP-32 (-Thr75 and -Thr34) in Nacb
shell and core, but in different populations of neurons (Nunes et al., 2013). Adenosine
antagonists acting on A1 or A2A receptors generally produce opposite effects to TBZ on
these markers. Thus, it has been demonstrated that the selective A2A receptor antagonist
MSX3 reduced the increase of pDARPP-32(Thr34) induced by TBZ in enkephalin-
positive neurons that also contain D2 receptors (Nunes et al., 2013). However, this A2A
antagonist did not reverse the induction of pDARPP-32(Thr75) in D1 containing
neurons, which probably reflects the fact that D1 receptors are not extensively co-
localized with A2A receptors (Nunes et al., 2013). In the present results, caffeine was
able to reverse the induction of pDARPP-32(Thr34) expression produced by TBZ,
pointing to a predominant effect of both drugs on D2-A2A receptors situated in striatal
enkephalin-containing MSN.
In summary, the present results are consistent with the hypothesis that DA is involved in
effort-related processes, and support the concept that adenosine receptors interact with
DA in modulation these functions (Salamone et al., 2009; Santerre et al., 2012; Pardo et
al., 2012; Nunes et al., 2013; Randall et al., 2014; Yohn et al., 2015). This study
illustrates the ability of the 3-choice T-maze task with active vs. passive reinforcing
activities to demonstrate the involvement of DA in the activational component of
motivation, which is consistent with previous studies showing that DA antagonism was
able to specifically shift preferences away from effortful sources of reinforcement
(Correa et al., 2016). The 3-choice T-maze task offers the chance to study preferences
between qualitatively different reinforcers in addition to food, which is in contrast to
previous tasks that involved choices between different quantities of food (Pardo et al.,
2012; Yohn et al., 2014) or foods with different palatability (Salamone et al., 2006;
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Farrar et al., 2010; Pardo et al., 2015). The present results indicate that DA depletion
with TBZ reduces the relative intrinsic reinforcing characteristics of wheel running in an
empirical sense, in a manner similar to DA antagonism (Correa et al., 2016). The
intrinsic reinforcing value of voluntary physical activities such as lever pressing, barrier
climbing, or wheel running is of critical importance for understanding several aspects of
motivation and decision-making (Salamone et al., 1997, 2016; Salamone and Correa
2002, 2012; Hosking et al. 2014).
The present work has potential clinical relevance, because DA has been implicated in
aspects of depression such as anergia, psychomotor slowing, decreased energy levels
and fatigue (Stahl, 2002; Salamone et al., 2006; Treadway and Zald, 2011). In addition,
a lack of physical activity can contribute to the development of depression (Lambert
2006). Moreover, effort-related motivational symptoms such as anergia, fatigue, and
psychomotor slowing seen in depressed humans are very resistant to classical
antidepressant treatments such as 5-HT uptake inhibitors (Stahl, 2002; Fava et al.,
2014). Caffeine has been demonstrated to improve motor symptoms in PD patients and
in animal models (Postuma et al., 2012; Qi and Li 2014), and it can enhance the
antidepressant-like activity of common antidepressant drugs in traditional tests of
depression such as the forced swim test (Szopa et al., 2016). The present results suggest
that studies with caffeine and more selective adenosine antagonists may offer useful
clues for developing novel treatments for this set of symptoms.
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GENERAL CONCLUSIONS
The present thesis reviews the literature and describes studies investigating the effect2
of caffeine and other selective adenosine antagonists (A1/A2A), either alone or in
combination with ethanol, on different mood, memory and motivated behaviors
(Chapters 1-4). It also reviews and evaluates the effect of caffeine on depressive
symptoms, focusing on potential therapeutic effects on motivational impairments or
anergia-like symptoms induced by reduced DA transmission (Chapers 5-6).
Chapter 1 summarized previous literature about the effects of caffeine in combination
with ethanol, focusing on animal studies and behaviors related to the abuse potential of
both drugs. Caffeine is consumed in combination with ethanol under the popular belief
that caffeine can ameliorate the debilitating effects of ethanol. From the animal studies
it can be concluded that although caffeine at low doses can in fact counteract some
effects induced by ethanol, such as anxiety, sedation, narcosis, locomotion and
incoordination, higher doses of caffeine can have opposite effects, impairing those
behaviors even further. However, it is also evident that many important aspects of
motivated behaviors regulated by ethanol are still not explored. Moreover, apparently
contradictory results could be resolved if a broader range of doses of both drugs were
evaluated systematically.
Caffeine can have beneficial effects on arousal, attention or mood when consumed at
low to moderate doses. However, the consumption of high concentrations of caffeine is
becoming popular with the introduction to the market of the so-called “energy drinks”.
The results from Chapter 2 show that caffeine at high doses can produce impairing
effects on locomotion and coordination, increase anxiety, and also increase plasma
corticosterone levels. Theophylline is an active metabolite of caffeine that is also
present in some “energy drinks”. This methylxantine is as efficacious as caffeine at
producing anxiety and locomotor suppression, and at inducing hormonal markers of
stress, though caffeine seems to be more potent in this regard. Thus, both
methylxantines can have undesired effects at high doses, but it is necessary the use
higher doses of theophylline in order to produce those effects.
Because the highest dose of caffeine used in the previous studies produced very robust
impairing effects, for subsequent studies in this thesis the highest dose used in chapter 2
was eliminated, but a broad range of caffeine doses from low to high (7.5-60 mg/kg)
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was used in the following chapter. Chapter 3 presents the effects of caffeine
administered alone or in combination with ethanol on social motivation and long-term
social memory. Caffeine dose-dependently decreased social interaction and impaired
social preference at a range of doses that has anxiogenic effects (30-60 mg/kg).
However, although the highest doses of ethanol also reduced social interaction, they did
not affect preference for the conspecific. Moreover, ethanol improves social exploration
at low doses. Thus, ethanol at a range of doses that has anxiolytic effects keeps social
exploration mostly intact, and was able to reverse the decrease in social interaction
induced by a moderate dose of caffeine. However, the results with tasks involving long-
term social memory indicate that ethanol has a potent amnesic effect, even at low doses,
and caffeine cannot rescue that effect. Moreover, caffeine itself also has amnesic effects
at high doses.
From the studies about the role of A1 or A2A receptor involvement on social behaviors,
the general conclusion is that they do not seem to mediate the effect of high doses of
caffeine. It is possible that A1 receptor antagonism could be mediating the effects of low
doses, since CPT produced the same pattern of effects as the low doses of caffeine in
social interaction and preference. However, MSX-3 (the selective A2A receptor
antagonist) potentiated social interaction keeping preference intact, thus leading us to
suggest that A2A receptors are not involved in the effects of caffeine on this behavior.
Moreover, neither CPT nor MSX-3 produced an effect on memory, thus separating the
impairing effects of high doses of caffeine on memory from its actions on A1 and A2A
receptors. Only the A2A antagonist had a positive effect, reducing memory impairments
induced by ethanol.
Consistently in Chapter 4, A2A receptor KO mice showed high levels of social
interaction despite their anxiogenic profile, and these animals were not affected by an
impairing dose of ethanol (1.0 g/kg) on social interaction. Suggesting a possible
predominant role of A2A receptors on attenuating ethanol-induced decreases on social
interaction. And also suggesting that A2A receptors could be therapeutic targets to study
social impairments induced by different genetic or pharmacological manipulations.
However, although MSX-3 did not impair long term social memory, KO mice spent the
same amount of time exploring the familiar and novel conspecifics. This memory
impairment could be due to neuroadaptations that may occur in this KO animals, or
perhaps to differences in sensitivity to novelty in these animals.
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In terms of the potential therapeutic effect of caffeine on activational/motivational
symptoms of depression, as summarized in Chapter 5, caffeine has been shown to be
effective in animal models of depression, reversing the effects of adenosine agonism or
improving even further the effects of antidepressants on animal models such as the FST
or TST. However, there are not systematic studies performed in humans, and the studies
focusing on motivational symptoms (anergia or lack of motivation) in humans and in
animals are scarce. The results from the T-maze barrier test demonstrate that caffeine
does not improve learning in this test but it is very effective at reversing the impairing
effects of TBZ on the selection of the high effort option (HD arm). In addition, caffeine
reversed the anergia-like effects induced by TBZ in the T-maze that evaluates
preferences for reinforcers based on effort and behavioral activation. TBZ decreased
time spent interacting with the RW, but animals compensated increasing time spent in a
more sedentary option (i.e. drinking sucrose). However, DA depletion did not affect
sucrose intake or locomotion in the RW when evaluated in a non-choice situation,
suggesting an anergia-like effect and not a non-specific effect on appetite or
locomotion. Caffeine reversed the effect of TBZ suggesting a therapeutic effect on the
anergia-like symptoms induced by DA depletions. At these low doses, and based on the
results about DARPP-32 phosphorylation patterns, is seems reasonable to suggest that
caffeine acts via adenosine receptors. Thus, TBZ increased phosphorylation of
DARPP32 at Thr34 and produced an increase on pDARPP32-Thr75, logically as a
consequence of the decrease in DA levels instigated by this DA depleting agent, and as
demonstrated by the HPLC measurements of DA levels in ventral striatum. Caffeine
decreased pDARPP-32(Thr34) expression induced by TBZ, but did not change the
levels of pDARPP-32(Thr75) induced by TBZ, suggesting a predominant role of D2-
A2A receptors on caffeine-TBZ interactions. These results support the idea that A2A
receptors play a predominant role in mediating the therapeutic actions of caffeine.
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APPENDIX 1:
Impact of high doses of caffeine on acute and sensitized motor
activity induced by ethanol in mice.
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1. Abstract
Energy drinks are highly consumed beverages rich in caffeine. In humans, energy drinks
are very frequently consumed with alcohol in order to reduce sedation and ataxia
induced by high doses of this drug of abuse. Caffeine stimulates locomotion but can
also produce motor impairments at high doses. To determine if caffeine can actually
reverse the motor stimulating and ataxic effects of ethanol, we used an open field test to
evaluate the impact of caffeine (7.5, 15 and 30 mg/kg, IP) on several motor parameters
affected by acute or repeated administration of ethanol (1.5 and 2.5 g/kg, IP) in adult
male CD1 mice. Acutely, both caffeine and ethanol increased locomotion in a dose
dependent manner. Moreover, when ethanol was administered to animals pretreated
with caffeine there was an additive effect of both substances at the low dose of ethanol,
and a potentiation of the stimulating effects of the high dose of ethanol in horizontal
locomotion. Caffeine reversed the suppressive effect of ethanol on rearing that was
supported by the wall, but was not able to reverse the ethanol-induced impairment in
rearing that was not supported, which is an index of postural stability. Ethanol (1.5
g/kg) administered repeatedly in the open field produced sensitization of horizontal
locomotion and rearing supported by the wall. However, acute administration of
caffeine to mice previously preexposed to ethanol produced a dose dependent reduction
in locomotion compared to mice preexposed to saline. On the other hand, repeated
administration of caffeine (15 mg/kg) did not induced sensitization but it made animals
more sensible to the stimulant effects of ethanol (1.5 g/kg). Thus, caffeine potentiated
the stimulating effects of an acute dose of ethanol. The neural substrate underlying this
effect could be the dopamine-adenosine functional interaction in the nucleus
accumbens, a brain structure important for the regulation of locomotion, behavioral
activation, and processes such as incentive salience and vigor involved in goal directed
responses.
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2. Methods
2.1. Subjects
Adult Swiss CD1 mice (30-45 g) were purchased from Janvier (France). Mice were housed
in groups of three per cage, with standard laboratory rodent chow and tap water available
ad libitum. They were maintained in the colony at 22 ± 1ºC with lights on from 8:00 to
20:00 hours. All experimental procedures complied with the European Community
Council directive (86/609/ECC) for the use of laboratory animal subjects and with the
“Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research”
(National Research Council 2003).
2.2. Drugs
Ethanol (Panreac Quimica S.A., Spain) was diluted to 20% (v/v) in physiological saline
(0.9 % w/v) and administered intraperitoneally (IP) 10 minutes before testing. Caffeine
(Sigma-Aldrich, Spain) was dissolved in 0.9% w/v saline and administered IP 30 minutes
before testing. Saline solution was used as vehicle.
2.3. Apparatus and testing procedures.
Open Field (OF). The OF apparatus consists of a clear glass cylinder 25 cm in diameter
and 30 cm high. The floor of the cylinder was divided into four equal quadrants by two
intersecting lines drawn on the floor. Animals were placed in the center of the cylinder and
immediately observed for 15 minutes. The behavioral test room was illuminated with a soft
light, and external noise was attenuated. Horizontal and vertical locomotion in the OF were
simultaneously recorded and registered manually. For horizontal locomotion an activity
count was registered each time the animal crossed from one quadrant to another with all
four legs. A count of vertical locomotion was registered each time the animal raised its
forepaws in the air higher than its back (unsoported rear), or rested them on the wall
(suported rear).
Western Blotting. Mice were deeply anaesthetized with CO2, and when the absence of
reflexes was observed the animals were dislocated. The vermis was immediately removed
and dissected. Cerebellar tissue samples were homogenized in icecold lysis buffer [137mM
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NaCl, 20 mM Tris-HCl (pH 8.8), 1% NP40, 10 μg/ml of aprotinin, leupetin, 0.5 mM orto
sodium vanadate and 0.1 mM PMSF, protease inhibitors]. Homogenates were centrifuged
at 14,000 rpm for 15 minutes at 4°C. Aliquotes o supernatants were collected and used for
Bradford quantification of total protein and others stored at -80ºC until analyses. Before
subjected, every sample was boiled for 5 minutes. Equal amounts (50 μg) of vermis protein
samples were separated by 15% SDS-PAGE and transferred to nitrocellulose membrane
for 80 minutes at 30 volts. Membranes were block with 5% non-fat dry milk in TBS-
Tween 0.1% for one hour and later incubated with polyclonal rabbit anti- (1:100, Santa
Cruz Biotechnology) overnight at 4°C. After rinses with TBS 1% triton X-100, filters
reacted with goat anti-rabbit peroxidaseconjugated secondary antibody and developed by
enhanced chemiluminescence (1:20,000; Bio-Rad). Filters were probed with anti-αtubulin
monoclonal antibody (1:400; Chemicon, Millipore) as an internal standard for protein
quantification. The film signals were scanned and levels of the band density were blind
processed and quantified by densitometry with ImageJ software. Every sample was
replicated at least twice to ensure the reproducibility of the method.
Blood ethanol determinations. Additional mice (n=6 per group) were used to determine
whether caffeine influenced blood ethanol levels at the same doses and times used in the
behavioral studies. For that purpose animals were injected with caffeine (0 or 30 mg/kg)
and with ethanol (2.5 g/kg). Trunk blood samples (20 μl) were collected 10 and 20 min
after ethanol and caffeine administration respectively. Following Boehm et al. (2000), each
blood sample was immediately placed in a microcentrifuge tube containing 50 μl of ice-
cold 5% ZnSO4 solution. A 50-μl aliquot of 0.3 N Ba(OH)2 and 300 μl of deionized water
was added. After centrifugation at 4°C (5 min, 12,000 rpm), the supernatant was removed
and blood ethanol concentrations were determined by headspace gas chromatography with
a flame-ionized detector (CE Instruments GC 8000, HS 850).
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3. Experiments
Experiment 1: Acute administration of caffeine, ethanol or their interaction on
locomotion.
Locomotor activity was evaluated in the OF. Horizontal and vertical locomotion
(supported and unsupported rear) was registered manually during 10 minutes. Caffeine
(0.0, 7.5, 15.0 and 30.0 mg/kg) was administered 30 minutes before testing and ethanol
(0.0, 1.5, 2.5 and 3.5 g/kg) was administered 10 minutes before test. The interval time
between drug administration and beginning of testing was the same for all subsequent
experiments.
Experiment 2:  Effect of repeated administration of ethanol on locomotion.
During 5 sessions in alternating days, animals were tested in the OF after ethanol (1.5 or
2.5 g/kg, IP) or saline administration.
Experiment 3: Effect of acute administration of caffeine (0, 15, 30 mg/kg) on ethanol
(1.5 g/kg)-induced locomotor sensitization.
Two days after the last drug administration, animals in experiment 2 received an acute
administration of caffeine (0, 15 or 30 mg/kg) in order to observe if there was a cross-
sensitization effect.
Experiment 4:  Effect of repeated administration of caffeine (0 or 15 mg/kg) on
locomotion and acute chalenge with ethanol (0.0 or 1.5 g/kg).
During 5 sessions in alternating days, two new groups of animals received saline or
caffeine (15 mg/kg), IP) and were tested in the OF after drug administration. Two days
after the last administration, animals received an acute administration of ethanol (0.0 or 1.5
g/kg) and were tested again in the OF.
Experiment 6. Western blotting for DARPP-32.
After completion of experiments 1 and 5, animals were anesthesized and brains were
col.lected. Striatum samples were analyzed by western blotting for DARPP-32, pDARPP-
32(Thr75), and pDARPP-32(Thr34).
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Experiment 7. Blood ethanol concentration.
Additional mice were used to determine whether caffeine influenced the blood levels of
ethanol at the same doses and times as those used in the behavioral studies. For that
purpose animals received caffeine (0 or 30 mg/kg) and 30 min later ethanol (2.5 g/kg) was
administered.
4. Preliminary results
Experiment 1: Acute administration of caffeine, ethanol or their interaction on
locomotion in the open field (OF).
One way-ANOVA showed an overall
effect of caffeine on horizontal crosses
(F(3,30)=4.06, p<0.05), as well as on
supported rear (F(3,30)=3.48, p<0.05).
Planned comparisons showed that
caffeine at low and moderate doses (7.5
and 15 mg/kg) significantly increased
horizontal locomotion (p<0.05 and
p<0.01, respectively) (Fig 1A). These
doses of caffeine also produced
significant increments in the number of
unsupported rears (p<0.05) (Fig 1C). No
significant effect of caffeine treatment on
unsupported rear was observed
(F(3,30)=0.45, n.s).
Figure 1. Horizontal locomotion (A), supported
rear (B) and unsupported rear (C) in the OF after
an acute administration of caffeine. Data are
expressed as mean (±SEM) number of counts
during 10 minutes. **p<0.01, *p<0.05
significantly different from vehicle
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The effect of ethanol was also analyzed
by a one-way ANOVA revealed an
overall effect of ethanol treatment on
horizontal crosses (F(3,39)=3.75,
p<0.05), supported rear (F(3,39)=24.11,
p<0.01), and unsupported rear
(F(3,39)=19.13, p<0.01). Planned
comparisons showed that ethanol
significantly increased horizontal crosses
at the dose of 2.5 g/kg (p<0.05) (Fig 2A).
Supported rear was decreased by the
highests doses of ethanol (2.5 and 3.5
g/kg, p<0.01), (Fig 2B). All ethanol
doses significantly decreased
unsupported rear (p<0.01) (Fig 2C).
Figure 2. Horizontal locomotion (A),
supported rear (B) and unsupported rear
(C) in the OF after acute administraton of
ethanol. Data are expressed as mean
(±SEM) number of counts during 10
minutes. **p<0.01, *p<0.05
significantly different from vehicle.
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Figure 3. Horizontal locomotion (A),
supported rear (B), and unsupported
rear (C) in the OF after acute
coadministration of caffeine and
ethanol.  Mean (±SEM) number of
counts during 10 minutes.  **p<0.01,
*p<0.05 significantly different from 0
mg/kg caffeine in the same ethanol
dose.
Factorial ANOVA (Caffeine x
Ethanol) showed an overall effect
of caffeine (F(2, 112)=11.18,
p<0.01), ethanol (F(3, 112)=59.35,
p<0.01), and caffeine-ethanol
interaction (F(6, 112)=6.64,
p<0.01), on horizontal crosses in
the OF. Planned comparisons
revealed that caffeine 30 mg/kg
coadministered with ethanol 1.5
g/kg, produced a significant
increase in locomotion compared
with saline plus ethanol 1.5 g/kg
(p<0.05). Caffeine 15 mg/kg plus
ethanol 2.5 g/kg, increased
stimulation induced by saline plus
ethanol 2.5 g/kg (p<0.01). The
same pattern of results was observed for caffeine 30 mg/kg plus ethanol 2.5 g/kg (p<0.01),
suggesting an additive effect of caffeine on locomotion induced by low doses of ethanol,
and a potentiation of the stimulation induced by ethanol at stimulant doses (2.5 g/kg).
There was not a significant effect of caffeine (15 or 30 mg/kg) administered with a
locomotor suppressant dose of ethanol (3.5 g/kg) or in the saline treated groups (Fig 3A).
The factorial ANOVA (Caffeine x Ethanol) for the variable supported rear, as a measure of
vertical locomotion, also showed an overall effect of caffeine [F(2,112)=3.81, p<0.05],
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ethanol (F(3,112)=62.26, p<0.01), and their interaction (F(6,112)=2.29, p<0.05). Planned
comparisons showed a significant increase of supported rear after caffeine at dose of 15
mg/kg (p<0.01). Caffeine 15 and 30 mg/kg increased supported rearing when administered
with ethanol 1.5 g/kg, compared with saline in the ethanol 1.5 g/kg treated group (p<0.01)
(Fig 3B). Finally, the factorial ANOVA (Caffeine x Ethanol) for unsupported rear (Fig
3C) showed a significant effect of ethanol treatment (F(3,112)=66.89, p<0.01). However,
there was no significant effect of caffeine (F(2,112)=0.94, n.s.), and no significant
interaction (F(6,112)=0.83, n.s.).
Experiment 2:  Effect of repeated administration of ethanol on locomotion.
Repeated measures ANOVA showed a significant effect of treatment (saline or 1.5 g/kg
ethanol) (F(1,64)=30.87, p<0.01), a significant effect of session (1 and 5) (F(1,64)=18.15,
p<0.01) and treatment x session interaction (F(1,64)=8.24, p<0.01). Planned comparisons
showed a locomotor stimulant effect of ethanol (1.5 g/kg) in the first session compared
with saline treatment (p<0.01). The fifth administration (session 5) of ethanol, increased
locomotion compared with its first administration (session 1) (p<0.01). This increase in
locomotion over sessions was not observed in the saline treated group, suggesting a
sensitization of locomotion induced by ethanol (Fig 4A). The repeated measures ANOVA
showed a significant effect of treatment on supported rear (F(1,64)=6.42, p<0.01), no
significant effect of session (F(1,64)=3.32, n.s.), but a significant effect of treatment x
session interaction (F(1,64)=4.61, p<0.05) (Fig 4B). Planned comparisons showed that
ethanol (1.5 g/kg) increased the number of supported rears when administered in session 5
compared with saline (p<0.01), and also compared with its administration in the session 1
(p<0.05). A third repeated measures ANOVA showed a significant effect of treatment on
unsupported rear (F(1,64)=127.4, p<0.01), a significant effect of session (F(1,64)=21.62,
p<0.01), but did not show a significant effect of treatment x session interaction
(F(1,64)=2.60, n.s.) (Fig 4C).
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Figure 4. Effect of repeated administration of ethanol (0.0, 1.5 or 2.5 g/kg) on horizontal
locomotion (A and D), supported rear (B and E) and unsupported rear (C and F) in the OF
during sessions 1 and 5. Data are expressed as mean (±SEM) number of counts during 10
minutes. **p<0.01 significantly different from session 1. ##p<0.01 significantly different from
vehicle in the same session.
For the experiment in which the dose of ethanol was 2.5 g/kg, repeated measures ANOVA
(Session x Treatment) for horizontal locomotion showed a significant effect of treatment
(F(1,49)=18.41, p<0.01), but no significant effect of session (F(1,49)=0.26, n.s.), and no
significant interaction (F(1,49)=0.04, n.s.). Thus, ethanol at this dose (2.5 g/kg) did not
produced locomotor sensitization after repeated administration (Fig 4D). Repeated
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measures ANOVA (Session x Treatment) for the variable supported rear, showed a
significant effect of treatment (F(1,49)=126.93, p<0.01), but no significant effect of session
(F(1,49)=1.42, n.s.), and no significant interaction (F(1,49)=1.52, n.s.) (Fig 4E). Finally,
repeated measures ANOVA for unsupported rear, showed a significant effect of treatment
(F(1,49)=138.91, p<0.01), but no significant effect of session (F(1,49)=1.09, n.s.) and no
significant interaction (F(1,49)=0.57, n.s.) (Fig 4F). Thus, ethanol at this dose (2.5 g/kg)
did not change rearing after repeated administration.
Experiment 3:  Effect of acute administration of caffeine (0, 15, 30 mg/kg) on ethanol
(1.5 g/kg)-induced locomotor sensitization.
Figure 5. Effect of caffeine on
horizontal locomotion (A), supported
rear (B) and unsupported rear (C) in the
OF in mice treated with ethanol (1.5
g/kg) in previous days. Data are
expressed as mean (±SEM) number of
counts during 10 minutes. **p<0.01,
*p<0.05 significantly different from
vehicle in the same pretreatment group.
##p<0.01, #p<0.05 significantly
different from the same dose of caffeine
in animals that had received saline in
previous sessions.
The factorial ANOVA; previous
ethanol treatment (0.0 or 1.5 g/kg) x
caffeine dose (0, 15 or 30 mg/kg)
showed an overall effect of previous
ethanol dose (F1,65)=11.48, p<0.01),
caffeine dose (F2,65)=25.45,
p<0.01), and also a significant effect
of their interaction (F1,65)=3.82,
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p<0.05) on horizontal locomotion (Fig 5A). The same patter of results were observed on
supported rear (Fig 5B) ((F1,65)=9.66, p<0.01; (F2,65)=29.28, p<0.01; F1,65)=3.25,
p<0.05, respectively) and unsupported rear (Fig 5C) ((F1,65)=4.87, p<0.05;
(F2,65)=10.90, p<0.01; F1,65)=5.36, p<0.01 respectively). Planned comparison showed a
stimulant effect of caffeine at both doses (15 and 30 mg/kg) in the saline pretreated group
(p<0.01). Only the dose of 15 mg/kg of caffeine induced locomotion in the ethanol (1.5
g/kg) pretreated group (p<0.05). Interestingly, caffeine at the highest dose (30 mg/kg)
significantly decreased locomotion in animals pretreated with ethanol (1.5 g/kg) when
compared with the effect of this dose of caffeine in the vehicle pretreated group (p<0.01).
The effect of caffeine on supported rear showed a similar pattern of effects. Caffeine
increased supported rear at both doses (15 and 30 mg/kg, p<0.01 and p<0.05 respectively)
in the vehicle pretreated group. However, only caffeine 15 mg/kg significantly increase
this variable in the ethanol pretreated group (p<0.01). Caffeine 30 mg/kg decreased
supported rear in the ethanol preteated group compared with its effect in the vehicle
pretreated group (p<0.01). Finally, caffeine 15 mg/kg increased unsupported rear in the
ethanol preteated group, but at the highest dose (30 mg/kg), it significantly decreased this
variable (p<0.05). Moreover, the effect of this dose of caffeine in the ethanol pretreated
group was significantly different to the effect observed in the saline pretreated group
(p<0.05).
Experiment 4:  Effect of repeated administration of caffeine (0 or 15 mg/kg) on
locomotion, and acute chalenge with ethanol (0.0 or 1.5 g/kg).
The factorial ANOVA (treatment; caffeine 15 mg/kg or saline x session; 1 and 5) for
horizontal locomotion, showed an overall effect of repeated treatment (F(1,45)=7.55,
p<0.01), and also of session (F(1,45)=13.64, p<0.01). However, there was no significant
treatment x session interaction (F(1,45)=0.09, n.s), suggesting no sensitization effect of
repeated caffeine administration at a stimulating dose of 15 mg/kg. The same pattern of
effects was observed for supported rear. The factorial ANOVA showed a significant effect
of treatment (F(1,45)=6.82, p<0.05), as well as session (F(1,45)=10.59, p<0.01). But there
was no significant interaction (F(1,45)=3.12. n.s). On the other hand, the ANOVA for the
variable unsupported rear showed an overall effect of treatment (F(1,45)=17.19, p<0.01),
session (F(1,45)=10.59, p<0.01), and also treatment x session interaction (F(1,45)=39.12,
p<0.01). However, planned comparison on this last variable showed a significant increase
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of unsupported rear in session 5 compared with session 1 only in saline treated animals
(p<0.01) (Table 1).
Session 1 Session 5
Caffeine dose (mg/kg) 0 15 0 15
Horizontal crosses 55.2 ±4.1 80.5±7.2 71.7±6.2 100.0±11.2
Supporter rear 27.4±2.3 36.3±4.3 31.8±3.8 51.1±6.0
Unsupported rear 28.9±2.3 33.0±3.1 71.1±6.2** 31.5±3.3
Table 1. Effect of repeated administration of caffeine (0 or 15 mg/kg, IP) on horizontal
locomotion, supported rear and unsupported rear in the OF during sessions 1 and 5. Data are
expressed as mean (±SEM) number of counts during 10 minutes. **p<0.01 significantly different
from session 1.
All these animals, after two days of no treatment or test, received a dose of 1.5 g/kg
ethanol or saline. The factorial ANOVA yield no significant effect of previous treatment
(F(1,39)=0.41, n.s), no significant effect of ethanol dose (F(1,39)=0.11, n.s), and no
pretreatment x ethanol interaction (F(1,39)=2.11, n.s) (Fig 6A). The factorial ANOVA for
variable supporter rear yield a significant effect of ethanol (F(1,39)=6.36, p<0.01), but no
effect of previous treatment (F(1,39=0.14, n.s), and no significant interaction (1,39)=0.37,
n.s) (Fig 6B). For unsupported rear (Fig 6C), caffeine pretreatment did not yield a
significant effect (F(1,39)=3.15, n.s). However, the factor ethanol dose (F(1,39)=108.12,
p<0.01), as well as the interaction (F(1,39)=4.97, p<0.05) were significant. Planned
comparisons revealed significant differences between saline and ethanol (1.5 g/kg) treated
animals in unsupported rear in animals previously treated with saline, and also in the
groups previously treated with caffeine (15 mg/kg) (p<0.01). In addition, animals
previously treated with caffeine (15 mg/kg), showed less number of unsupported rearings
than animals treated with saline (p<0.01).
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Figure 6. Effect of ethanol (1.5 g/kg) on
horizontal locomotion (A), supported
rear (B) and unsupported rear (C) in the
OF in mice pretreated with caffeine (15
mg/kg) in previous days. Data are
expressed as mean (±SEM) number of
counts during 10 minutes. **p<0.01
significantly different from vehicle in
the same pretreatment group. ##p<0.01
significantly different from the same
dose of ethanol in animals that had
received saline in previous sessions.
Further analyses, were performed for the variable locomotion. We divided animals in high
and low ethanol induced locomotion using the median split among the groups that received
an acute administration of ethanol 1.5 g/kg. Preliminary results demonstrate that among the
low activity subgroups, there is no difference between caffeine preexposed and saline
preexposed groups. However, there seems to be a clear tendency between the two high
activity subgroups. Thus, a factorial ANOVA (previous treatment; caffeine vs saline x
level of activity; high vs low ethanol induced activity) yielded results close to significance:
Previous treatment (F(1,20)=3.30, p=0.08), level of activity (F(1,21)=30.9, p<0.01), and
interaction (F(1,31)=3.33 p=0.08). The low ethanol responders subgroup preexposed to
saline or caffeine (15 mg/kg) showed a horizontal locomotion average of 26.0±7.9 and
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25.8±5.0 respectively, while saline or caffeine preexposed animals that showed high
locomotor stimulation after ethanol administration had an average of 94.4±9.4 and
161.0±33.6 respectively.
Experiment 5. Western blotting for DARPP-32 (In progress).
Diaram showing the effect of an acute administration of caffeine at doses of 15 and 30 mg/kg in
animals previously exposed to saline or ethanol (1.5 g/kg) on DARPP-32, pDARPP-32(Thr75),
pDARPP-32(Thr34).
Experiment 6: Blood ethanol levels.
A two-way factorial ANOVA (ethanol x caffeine) showed a significant effect of ethanol
(F(1, 25)= 326.82, p<0.01) but, no significant effect of caffeine (F(1, 25)=0.31, n.s.), or of
the interaction (F(1, 25)=3.39, n.s.). These data suggest that the observed behavioral effects
of ethanol coadministered with caffeine are not due to changes in blood ethanol
concentration.
ETOH
(g/kg)
Caffeine (mg/kg)
0 30
1.5 0.89 ± 0.04 1.00 ± 0.07
2.5 2.12 ± 0.07 2.03 ± 0.05
Table 1. Effect of caffeine on blood ethanol levels. Mean ± SEM (n=7-8 per group) of blood
ethanol levels (in milligrams per deciliter) after acute IP administration of ethanol and caffeine at
the highest doses used.
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Conclusions
-Caffeine showed a bell-shaped dose response curve inducing stimulant effects on
horizontal locomotion and supported rear in the OF at low doses but not at the highest dose
used. Ethanol showed stimulant effects on locomotion at moderate-high (2.5 g/kg) doses
but suppressed vertical locomotion; an index of motor incoordination.
- Stimulant and non-stimulant doses of caffeine (15 and 30 mg/kg) potentiated locomotion
in animals treated with low and moderate doses of ethanol acutely. However, at the highest
dose of ethanol (3.5 g/kg) caffeine did not reversed ethanol’s suppressing effect in any of
the locomotion parameters.
- Repeated administration of ethanol (1.5 g/kg) induced motor sesitization. However, there
was no cross-sensitization with caffeine. Instead, a non-stimulant dose of caffeine (30
mg/kg) produced suppression in horizontal and vertical locomotion in ethanol sensitizated
mice. Repeated administration of ethanol (2.5 g/kg) did not induce motor sesitization.
-Thus, caffeine potentiates locomotion at stimulant doses of ethanol but at higher doses or
after suppresion of locomotion, caffeine at medium to high doses potentiates the
incoordinating effects of ethanol.
- Caffeine at a stimulant dose (15 mg/kg) did not induce sesitization after 5
administrations. However, animals pretreated with caffeine showed a tendency to have a
potentiated response to ethanol (1.5 g/kg) compared with saline treated animals, that was
more evident in those animals that showed stimulation of locomotion.
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1. Abstract
One of the behavioral tests used in present dissertation for the evaluation of anergia-like
effects induced by the VMAT2 inhibitor TBZ, is the 3-choice t-maze task (adapted from
Correa et al., 2016). In this test animals can chose between running on a wheel (RW) vs.
sedentary activities such as consuming sucrose or sniffing a neutral odor. Animals can
allocate their time in reinforcing activities with different activational requirements: RW,
which requires high levels of behavioral activation and effort, or with more sedentary
activities shuch as eating freely available sweet pellets or as a third option sniffing
through a hole where there is a cotton ball with a neutral odor. Under normal conditions,
animals spent most of their time running in the RW (65%), less time eating (4%) and a
few seconds sniffing the neutral odor (0.5%).
Administration of TBZ shifts behavior; decreasing time in the RW and increasing time
eating, with no change interacting with the neutral odor (as observed in chapter 6).
Thus, the 3-choice t-maze task, is sensitive to DA manipulations as observed in
previous studies (Correa et al., 2016). This type of task is used for the evaluation of
motivated behavior, thus it should be sensitive to factors that can change cost-benefit
analyses when choosing between reinforcers such as the effort required or the value of
the reinforcer (Cheeta et al., 1995; Pardo et al., 2015; Randall et al., 2011; Fisher and
Mazur, 1992).
The present work explores the sensitivity of the 3-choice T-maze task to manipulations
that change the value of the most preferred reinforcers used in this T-maze (RW and
sweel pellets). Common manipulations of the reinforcer’s value when it is palatable
food or solution is the devaluation of the reinforcer changing its taste (Pickens et al.,
2003; Pardo et al., 2015; Cheeta et al., 1995), prefeeding the animals with the same type
of food (Pardo et al., 2012; 2015), or using drugs that induce anorexic-like effects
(Randall et al., 2012). In the present experiments we devalued the food by changing the
taste of the sweet pellets making them bitter and by pre-feeding the animals ad libitum
with the sweet pellets. In another condition animals were deprived of standard food in
order to increase food value. On the other hand, because normal mice spent most of
their time running and much less time consuming sucrose we also assessed the impact
of increasing wheel resistance (an effort-related challenge) on these preferences.
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2. Methods
2.1. Subjects
CD1 adult male mice (N=7) purchased from Janvier, France S.A. were 15-17 weeks old
(30-45 g) at the beginning of the study. Mice were housed in groups of three or four per
cage, with standard laboratory rodent chow and tap water available ad libitum. The
colony was kept at a temperature of 22 2 ºC with lights on from 08:00 to 20:00 h. All
animals were under a protocol approved by the Institutional Animal Care and Use
Committee of Universitat Jaume I, and all experimental procedures complied with
European Community Council directive (86/609/ECC). All efforts were made to
minimize animal suffering, and to reduce the number of animals used.
2.2. Testing procedures
Three-choice running wheel T-maze task. The T-maze apparatus consisted of a
central corridor with two opposed arms. Each arm provided a different type of stimuli
(for details, see Fig. 1). In one of them sweet pellets (TestDietTM, 50% sucrose, 45 mg
each) were available, in another arm there was a RW, and in the third arm there was a
hole with a cotton ball socked with a neutral non-social odor. Training as well as test
sessions lasted 15 minutes. Mice were trained 5 days a week. Training phase 1: to avoid
neophobia to the sweet tasting pellets, animals were enclosed in that arm with the food
during 5 sessions. Training phase 2: during 4 more weeks animals were exposed, one 15
min session a day to the T-maze with free access to the three stimuli. Mice were
exposed to all the conditions during consecutive weeks, day before the manipulation
was considered as a baseline (BL) or normal performance.
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Experiment 1. Effect of sweet food devaluation on preference in the 3-choice T-
maze task.
Experiment 1.1. Change in taste: bitter pellets
Experiment 1.2. Change in appetite: Pre-feeding.
Experiment 2. Effect of food deprivation on preference in the 3-choice T-maze
task.
Experiment 3.  Effect of increasing RW resistance on on preference in the 3-choice
T-maze task.
Figure 1. Schematic representation of 3 choice T-maze task.
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4. Results
Experiment 1. Effect of sweet food devaluation on preference in the 3-choice T-
maze task.
Experiment 1.1. Change in taste: bitter pellets
Animals were trained as described before, and after reaching stable levels of time
interacting with the three different reinforcers, a drop of caffeine (1g/L) was added to
the sweet pellets in order to make them bitter. BL was assessed the day before.
Fig 2. Effect of devaluation of pellets (bitter pellets) in the 3-choice T-maze preference task.
Data are expressed as mean (±SEM) of time (seconds) spent interacting with RW (A), food (B),
neutral odor (C) and time in different compartments (D) during a 15 minutes session. **p<0.01,
*p<0.05 significantly different from BL.
A Student`s t-test for dependent samples showed a significant increase on time running
in the RW in food devaluation condition (bitter pellets) (t=4.56, p<0.01), and a
significant decreased on time spent eating compared with its BL (t=-2.53, p<0.01).
However there were not differences on time sniffing the neutral odor between both
conditions (t=2.0, n.s.) (Fig 2 A-C). The t-tests for dependent samples comparing time
in compartments between both conditions (BL vs. food devaluation) did not showed
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differences on time spent in RW compartment (t=1.13, ns), food compartment (t=-1.39,
ns) and neutral odor compartment (t=1.81, ns) (Fig 2 D).
Experiment 1.2. Change in appetite: Pre-feeding.
After reaching stable baseline levels, animals were preexposed to sweet pellets
overnight before the beginning of the experiment. The previous day was used as BL.
Fig 3. Effect of pre-feeding in the 3-choice T-maze preference task. Data are expressed as mean
(±SEM) of time (seconds) spent interacting with RW (A), food (B), neutral odor (C) and time in
different compartments (D) during a 15 minutes session. *p<0.05 significantly different from
BL.
The Student’s t-test for dependent samples showed no significant effect of prefeeding
on time spent RW although there was a tendency to increase (t=0.38, ns), and no
significant differences between conditions on time spent sniffing the neutral odor (t=10,
ns). However, there was a significant decrease on time eating in the pre-feed condition
compared with BL (t=2.6, p<0.05) (Fig 3 A-C). Student’s t-tests for dependent samples
for the variable time in compartments did not show significant differences between
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conditions on time spent in RW compartment (t=0.60, ns), food compartment (t=1.48,
ns) or neutral odor compartment (t=1.03, ns) (Fig 3. D).
Experiment 2. Effect of food deprivation on preference in the 3-choice T-maze
task.
Animals were retrained and, after reaching stable levels, they were food deprived the
night before the test in order to increase their appetite. The BL data correspond to the
day before test.
Fig 4. Effect of food deprivation in the 3-choice T-maze preference task. Data are expressed as
mean (±SEM) of time (seconds) spent interacting with RW (A), food (B), neutral odor (C) and
time in different compartments (D) during a 15 minutes session. **p<0.01, *p<0.05
significantly different from BL.
The food deprivation condition significantly decreased time in RW, and significantly
increased time eating compared with BL condition as showed by the Student’s t-test for
dependent samples (t=-3.47, p<0.05; t=4.04, p<0.01 respectively). However, there was
no significant difference between conditions on time spent sniffing the neutral odor
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(t=0.54, ns) (Fig 4. A-C). Student’s t-tests for time in compartments, did not show
significant differences between both conditions on time spent in food compartment
(t=2.49, ns), RW compartment (t=-2.28, ns), or odor compartment (t=-1.20, ns) (Fig 4.
D).
Experiment 3.  Effect of increasing RW resistance on preference in the 3-choice T-
maze task.
Mice were trained as in the previous experiments and after reaching stable levels of BL
level of performance, the RW resistance was increased during two consecutive days.
Test was performed during 3 consecutive days: in the first day animals had a wheel with
the standard resistance (0%). For the second day weights were attached to the wheel so
that the resistance increased 75%, and for the third day additional weights increased
resistance to 95%.
Fig 5. Effect of increasing RW resistance in the 3-choice T-maze preference task. Data are
expressed as mean (±SEM) of time (seconds) spent interacting with RW (A), food (B), neutral
odor (C) and time in different compartments (D) during a 15 minutes session., *p<0.05
significant different from 0% (normal RW).
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Repeated measures ANOVA showed an overall effect of RW resistance on time running
in the RW (F(2,12)=3.75, p<0.05). Planned comparison analysis showed a significant
decrease in time running when RW resistance was increased to 95% (p<0.01) (Fig 5.A).
There was not an overall effect of RW resistance on the variables time eating
(F(2,12)=1.12, ns.), or time sniffing (F(2,12)=0.07, ns) (Fig 5. B and C).
Repeated measures ANOVA did not show an overall effect of RW resistance on time in
food compartment (F(2,12)=3.28, ns), RW compartment (F(2,12)=3.04, ns), or odor
compartment (F(2,12)=0.34 ns) (Fig 5. D).
5. Discussion
In single trial situations, when several reinforcers are presented concurrently, animals
distribute their time taking into account different levels of preference. However, a low
preferred option can act as a good reinforcer and elicit high levels or response when it is
presented alone (Franciso et al., 2008), or can be selected when the value of a more
preferred reinforcer is modified.
In experiment 1 food devaluation was been tested, and animals showed a decrease on
time eating but compensated increasing even more the time in the most preferred
reinforcer; the RW, specially in the bitter pellets condition. Conversely in experiment 2,
increasing the value of food after food deprivation, there was a significant increase on
time spent eating and a compensatory decrease on time running in the RW compared to
BL. This condition increased 800% the time spent eating in relation to BL, but only
decreased 50% time in RW indicating that the animals were still engaged in the RW.
In experiment 3, attaching weights to the RW and thus increasing the effort required to
run, reduced time in the RW, but there was no compensatory increase in sucrose
preference. Time spent in the RW compartment is not reduced, suggesting that although
the total time running is lower, maybe the resting times were longer than under BL
conditions. Devaluation of RW motivational value by RW pre-exposure, has been tried
on a previous study (Correa et al., 2016). However, the parameters used (duration of
preexposure) were not enough to induce “satiation”, possibly because running in the
wheel becames habitual and therefore relatively insensitive to devaluation. The neutral
option was not affected by changing conditions in one of the other two reinforcers,
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under any of the present set of manipulations, confirming that this is a neutral stimuly.
Further studies should use manipulations of this stimuly to increase its value.
Thus, the shifts in preference induced by DA D2 antagonism (Correa et al., 2016) and
by TBZ in Chapter 6 did not follow the same pattern of results as observed when
running became more difficult after attaching weights to the RW (experiment 3). Thus,
the effects of DA antagonism or depletion on redirecting preferences away from RW
activity do not seem to mimic the effects of moderate increases in muscle exertion in the
same paradigm, and do not seem to be due to an inability to run in the RW. However, we
cannot rule out the possibility that those pharmacological manipulations increase
appetite, thus increasing food consumption and reducing time in the RW, although the
magnitude of the effect observed in the food deprivation experiment is much higher than
the one observed after DA antagonism or depletion.
In summary, we confirm that changes on preference are related with changes of the
reinforcer’s value, showing that the 3-choice T-maze task is sensitive to motivational
manipulations and mice allocate their behavior from one stimulus to another depending
on their motivational relevance. Thus, this paradigm could be also sensitive to
motivational impairments induced by drugs.
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1. Abstract.
Organisms frequently make cost/benefit analyses in which they weigh the value of
rewards vs. the costs involved in procuring them. These decision-making processes
include assessments of effort-related costs and other factors, and can involve cognitive
as well as physical effort. The mesolimbic dopamine (DA) system plays a critical role in
behavioral activation, exertion of effort, and effort-based decision-making, and DA
antagonism and depletion in this system has been shown to induce anergia in effort-
based decision tasks. Exercise has been demonstrated to have protective effects in
animal models of pathologies characterized by motor disturbances such as Parkinson’s
disease, which involves DA loss in the nigrostriatal system. However, the beneficial
effects of physical activity on symptoms such as mental fatigue or anergia, present in
many psychiatric and neurological pathologies, also need to be explored. To assess
DAergic involvement in the activational component of motivation, and in effort based
decision-making when multiple reinforcers are available, mice received injections of
tetrabenazine (TBZ), a VMAT-2 inhibitor that produces a reversible DA depletion.
Mice were tested in a 3-choice-T-maze task developed for the assessment of preference
between physical activity (wheel running) in one arm vs. sedentary reinforcers such as a
freely available sucrose pellets in another arm, as well as a non-social (neutral) odor in
the third arm. Additionally, to study the protective effects of physical exercise, different
groups of animals were exposed to a daily session of forced exercise during 9 weeks (5
days a week). Under standard conditions, mice spent more time running and less
consuming sucrose or sniffing. TBZ produced a shift in the relative preference; it
reduced the choice of the reinforcer that involved vigorous activity, but increased
consumption of a reinforcer that required little effort (sucrose). On the contrary, mice
that were extensively exposed to exercise did not show TBZ-induced shifts in
preference towards low-effort reinforcers such as sucrose or olfactory stimuli. These
results suggest that exercise could act as a preventive therapy for the anergia-inducing
effects of DA depletion. Thus, DA depletion produced effects indicative of anergia (lack of
energy), but did not impair the primary rewarding effects of sucrose.
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2. Methods.
Subjects.
CD1 male mice weighed 24-28 g at the beginning of the study (Janvier). All mice were
housed in groups of 3 or 4 animals per cage with tap water available ad libitum, and
were food-restricted to reach 85% freefeeding body weight throughout the study. The
colony was kept at a temperature of 22± 2 ºC with lights on from 08:00 to 20:00 h. All
animals were under a protocol approved by the Institutional Animal Care and Use
Committee of Universitat Jaume I, and all experimental procedures complied with
European Community Council directive (86/609/ECC). All efforts were made to
minimise animal suffering, and toreduce the number of animals used.
Drugs
Tetrabenazine (TBZ) [(R,R)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-
pyrido[2,1-a]isoquinolin-2-one] (CIMYT Quimica SL, Spain), was dissolved in a 20%
dimethylsulfoxide (DMSO) solution mixed with saline and pH adjusted with 1 N HCl to
bring the final solution to pH 5.5. DMSO (20%v/v) was used as its control. TBZ was
administered 120 min before testing.
Testing procedures and apparatus
Forced running wheels (RW). Mice (4 weeks old at the beginning of the
training) were trained in the Mouse Forced Exercise Talking Wheel System (Model
80800ª, Lafayette Intrument ©). Animals were divided in two groups. One group of
mice were exercised daily, 5 days per week, for 9 weeks, beginning at the start of the
dark cycle (10.00 h). Training consisted in 2 cycles of 15 min at 5 rpm, and 2 cicles of
15 min at 7 rpm with one minute of rest between cycles. The total distance travelled was
360 meters in 1 hour. The second group of mice was used as control group and they
were enclosed in the Forced RW but blocked in order to be exposed to the same
conditions but with non exercise. These two groups of mice constituted the “Forced”
and “Blocked” conditions.
Locomotion in the open field arena (OF). The OF apparatus consisted of a clear
glass cylinder 25 cm in diameter and 30 cm high. The floor of the cylinder was divided
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into four equal quadrants by two intersecting lines drawn on the floor. The behavioral
test room was illuminated with a soft light, and external noise was attenuated.
Horizontal and vertical locomotion was registered manually during 60 min. For
horizontal locomotion an activity count was registered each time the animal crossed
from one quadrant to another with all four legs. A count of vertical locomotion was
registered each time the animal raised its forepaws in the air higher than its back, or
rested them on the wall. Animals were testes in OF the last week of training (Figure 1)
Anxiety in the elevated plus maze (EPM). The 8th week of forced training
animals from Forced condition and Blocked condition were evaluated in an EPM
(Figure 1). This paradigm consists of two open and two enclosed arms arranged in a
plus conﬁguration. This anxiety paradigm measures the avoidance that rodents show to
elevated open spaces. Animals were placed in the central platform and assessed during 5
minutes. A trained observer registered time spent in the open arms, ratio of entries in the
open arms to total arm entries, latency to enter the open arms and total entries in the 4
arms as an index of locomotion. An entry into an arm was recorded when the animal
crossed the line that connected that arm with the central platform with all four legs.
Three-choice running wheel T-maze task. The T-maze apparatus consisted of a
central corridor with two opposed arms. Each arm provided a different type of stimuli
(for details, see Fig. 1). In one of them sweet pellets (TestDietTM, 50% sucrose, 45 mg
each) were available, in another arm there was a RW, and in the third arm there was a
hole with a cotton ball soaked with a neutral non-social odor. Training as well as test
sessions lasted 15 minutes. Mice were trained 5 days a week. Training phase 1: to avoid
neophobia to the sweet tasting pellets, animals were enclosed in that arm with the food
during 5 sessions. Training phase 2: during 2 more weeks animals were exposed, one 15
min session a day to the T-maze with free access to the three stimuli. Test phase: This
phase lasted during 3 weeks more (one week per TBZ dose). Animals started the t-maze
procedure after being trained 9 weeks in the forced RW.
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Figure 1. Schematic representation of the 3-choice RW T-maze task settings and
experiments timeline.
High Performance Liquid Chromatography (HPLC) for DA level
determination. Brain samples were extracted after 120 minutes of TBZ (0 and 2
mg/kg) administration. Mice were anesthetized with carbon dioxide for 30 s and
decapitated. Brains were quickly removed and frozen on a Leitz Wetzlar microtome.
Coronal sections 750 μm thick were cut through the striatum. A 16-gauge stainless-steel
tube was used to dissect bilateral cylindrical samples from the ventral striatum and
anterior cingulated (Acg). These tissue samples were then placed in 200 μl of 0.1 N
perchloric acid, and then homogenized, centrifuged, and frozen. The supernatant was
subsequently analyzed for DA content using HPLC with electrochemical detection
(ESA Coulochem II system). The electrochemical parameters were as follows: channel
1= − 100 mV, channel 2 = +200 mV, and guard cell = +350 mV. Each liter of mobile
phase contained 27.6 g sodium phosphate monobasic, 8.0% of methanol 750 μl of 0.1M
EDTA, and 2875 μl of 0.4M sodium octyl sulfate dissolved in deionized ultrapure H2O
with a final pH of 4.5. The flow rate was 1.0 ml/min.
Plasma corticosterone determination. 60 minutes after being trained in Forced
RW animals were sacrificed by decapitation under deep anesthesia. Animals were
anesthetized with a 1.0 ml/kg IP injection of a cocktail solution containing 10.0 ml of
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100 mg/ml ketamine plus 0.75 ml of 20.0 mg/ml xylazine (both from Phoenix
Scientific, Inc., St. Joseph, MO, USA), 30 minutes before decapitation. Blood samples
were collected in heparinized (15 units/ml of blood) Eppendorf tubes and centrifuged at
4000 rpm for 10 min. Supernatant was taken and stored at -20°C until corticosterone
determination. Plasma corticosterone levels were measured spectrophotometrically
using a commercially available enzymatic immunoassay kit (Rodents Corticosterone
Enzyme Immunoassay System, OCTEIA Corticosterone; Immunodiagnostic Systems
LTD, Boldon, England). Blood corticosterone concentration (ng/ml) was determined
using a logarithmic adjustment of the standard curve.
DARPP-32 immunohistochemistry. After 120 min of TBZ (0 or 2 mg/kg)
administration animals trained in Forced RW (Forced and Blocked) were anesthetized
with CO2 and transcardially perfused with 0.9% physiological saline with heparine
(0.06%) for 5 min, followed by perfusion with 3.7% formaldehyde for 5 min. Brains
were fixed for 24 h by immersion in 3.7% formaldehyde and then transferred into a
30% sucrose solution and stored at 4°C before brain sectioning. Free floating coronal
sections of brains (40 µm) were serially cut using a Cryostat 9 (Thermo Fisher) and
rinsed in 0.01 M phosphate buffer (PBS). To measure the immunoreactivity to
phosphorylated DA and c-AMP-regulated phosphoprotein 32 kDa (pDARPP-32),
nonspecific binding sites were blocked, and cells were permeabilized in a solution
containing 0.1% Triton X-100 (T.X), 1% Bovine Albumin serum (BSA) in PBS for 30
min at room temperature on a rotating platform before primary antibody incubation.
pDARPP-32 immunoreactivity was visualized with a polyclonal rabbit antibody for
pDARPP-32 phosphorylated at the threonine 34 residue (pDARPP32-Thr34, 1:1000;
Santa Cruz Biotechnology), or polyclonal rabbit antibody for pDARPP-32
phosphorylated at the threonine 75 residue (pDARPP32-Thr75, 1:500; Santa Cruz
Biotechnology). These antibodies were dissolved in solutions that also contained 1%
BSA and 0.1% T.X in PBS for 24 h (pDARPP32-Thr34) or 48 hours (pDARPP32-
Thr75) incubation at 4°C. After the primary antibody treatment, the sections were rinsed
in PBS (3 times for 5 min) and incubated in the secondary antibody, anti-rabbit HRP
conjugate envision plus (DAKO) for 1.5 h on a rotating shaker at room temperature.
Finally, sections were washed and rinsed for 1-3 min in 3,3diaminobenzidine
chromagen (DAKO) Processed sections were then mounted to microscope slides
(Menzel-Gläser, Superfrost ® Plus, Thermo scientific), air dried, and cover-slipped using
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Eukitt® (Sigma Aldrich) as a mounting medium. The sections were examined and
photographed using a Nikon Eclipse E600 (Melville, NY, USA) upright microscope
equipped with an Insight Spot digital camera (Diagnostic Instruments, Inc). Images of
the regions of interest were magnified at 20X and captured digitally using Stereo
Investigator software.
Statistical analysis
All the behavioral experiments followed a within-subjects design, and were analyzed
with repeated measures analysis of variance (ANOVA). . When the overall ANOVA
was significant, non-orthogonal planned comparisons using the overall error term were
used to compare each treatment with the vehicle control group (Keppel, 1991). For
these comparisons,  level was kept at 0.05 because the number of comparisons was
restricted to the number of treatments minus one. Biochemical studies were analyzed
with one-way ANOVA or with a non-parametric Mann Whitney-U test in the HPLC
experiment . All data were expressed as mean ± SEM, and significance was set at
p<0.05. STATISTICA 7 software was used for statistical analyses of the data.
3. Experiments
Experiment 1. Effect of Forced RW and Blocked RW training on body weight,
food intake, and stress-related parameters.
During the 9 weeks of exercise training different variables that can be sensitive to stress
were registered:
- Total amount of lab chow comsumption in home cage was registered twice a
week.
- Mice were weighted twice a week before during RW training.
- Defecation has been used as a measure of emotionality in rats (Hall, 1934;
Sanberg, 1989), the number of fecal pellets deposited by mice in each group
(forced vs. blocked RW) was recorded after their daily training session.
- Plasma corticosterone levels were quantified after the last session of training.
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Experiment 2: Effect of previous RW training on EPM performance.
Experiment 3: Exploratory locomotion in a novel OF.
Experiment 4: Effect of TBZ on 3-choice T-maze performance
Experiment 5: Experiment 3. Effect of TBZ on DA tissue levels in striatum and
Anterior Cingulate.
Experiment 6: Effect of TBZ on pDARPP-32(Thr34) and pDARPP-32(Thr75) in
mice after completion of RW training.
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4. Results
Experiment 1. Effect of Forced RW and Blocked RW training on body weight,
food intake, and stress-related parameters.
Figure 2. Body weight, food consumption, fecal bolus, and corticosterone levels after training. Mean
(±SEM) body weight in grams (A), standard food consumed in home cage in grams (B), number of fecal
bolus excreted during training session (C), and plasmatic corticosterone levels after the training session in
nanograms per mililiter of blood (D).
Factorial ANOVA for the variable food consumption (chow consumed in their home
cages during 8 weeks of training), did not showed an overall effect of condition
(Control or Forced) (F(1,72)=0.01, n.s.), week of training (F(7,42)=1.92, n.s.) or
interaction (F(7,42)=0.56, n.s) (Fig 2A). The factorial ANOVA for body weight showed
a significant effect of training (F(1,22)=7.71, p<0.05), and a significant effect of week
of training (F(8,176)=27.02, p<0.01), but no significant interaction (F(8,176)=0.71, n.s.)
(Fig 2B). The ANOVA on the impact of training condition and week of training on
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number of fecal bolus during training session showed no effect of training
(F(1,22)=0.10, n.s.), week of training (F(8,176)=1.66, n.s.), or condition x week
interaction (F(8,176)=1.10, n.s.) (Fig 2C). All these results indicate that this schedule of
force training has no signifficant impact on amount of food consumed or excretion and
body mass. In addition, forced training condition did not increased plasma
corticosterone levels as showed by a t-test for independent samples (t=-0.10, n.s). Thus,
there were no significant differences between control and forced animals after training
on this neuroendocrine parameter of stress (Fig 2D).
Experiment 2: Effect of previous RW training on EPM performance.
Figure 3. Anxiety measures in the elevated plus maze. Mean (±SEM) latency in seconds to enter an open
arm for the first time (A), time spent in open arms in seconds (B), ratio entries into open arms compared
to total entries in all arms  (C), and total number of entries in the four arms as a measure of locomotion
(D).
Training condition did not affect any of the parameters recorded in the EMP. Student’s
t-test for independent samples did not show significant differences between both
training conditions in latency to enter into the open arm for the first time (t=-1.78, n.s.),
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time in open arms (t=-0.10, n.s.), and ratio of entries in open arms (t=0.13, n.s.).
Suggesting that animals trained in forced RW did not have an anxiogenic-like pattern of
behavior in comparison with control group. There were not differences between both
conditions on total crosses either (t=-1.21, n.s.).
Experiment 3: Exploratory locomotion in a novel OF.
Figure 4. Exploration in novel open field. Mean (±SEM) of number of crosses between quadrants (A)
and number of rearings (B).
Factorial ANOVA showed a significant effect of time in the OF on both groups of
animals (F(3,42)=29.0, p<0.01). However, there was not a significant effect of training
condition on horizontal locomotion F(1,14)=0.07, n.s.), and no significant interaction
(F(3,42)=1.00, n.s) (Fig 4A). The same pattern of results was observed for vertical
locomotion. Factorial ANOVA did not show a significant effect of training condition
(F(1,15)=0.44, n.s.), there was a significant effect of time in the OF (F3,42)=35.47,
p<0.01), but no significant effect of time x condition interaction (F(3,42)=1.64, n.s.).
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Experiment 4: Effect of TBZ on 3-choice T-maze performance
Factorial ANOVA (condition x treatment) did not showed an effect of condition
(F(1,22)=0.20, n.s) or dose (F(2,44)=2.39, n.s) on time spent running in the RW.
However there was a significant effect of condition x treatment interaction
(F(2,44)=6.76, p<0.01). Planned comparisons showed a significant decrease on time in
the RW after TBZ administration at a dose of 2 mg/kg in the control group (p<0.01), but
not in animals trained in the forced RW. On the other hand, the ANOVA for the sucrose
consumption did not show a significant effect of condition (F(1,22)=0.11, n.s),
treatment (F(2,44)=2.76, n.s), or interaction (F(2,44)=2.88, n.s) on time spent eating.
However a tendency to increase time eating was observed in the control group. There
was no significant effect of condition (F(1,22)=1.49, n.s), treatment (F(2,44)=2.24, n.s),
and condition x treatment interaction  F(2,44)=0.64, n.s) on the variable time sniffing
the neutral odor.
Figure 5. Effect of TBZ on mice from the control
group (blocked RW) and the group forced to
exercise, in time spent with the 3 stimuli in the T
maze. Mean  (±SEM) of time running in the RW
A), time eating the sucrose pellets B), and time
sniffing the hole C). **p<0.01  *p<0.05
significantly different from TBZ 0 mg/kg in the
same group. #p<0.05 significantly different from
control group at the same dose of TBZ.
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Experiment 5: Effect of TBZ on DA tissue levels in Striatum and Anterior
Cingulate.
Figure 6. DA tissue levels in ventral striatum and in anterior cingulate cortex as measured by HPLC.
Mean  (±SEM) nanograms of DA per milligram of brain tissue.
Factorial ANOVA (brain region x treatment) showed an overall effect of brain region
(F(12,36)=1.18, p<0.05), and treatment (F(1,18)=4.38, p<0.05) on DA levels, but no
significant effect of brain region x treatment interaction (F(1,18)=1.32, n.s.).
Experiment 6: Effect of TBZ on pDARPP-32(Thr34) and pDARPP-32(Thr75) in
mice after completion of RW training.
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Figure 7. Upper part: Diagram of coronal sections with bregma coordinates (0.97 and 1.18) taken
from Franklin and Paxinos (2007), showing location of the brain areas for pDARPP-32(Thr34) and
pDARPP-32(Thr75) counting. Lower part: Photomicrographs of pDARPP-32(Thr34) and pDARPP-
32(Thr75) immunoreactivity staining in nucleus Accumbens Core from representative animals. Images at
20x, scale bar = 100 μm.
Factorial ANOVA (treatment x condition) revealed a significant effect of treatment
(F(1,15)=4.25, p<0.05), condition (F(1,15)=11.35, p<0.01) and treatment x condition
interaction (F(1,15)=4.61, p<0.05) on DARPP32-thr34 levels in nAcb core. Planned
comparisons analysis showed a significant increase on DARPP32-Thr34 after TBZ (2
mg/kg) administration in control group (p<0.05) but not in forced group.
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Figure 8. Effects of TBZ on pDARPP-32(Thr34) levels on nucleus Accumbens Core core in control and
forced exercised animals. Mean (±SEM) of number of pDARPP-32(Thr34) staining in 300 µm2 ROI.
*p<0.05 significant differences from vehicle treatment in the same condition.
5. Discussion
TBZ produced a shift in the relative preference; it reduced the choice of the reinforcer
that involved vigorous activity, but increased consumption of a reinforcer that required
little effort (sucrose). In previous studies we have demonstrated in mice and rats (Nunes
et al., 2013; López-Cruz et al., 2014), that none of these doses of TBZ (1 or 2 mg/kg)
significantly reduced RW performance or free sucrose consumption when they were not
presented concurrently. Thus, the possibility of choosing changed the impact of the
drug. However, mice that were extensively exposed to exercise did not show TBZ-
induced shifts in preference towards low-effort reinforcers such as sucrose or olfactory
stimuli.
TBZ did not significantly decrease DA levels in striatum although a tendency was
observed. However, it increased levels of the phosphorilated form of DARPP-32(Thr34)
in control animals but not in animals previously trained in the forced RW.
These results suggest that exercise could act as a preventive therapy for the anergia-
inducing effects of DA depletion. Thus, DA depletion produced effects indicative of
anergia (lack of energy), but did not impair the primary effect of sucrose.
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